[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"R & D Systems, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":399},{"warningLetters":4,"total":398},[5,30,52,74,96,110,130,146,166,184,201,218,237,262,281,296,315,334,354,378],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":20,"body_fetched_at":29,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":25,"medical_device_id":20,"response_letter_date":20},3493,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-03-04T05:17:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-03042021\">Cantronic Systems Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Device Adulterated and Misbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-07202023\">\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cantronic Systems Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>#8-62 Fawcett Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coquitlam\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V3K 6V5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jzahn@cantronics.com %E2%80%93 James Zahn\"> jzahn@cantronics.com – James Zahn\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.cantronics.com on February 11, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the FeverScan M3000N, FeverScan M3000L, LGC300 Body Temperature Scanner, FeverScan M3000B, FeverScan M3000SD, FeverScan M3000S, FeverScan M3000P02, FeverScan M3000P03, FeverScan M3000P04, and FeverScan M3000P05 (collectively,“Temperature Scanners”), for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), your Temperature Scanners are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\u003C\u002Fp>\n\n\u003Cp>Your Temperature Scanners are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.cantronics.com\u002F, includes statements that indicate that your Temperature Scanners are intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The FeverScan M3000N is ideal for mass temperature screening in public transport situations.” [Published on your website, https:\u002F\u002Fwww.cantronics.com\u002Findex.php\u002Ftemperature-screening-cameras]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cul>\n\t\u003Cli>“The FeverScan M3000P04 is capable of evaluating multiple people in real time” [Published on the FeverScan M3000P04 datasheet, https:\u002F\u002Fwww.cantronics.com\u002Fimages\u002Fdatasheet\u002FFeverScan-M3000P04-.pdf]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n&nbsp;\u003Cbr>\nYour firm’s response should be sent to:\u003Cbr>\n&nbsp;\u003Cbr>\nAttn: CAPT Alan Stevens\u003Cbr>\nActing Director, Division of Drug Delivery and General Hospital Devices,\u003Cbr>\nand Human Factors\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nDocument Control Center (DCC) – WO66-G609\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n&nbsp;\u003Cbr>\nRefer to the reference number CMS 613542 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at \u003Ca href=\"mailto:Jake.Lindstrom@fda.hhs.gov\">Jake.Lindstrom@fda.hhs.gov\u003C\u002Fa> or \u003Cspan>(301) 796-5716\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:&nbsp;Dallas Thomas\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FDAbasics LLC\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15815 SW 11th Court Rd\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ocala, FL 34473\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003Ca href=\"mailto:dallas@fdabasics.com\">dallas@fdabasics.com\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nCantronic Systems Inc.\n\n#8-62 Fawcett Rd\n\nCoquitlam BC V3K 6V5\n\nCanada\n\njzahn@cantronics.com – James Zahn\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.cantronics.com on February 11, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the FeverScan M3000N, FeverScan M3000L, LGC300 Body Temperature Scanner, FeverScan M3000B, FeverScan M3000SD, FeverScan M3000S, FeverScan M3000P02, FeverScan M3000P03, FeverScan M3000P04, and FeverScan M3000P05 (collectively,“Temperature Scanners”), for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), your Temperature Scanners are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\n\nYour Temperature Scanners are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.cantronics.com\u002F, includes statements that indicate that your Temperature Scanners are intended to scan multiple individuals simultaneously, including:\n\n“The FeverScan M3000N is ideal for mass temperature screening in public transport situations.” [Published on your website, https:\u002F\u002Fwww.cantronics.com\u002Findex.php\u002Ftemperature-screening-cameras]\n\n“The FeverScan M3000P04 is capable of evaluating multiple people in real time” [Published on the FeverScan M3000P04 datasheet, https:\u002F\u002Fwww.cantronics.com\u002Fimages\u002Fdatasheet\u002FFeverScan-M3000P04-.pdf]\n\nYour firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.\n\nYour response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to:\n\nAttn: CAPT Alan Stevens\n\nActing Director, Division of Drug Delivery and General Hospital Devices,\n\nand Human Factors\n\nU.S. Food and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\n\nDocument Control Center (DCC) – WO66-G609\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nRefer to the reference number CMS 613542 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at Jake.Lindstrom@fda.hhs.gov or (301) 796-5716.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC: Dallas Thomas\n\nFDAbasics LLC\n\n15815 SW 11th Court Rd\n\nOcala, FL 34473\n\ndallas@fdabasics.com","Cantronic Systems Inc.","cantronic-systems-inc-613542-03042021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-03042021","2026-10-26T08:08:10.929569+00:00","Warning Letter","Closed Out","2021-03-04","613542","Medical Devices","2023-07-25","2026-08-20T03:18:47.735+00:00",{"id":31,"raw":32,"subject":36,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":20,"letter_url":43,"updated_at":44,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":46,"product_type":27,"closeout_date":47,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":20,"reference_number":20,"action_taken_date":51,"medical_device_id":20,"response_letter_date":20},1927,[33,34,35,11,36,13,37,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-16T04:00:00Z\">08\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fking-systems-corp-dba-ambu-inc-661617-08162023\">King Systems Corp. dba Ambu, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambu-usa-661617-06042025\">\u003Ctime datetime=\"2025-06-16T04:00:00Z\">06\u002F16\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steven Block\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>King Systems Corp. dba Ambu, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6721 Columbia Gateway Drive, Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Columbia\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21046\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 661617\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 16, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Block:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, King Systems Corp., dba Ambu, Inc., located at 15011 Herriman Blvd, Noblesville, IN 46060 on two days from May 15, 2023 through May 16, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your\u003Cbr>\nfirm is a manufacturer of the King LTS-D branded supraglottic airway with gastric access lumen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the King LTS-D branded supraglottic airway with gastric access lumen is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Statements on your website (https:\u002F\u002Fwww.ambuusa.com\u002Fairway-management-andanaesthesia\u002Flaryngeal-tubes\u002Fproduct\u002Fambu-king-lts-d-disposable-laryngeal-tube) promote the device with an intended use for pediatric populations weighing less than 5 kg, 5-12kg, 12-25kg, and 25-35 kg. However, the cleared indication for use for your device is for adult patients (K033189.pdf (fda.gov); K033186.pdf (fda.gov); K021634.pdf (fda.gov), and not for pediatric sizes. Use of this device in a pediatric population raise different questions of safety and effectiveness that may lead to patient adverse events. Therefore, please remove these unsupported performance claims from your website, or please provide a 510(k) with this proposed indication for use. For additional information, please refer to the following guidance: Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 661617\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Malvina Eydelman\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT &amp; Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations, Division 1 - East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteven Block\n\nRecipient Title\n\nPresident & CEO\n\nKing Systems Corp. dba Ambu, Inc.\n\n6721 Columbia Gateway Drive, Suite 200\n\nColumbia, MD 21046\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 661617\n\nAugust 16, 2023\n\nDear Mr. Block:\n\nDuring an inspection of your firm, King Systems Corp., dba Ambu, Inc., located at 15011 Herriman Blvd, Noblesville, IN 46060 on two days from May 15, 2023 through May 16, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your\n\nfirm is a manufacturer of the King LTS-D branded supraglottic airway with gastric access lumen. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection also revealed that the King LTS-D branded supraglottic airway with gastric access lumen is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nThe device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nStatements on your website (https:\u002F\u002Fwww.ambuusa.com\u002Fairway-management-andanaesthesia\u002Flaryngeal-tubes\u002Fproduct\u002Fambu-king-lts-d-disposable-laryngeal-tube) promote the device with an intended use for pediatric populations weighing less than 5 kg, 5-12kg, 12-25kg, and 25-35 kg. However, the cleared indication for use for your device is for adult patients (K033189.pdf (fda.gov); K033186.pdf (fda.gov); K021634.pdf (fda.gov), and not for pediatric sizes. Use of this device in a pediatric population raise different questions of safety and effectiveness that may lead to patient adverse events. Therefore, please remove these unsupported performance claims from your website, or please provide a 510(k) with this proposed indication for use. For additional information, please refer to the following guidance: Deciding When to Submit a 510(k) for a Change to an Existing Device - Guidance for Industry and Food and Drug Administration Staff (fda.gov).\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 661617 when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan, Compliance Officer, at 410-779-5134 or sean.moynihan@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Malvina Eydelman\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT & Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations, Division 1 - East","King Systems Corp. dba Ambu, Inc.","king-systems-corp-dba-ambu-inc-661617-08162023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fking-systems-corp-dba-ambu-inc-661617-08162023","2026-10-26T08:09:09.153468+00:00","2023-08-22","661617","2025-06-16","Steven Block","2026-08-20T00:46:11.037+00:00","VIA UNITED PARCEL SERVICE","2023-08-16",{"id":53,"raw":54,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":19,"fei_number":20,"letter_url":64,"updated_at":65,"action_type":23,"case_status":66,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":20,"issuing_office":58,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":20,"reference_number":20,"action_taken_date":73,"medical_device_id":20,"response_letter_date":20},3177,[55,56,57,58,59,13,13,13],"\u003Ctime datetime=\"2021-08-31T13:20:00Z\">08\u002F31\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-25T04:00:00Z\">08\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcloud-9-systems-llc-dba-cloud-9-vapor-616660-08252021\">Cloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brendon Gunn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1055 W Red Cliffs Dr Ste B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Washington\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84780-2541\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brendongunn@gmail.com\"> brendongunn@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mr. Gunn:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of \u003Cspan>the U.S.\u003C\u002Fspan> Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor \u003Cspan>manufactures and distributes\u003C\u002Fspan> e-liquid\u003Cb> \u003C\u002Fb>products for commercial distribution in the United States, and that the e-liquid\u003Cb> \u003C\u002Fb>products are manufactured\u003C\u002Fspan> \u003Cspan>and offered for sale or distribution to customers in the United States.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquid\u003Cb> \u003C\u002Fb>products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">\u003Cspan>https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. §&nbsp;387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. §&nbsp;387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. §&nbsp;387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report und\u003Cspan>e\u003C\u002Fspan>r sec\u003Cspan>t\u003C\u002Fspan>ion&nbsp;905(j\u003Cspan>)\u003C\u002Fspan>(\u003Cspan>1\u003C\u002Fspan>)(A\u003Cspan>)(i\u003C\u002Fspan>\u003Cspan>i\u003C\u002Fspan>) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)). \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>A\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cb> \u003C\u002Fb>\u003Cb>\u003Cspan>\u003Cspan>New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA has determined that you \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>manufacture,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>sell, and\u002For distribute to customers in the United States Cloud 9 Vapor Ape Escape 3MG 30ml e-liquid product without a marketing authorization order. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The tobacco product listed above is a new tobacco product because it\u003Cb> \u003C\u002Fb>was not commercially marketed in the United States as of February 15, 2007. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. §&nbsp;331(p)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003Cu> \u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 16,300 product(s) listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list.&nbsp; You should take prompt action to address any violations that are\u003Cb> \u003C\u002Fb>referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act.&nbsp; If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.&nbsp; This letter notifies you of our findings and provides you with an opportunity to address them.&nbsp; \u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You can find the FD&amp;C Act through links on FDA’s homepage at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">\u003Cspan>\u003Cspan>http:\u002F\u002Fwww.fda.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, \u003Cspan>ER2100187\u003C\u002Fspan>, in your response and direct your response to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or \u003C\u002Fspan>\u003Ca href=\"mailto:Lillian.Ortega@fda.hhs.gov\">\u003Cspan>Lillian.Ortega@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nBrendon Gunn\n\nRecipient Title\n\nOwner\n\nCloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor\n\n1055 W Red Cliffs Dr Ste B\n\nWashington, UT 84780-2541\n\nUnited States\n\nbrendongunn@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Gunn:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cloud 9 Vapor Ape Escape 3MG 30ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 16,300 product(s) listed with FDA. It is your responsibility to ensure that your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.\n\nYou can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100187, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Cloud 9 Systems, LLC d\u002Fb\u002Fa Cloud 9 Vapor","cloud-9-systems-llc-dba-cloud-9-vapor-616660-08252021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcloud-9-systems-llc-dba-cloud-9-vapor-616660-08252021","2026-10-26T08:08:15.930718+00:00","Issued","2021-08-31","616660","Tobacco","Brendon Gunn","2026-08-20T02:38:35.246+00:00","VIA UPS and Electronic Mail","2021-08-25",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":20,"letter_url":87,"updated_at":88,"action_type":23,"case_status":66,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":20,"issuing_office":80,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},21670,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-05T04:00:00Z\">10\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsilgan-dispensing-systems-734538-10052026\">Silgan Dispensing Systems\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Earl Lawson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Silgan Dispensing Systems\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 Haxall Point, Suite 701\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>23219\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 5, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-04\u003C\u002Fp>\u003Cp>To Mr. Earl Lawson:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facility and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection and Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Silgan Unicep Packaging, LLC, Facility Establishment Identifier (FEI) 3011913386, at 4122 South Grove Road, Spokane, Washington, from March 26 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during a review of the product labeling, including the product website at the internet address \u003Cstrong>(b)(4)\u003C\u002Fstrong> website in July 2026. Based on our review, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We reviewed your April 22, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm contract manufactures non-sterile over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, including those labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to adequately investigate out-of-specification (OOS) microbiological testing results for components used to manufacture your drug products.\u003C\u002Fp>\u003Cp>For example, in November 2025, you obtained OOS microbiological results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You prepared \u003Cstrong>(b)(4)\u003C\u002Fstrong> independent samples from each lot. You tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the samples for total aerobic microbial count and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples for total yeast and mold count. One sample from each lot exceeded your total yeast and mold count acceptance criterion of no more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units per gram.\u003C\u002Fp>\u003Cp>You did not perform an appropriate investigation into the OOS results. Rather, you invalidated the OOS results by averaging the \u003Cstrong>(b)(4)\u003C\u002Fstrong> total yeast and mold count sample results to obtain a passing result. You also revised your microbiological sampling plan to allow for averaging of test results for component testing. This practice is not in accordance with the United States Pharmacopeia &lt;61&gt; test method and is unacceptable as it obscures the detection of non-uniform microbiological contamination within a lot. You subsequently released \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots and used them in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, distributed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Notably, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a Class I recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured at your facility due to potential fungal contamination in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The investigation associated with this recall is inadequate. For example, you implemented \u003Cstrong>(b)(4)\u003C\u002Fstrong> of incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to filling to reduce bioburden, but subsequent OOS microbiological results obtained from \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots demonstrate this corrective action was ineffective. Additionally, your change control associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process did not include ensuring appropriate validation of the process as well as evaluation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Further, you lacked cleaning procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line, did not conduct cleaning validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line, and failed to include yeast and mold microbiological testing as part of your environmental monitoring program. Though your investigation into the potential fungal contamination documented an evaluation of the cleaning procedures and environmental monitoring, it did not identify nor appropriately follow-up on these risks related to potential mold contamination.\u003C\u002Fp>\u003Cp>In your response to the OOS microbiological test results, you state that you plan to update your work instructions to prohibit averaging of results. You commit to conducting a retrospective review of all drug product OOS events over a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period to identify inadequate investigations and initiate customer notifications where warranted. You also commit to engaging a consultant for root cause analysis and failure investigation training, as well as updating the change control with a risk assessment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You limit the retrospective review to documented OOS events and do not extend it to all microbiological test results to identify instances in which you inappropriately applied averaging to individual failing results to obtain overall passing results. This practice potentially resulted in the improper release of drug products. Furthermore, your response lacks an adequate plan to address product quality risks. It relies solely on procedural and documentation updates without an effectiveness verification plan and fails to address the systemic quality oversight failures that allowed these practices.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. For more information about handling OOS and failing test results, and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating OOS microbiological results and out-of-trend results.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS: o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS and out-of-limit (OOL) result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit (QU) oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003Cbr>o A similar review and remediation of your system for handling out-of-limit findings (i.e., data that falls outside action limits)\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>o Furthermore, provide your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation study and updated cleaning procedures that demonstrate effectiveness in cleaning mold. Also provide the updated environmental monitoring study (WI-00480 Environmental Monitoring (Microbial) of Manufacturing and Laboratory Facilities Rev. 24) referenced in your response indicating sample locations, frequency, and duration, as well as alert and action limits.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result whether or not later invalidated. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU failed to adequately oversee your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product manufacturing operations. For example, your QU failed to:\u003C\u002Fp>\u003Cul>\u003Cli>Validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\u003C\u002Fli>\u003Cli>Follow a written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Maintain written records so that the quality standards of each drug product can be evaluated at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to revising your vendor evaluation and control procedure, updating your stability program master plan, and retrospectively generating stability study reports for all drug products. You also commit to updating your periodic product review procedure and completing retrospective annual product reviews for all manufactured drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide supporting documentation to verify the adequacy and effectiveness of your corrective actions, nor did you address the systemic quality oversight failure that allowed deficiencies to persist undetected for multiple years, including the absence of stability study reports since 2020 and the failure to complete annual product reviews for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your drug products since 2024.\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance documents \u003Cem>ICH Q10 Pharmaceutical Quality System\u003C\u002Fem>, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload, and \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of the product labeling, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from product labeling, including the product website \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, \u003Cstrong>(b)(4)\u003C\u002Fstrong> intended for use as \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. As such, these drug products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here,\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 22, 2026, FDA held a teleconference with you, recommending that you recall drug products manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> currently in distribution from the U.S. market. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> currently distributed within the U.S. market. The recall was posted to the FDA’s Enforcement Report website at \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs at this facility.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\u003Cbr>flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3011913386 and ATTN: Renee A. Marcsisin, Ph.D. in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Earl Lawson\n\nRecipient Title\n\nPresident\n\nSilgan Dispensing Systems\n\n1001 Haxall Point, Suite 701\n\nRichmond, VA 23219\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 5, 2026\nWARNING LETTER\nReference number: 320-27-04\nTo Mr. Earl Lawson:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products, processes, facility and records. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection and Review\nViolations were observed and documented during an inspection of your drug manufacturing facility, Silgan Unicep Packaging, LLC, Facility Establishment Identifier (FEI) 3011913386, at 4122 South Grove Road, Spokane, Washington, from March 26 to April 2, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during a review of the product labeling, including the product website at the internet address (b)(4) website in July 2026. Based on our review, “(b)(4)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe reviewed your April 22, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm contract manufactures non-sterile over-the-counter (OTC) (b)(4) drug products, including those labeled for use in (b)(4). You failed to adequately investigate out-of-specification (OOS) microbiological testing results for components used to manufacture your drug products.\nFor example, in November 2025, you obtained OOS microbiological results for (b)(4) lots (b)(4). You prepared (b)(4) independent samples from each lot. You tested (b)(4) of the samples for total aerobic microbial count and the (b)(4) samples for total yeast and mold count. One sample from each lot exceeded your total yeast and mold count acceptance criterion of no more than (b)(4) colony forming units per gram.\nYou did not perform an appropriate investigation into the OOS results. Rather, you invalidated the OOS results by averaging the (b)(4) total yeast and mold count sample results to obtain a passing result. You also revised your microbiological sampling plan to allow for averaging of test results for component testing. This practice is not in accordance with the United States Pharmacopeia \u003C61> test method and is unacceptable as it obscures the detection of non-uniform microbiological contamination within a lot. You subsequently released (b)(4) lots and used them in the manufacture of (b)(4) Lot (b)(4), distributed in (b)(4).\nNotably, on (b)(4), your customer, (b)(4), initiated a Class I recall of (b)(4) lots of (b)(4) manufactured at your facility due to potential fungal contamination in your (b)(4). The investigation associated with this recall is inadequate. For example, you implemented (b)(4) of incoming (b)(4) prior to filling to reduce bioburden, but subsequent OOS microbiological results obtained from (b)(4) lots demonstrate this corrective action was ineffective. Additionally, your change control associated with the (b)(4) process did not include ensuring appropriate validation of the process as well as evaluation of the (b)(4).\nFurther, you lacked cleaning procedures for the (b)(4) line, did not conduct cleaning validation of the (b)(4) line, and failed to include yeast and mold microbiological testing as part of your environmental monitoring program. Though your investigation into the potential fungal contamination documented an evaluation of the cleaning procedures and environmental monitoring, it did not identify nor appropriately follow-up on these risks related to potential mold contamination.\nIn your response to the OOS microbiological test results, you state that you plan to update your work instructions to prohibit averaging of results. You commit to conducting a retrospective review of all drug product OOS events over a (b)(4) period to identify inadequate investigations and initiate customer notifications where warranted. You also commit to engaging a consultant for root cause analysis and failure investigation training, as well as updating the change control with a risk assessment of the (b)(4).\nYour response is inadequate. You limit the retrospective review to documented OOS events and do not extend it to all microbiological test results to identify instances in which you inappropriately applied averaging to individual failing results to obtain overall passing results. This practice potentially resulted in the improper release of drug products. Furthermore, your response lacks an adequate plan to address product quality risks. It relies solely on procedural and documentation updates without an effectiveness verification plan and fails to address the systemic quality oversight failures that allowed these practices.\nInadequate investigations can lead to unidentified root causes, ineffective corrective action and preventive action (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. For more information about handling OOS and failing test results, and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating OOS microbiological results and out-of-trend results.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for US products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS: o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS and out-of-limit (OOL) result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit (QU) oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\no A similar review and remediation of your system for handling out-of-limit findings (i.e., data that falls outside action limits)\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, OOL results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\no Furthermore, provide your (b)(4) validation study and updated cleaning procedures that demonstrate effectiveness in cleaning mold. Also provide the updated environmental monitoring study (WI-00480 Environmental Monitoring (Microbial) of Manufacturing and Laboratory Facilities Rev. 24) referenced in your response indicating sample locations, frequency, and duration, as well as alert and action limits.\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result whether or not later invalidated. The investigations should detail your findings regarding the root causes of the contamination.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n2. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour QU failed to adequately oversee your OTC (b)(4) drug product manufacturing operations. For example, your QU failed to:\nValidate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\nFollow a written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nMaintain written records so that the quality standards of each drug product can be evaluated at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\nIn your response, you commit to revising your vendor evaluation and control procedure, updating your stability program master plan, and retrospectively generating stability study reports for all drug products. You also commit to updating your periodic product review procedure and completing retrospective annual product reviews for all manufactured drug products.\nYour response is inadequate. You did not provide supporting documentation to verify the adequacy and effectiveness of your corrective actions, nor did you address the systemic quality oversight failure that allowed deficiencies to persist undetected for multiple years, including the absence of stability study reports since 2020 and the failure to complete annual product reviews for (b)(4) of your drug products since 2024.\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour firm’s quality systems are inadequate. See FDA’s guidance documents ICH Q10 Pharmaceutical Quality System, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload, and Quality Systems Approach to Pharmaceutical CGMP Regulations, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nUnapproved New Drug Violations\nBased on a review of the product labeling, “(b)(4)” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from product labeling, including the product website (b)(4), that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as a drug include, but may not be limited to, the following:\n(b)(4)\nBased on the above labeling evidence, (b)(4) intended for use as (b)(4) drug product. As such, these drug products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here,1 a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nDrug Recall\nOn July 22, 2026, FDA held a teleconference with you, recommending that you recall drug products manufactured with (b)(4) lots (b)(4) currently in distribution from the U.S. market. On (b)(4), your customer, (b)(4), initiated a voluntary recall of (b)(4) lots (b)(4) currently distributed within the U.S. market. The recall was posted to the FDA’s Enforcement Report website at (b)(4)\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs at this facility.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\nflaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3011913386 and ATTN: Renee A. Marcsisin, Ph.D. in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: (b)(4)\n__________________________\n1 (b)(4)","Silgan Dispensing Systems","silgan-dispensing-systems-734538-10052026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsilgan-dispensing-systems-734538-10052026","2026-11-17T01:02:03.701861+00:00","2026-10-13","734538","Drugs Over-the-Counter Drugs","Mr. Earl Lawson","2026-10-14T12:32:35.007+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-05",{"id":97,"raw":98,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":19,"fei_number":20,"letter_url":106,"updated_at":107,"action_type":23,"case_status":66,"posted_date":25,"marcs_cms_no":108,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":109,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":25,"medical_device_id":20,"response_letter_date":20},3487,[99,9,100,11,101,13,13,13],"\u003Ctime datetime=\"2021-03-04T21:30:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fomnisense-systems-pte-ltd-613561-03042021\">Omnisense Systems Pte Ltd.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Omnisense Systems Pte Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8 Penjuru Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>609189\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Leonard Lim\u003Cbr>\nOmnisense Systems Pte Ltd\u003Cbr>\n8 Penjuru Lane,\u003Cbr>\n609189\u003Cbr>\nSINGAPORE\u003C\u002Fp>\n\n\u003Cp>Leonard Lim\u003Cbr>\nOmnisense Systems USA Inc\u003Cbr>\n1881-1887 West State Road 84,\u003Cbr>\nBldg. 1 Unit 102, Fort Lauderdale,\u003Cbr>\nFlorida 33315\u003Cbr>\nUSA\u003C\u002Fp>\n\n\u003Cp>enquiries@omnisense-systems.com\u003Cbr>\nenquiries@omnisense-systems.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.omnisense-systems.com\u002F on February 18, 2021. The FDA has observed that your website offers a product for measuring human body temperature, specifically the Sentry MK4, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca id=\"footnoteref1_udsi5j6\" href=\"#footnote1_udsi5j6\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Sentry MK4 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“From H1N1, MERS, Ebola and now COVID-19, our fever detection system have been the trusted solution to secure critical installations and national borders.” [Published on your website, https:\u002F\u002Fwww.omnisense-systems.com\u002F]&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Drawing on our proven performance of Sentry MK3, the system that protected many organizations and institutions from H5N1 to COVID-19, the Sentry MK4 is a culmination of more than a decade experience of developing a remarkable fever screening system.” [Published in the Sentry MK4 Brochure available on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“At the forefront of pandemic defence, the Sentry MK4 Mass Fever Screening System stands guard against infectious diseases and viruses. Already deployed in commercial buildings, industrial plants, airports, hospitals, banks and other critical facilities, the Sentry MK4 is an essential security solution for any modern organization seeking to safeguard human assets and sustain business operations during a pandemic outbreak.” [Published in the Sentry MK4 Brochure available on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>The Sentry MK4 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA.&nbsp; Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce this product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS\u003Ca id=\"footnoteref2_g1ojxap\" href=\"#footnote2_g1ojxap\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>. In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19\u003Ca id=\"footnoteref3_k33jlc7\" href=\"#footnote3_k33jlc7\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa>. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.omnisense-systems.com\u002F, includes statements that indicate that the Sentry MK4 is intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Mass Fever Screening System” [Published in numerous places on your website, such as your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“Sentry MK4 – Mass Fever Screening System scans, detects and tracks febrile persons with elevated skin temperature at any venue with large human traffic” [Published on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Ca id=\"footnoteref4_d5ba5ad\" href=\"#footnote4_d5ba5ad\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa>[ ] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to \u003C\u002Fstrong>COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613561 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCC:&nbsp;\u003C\u002Fp>\n\n\u003Cp>Andrew Southern\u003Cbr>\nInvisible Health Technologies\u003Cbr>\n520 West 27th St.Suite 407\u003Cbr>\nNew York, NY 10001\u003Cbr>\nandrew@invisiblehealthtechnologies.com\u003C\u002Fp>\n\n\u003Cp>Andrew Southern\u003Cbr>\nInvisible Health Technologies\u003Cbr>\n3250 NE 1st Ave, Suite 305\u003Cbr>\nMiami, FL 33137\u003Cbr>\nandrew@invisiblehealthtechnologies.com\u003C\u002Fp>\n\n\u003Cp>Adam Lim\u003Cbr>\nNative Instinct LLC\u003Cbr>\n3206 Canal Drive,\u003Cbr>\nBoynton Beach, FL 33435\u003Cbr>\nadam@nativeinstinct.co\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_udsi5j6\">\u003Ca href=\"#footnoteref1_udsi5j6\">1\u003C\u002Fa>As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_g1ojxap\">\u003Ca href=\"#footnoteref2_g1ojxap\">2\u003C\u002Fa>Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_k33jlc7\">\u003Ca href=\"#footnoteref3_k33jlc7\">3\u003C\u002Fa>President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_d5ba5ad\">\u003Ca href=\"#footnoteref4_d5ba5ad\">4\u003C\u002Fa>Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload. \u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nOmnisense Systems Pte Ltd.\n\n8 Penjuru Lane\n\n609189\n\nSingapore\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nLeonard Lim\n\nOmnisense Systems Pte Ltd\n\n8 Penjuru Lane,\n\n609189\n\nSINGAPORE\n\nLeonard Lim\n\nOmnisense Systems USA Inc\n\n1881-1887 West State Road 84,\n\nBldg. 1 Unit 102, Fort Lauderdale,\n\nFlorida 33315\n\nUSA\n\nenquiries@omnisense-systems.com\n\nenquiries@omnisense-systems.com\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.omnisense-systems.com\u002F on February 18, 2021. The FDA has observed that your website offers a product for measuring human body temperature, specifically the Sentry MK4, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-191 in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Sentry MK4 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n• “From H1N1, MERS, Ebola and now COVID-19, our fever detection system have been the trusted solution to secure critical installations and national borders.” [Published on your website, https:\u002F\u002Fwww.omnisense-systems.com\u002F]\n\n• “Drawing on our proven performance of Sentry MK3, the system that protected many organizations and institutions from H5N1 to COVID-19, the Sentry MK4 is a culmination of more than a decade experience of developing a remarkable fever screening system.” [Published in the Sentry MK4 Brochure available on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\n\n• “At the forefront of pandemic defence, the Sentry MK4 Mass Fever Screening System stands guard against infectious diseases and viruses. Already deployed in commercial buildings, industrial plants, airports, hospitals, banks and other critical facilities, the Sentry MK4 is an essential security solution for any modern organization seeking to safeguard human assets and sustain business operations during a pandemic outbreak.” [Published in the Sentry MK4 Brochure available on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\n\nThe Sentry MK4 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce this product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS2. In addition, on March 13, 2020, the President declared a national emergency in response to COVID-193. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.omnisense-systems.com\u002F, includes statements that indicate that the Sentry MK4 is intended to scan multiple individuals simultaneously, including:\n\n• “Mass Fever Screening System” [Published in numerous places on your website, such as your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\n\n• “Sentry MK4 – Mass Fever Screening System scans, detects and tracks febrile persons with elevated skin temperature at any venue with large human traffic” [Published on your Sentry MK4 webpage, https:\u002F\u002Fwww.omnisense-systems.com\u002Fproducts\u002Fsentry-mk4-mass-fever-screening-system\u002F]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”4[ ] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613561 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nAndrew Southern\n\nInvisible Health Technologies\n\n520 West 27th St.Suite 407\n\nNew York, NY 10001\n\nandrew@invisiblehealthtechnologies.com\n\nAndrew Southern\n\nInvisible Health Technologies\n\n3250 NE 1st Ave, Suite 305\n\nMiami, FL 33137\n\nandrew@invisiblehealthtechnologies.com\n\nAdam Lim\n\nNative Instinct LLC\n\n3206 Canal Drive,\n\nBoynton Beach, FL 33435\n\nadam@nativeinstinct.co\n\n1As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.","Omnisense Systems Pte Ltd.","omnisense-systems-pte-ltd-613561-03042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fomnisense-systems-pte-ltd-613561-03042021","2026-10-26T08:09:38.012982+00:00","613561","2026-08-20T03:19:14.374+00:00",{"id":111,"raw":112,"subject":116,"body_html":117,"body_text":118,"firm_name":119,"letter_id":120,"created_at":121,"fei_number":20,"letter_url":122,"updated_at":123,"action_type":23,"case_status":66,"posted_date":124,"marcs_cms_no":125,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":126,"body_fetched_at":127,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":129,"medical_device_id":20,"response_letter_date":20},520,[113,114,115,11,116,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025\">Contec Medical Systems Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kun “James” Hu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Contec Medical Systems Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 112 Qinhuang West Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Economic and Technical Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Qinhuangdao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>066004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>Dear Kun “James” Hu:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>A. The cause of nonconformities identified are not adequately investigated.\u003C\u002Fp>\u003Cp>B. Corrective actions taken are not documented per your firm’s CAPA procedure.\u003C\u002Fp>\u003Cp>C. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\u003C\u002Fp>\u003Cp>D. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\u003C\u002Fp>\u003Cp>B. Test reports do not confirm that design outputs meet design inputs. For example,\u003C\u002Fp>\u003Cp>i. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\u003C\u002Fp>\u003Cp>ii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\u003C\u002Fp>\u003Cp>C. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\u003C\u002Fp>\u003Cp>The adequacy of the response dated July 1, 2025, cannot be determined at this time.\u003C\u002Fp>\u003Cp>While your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\u003C\u002Fp>\u003Cp>The adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\u003C\u002Fp>\u003Cp>Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003Cbr>Bram Zuckerman&nbsp;&nbsp;\u003Cbr>Director Office of Cardiovascular Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Marco Mu\u003Cbr>MID-LINK INTERNATIONAL CO., Ltd\u003Cbr>2219 Rimlang Drive, Suite 301\u003Cbr>Bellingham, Washington, US 98226\u003Cbr>Phone: 702-209-5185\u003Cbr>Fax: 360-925-3199\u003Cbr>Email: us.agent@mid-link.net\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKun “James” Hu\n\nRecipient Title\n\nCEO\n\nContec Medical Systems Co., Ltd.\n\nNo. 112 Qinhuang West Street\n\nEconomic and Technical Development Zone\n\nQinhuangdao Shi\n\nHebei Sheng, 066004\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nOctober 2, 2025\nDear Kun “James” Hu:\nDuring an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\nA. The cause of nonconformities identified are not adequately investigated.\nB. Corrective actions taken are not documented per your firm’s CAPA procedure.\nC. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\nD. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\nThe response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\nA. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\nB. Test reports do not confirm that design outputs meet design inputs. For example,\ni. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\nii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\nC. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\nD. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\nThe adequacy of the response dated July 1, 2025, cannot be determined at this time.\nWhile your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\nThe response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\n4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\nThe adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\nGiven the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\nYour firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBram Zuckerman\nDirector Office of Cardiovascular Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMarco Mu\nMID-LINK INTERNATIONAL CO., Ltd\n2219 Rimlang Drive, Suite 301\nBellingham, Washington, US 98226\nPhone: 702-209-5185\nFax: 360-925-3199\nEmail: us.agent@mid-link.net","Contec Medical Systems Co., Ltd.","contec-medical-systems-co-ltd-717941-10022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025","2026-10-26T08:08:17.623451+00:00","2025-10-28","717941","Kun “James” Hu","2026-08-19T16:12:22.676+00:00","VIA Electronic Mail","2025-10-02",{"id":131,"raw":132,"subject":116,"body_html":136,"body_text":137,"firm_name":138,"letter_id":139,"created_at":140,"fei_number":20,"letter_url":141,"updated_at":88,"action_type":23,"case_status":66,"posted_date":142,"marcs_cms_no":143,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":144,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":145,"medical_device_id":20,"response_letter_date":20},21920,[133,134,135,11,116,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-07T04:00:00Z\">10\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026\">Olympus Medical Systems Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951 Ishikawa-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@olympus.com\"> (b)(6)@olympus.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #729208\u003C\u002Fp>\u003Cp>October 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. White:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\u003C\u002Fp>\u003Cul>\u003Cli>Olympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\u003C\u002Fli>\u003Cli>Aomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\u003C\u002Fli>\u003Cli>Olympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\u003C\u002Fli>\u003Cli>Shirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\u003C\u002Fli>\u003Cli>Olympus Winter &amp; IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\u003C\u002Fli>\u003Cli>Gyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\u003C\u002Fp>\u003Cp>A Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Design Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\u003C\u002Fp>\u003Cp>a. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your \u003Cem>Risk Management Report\u003C\u002Fem> (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\u003C\u002Fp>\u003Cp>b. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated \u003Cem>Risk Management Report\u003C\u002Fem> (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_\u003Cem>Risk Management Report\u003C\u002Fem>) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility:\u003C\u002Fp>\u003Cp>i. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO\u003Csub>2\u003C\u002Fsub> lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\u003C\u002Fp>\u003Cp>ii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\u003C\u002Fp>\u003Cp>iii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\u003C\u002Fp>\u003Cp>iv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and \u003Cem>Traceability Activities\u003C\u002Fem> (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Nonconforming Product Violations – Brooklyn Park and Hinode facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 \u003Cem>Global NC Management\u003C\u002Fem> and GSOP‑00023 \u003Cem>Global CAPA Management\u003C\u002Fem>. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in \u003Cem>Global Nonconformance Management\u003C\u002Fem> GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\u003C\u002Fp>\u003Cp>b. At the Hinode facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 \u003Cem>Global Complaint Investigation\u003C\u002Fem> and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\u003C\u002Fp>\u003Cp>ii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Production and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to validate the heat sealing process for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in \u003Cem>Operational Qualification (OQ) Report\u003C\u002Fem> D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\u003C\u002Fp>\u003Cp>During the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from \u003Cem>Process Validation\u003C\u002Fem> GSOP-7.5-1 to \u003Cem>Global Process Validation\u003C\u002Fem> GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Universal Tray products and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\u003C\u002Fp>\u003Cp>ii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer SN01. The \u003Cem>OQ Report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010012) and \u003Cem>PQ Report for BP \u003Cstrong>(b)(4)\u003C\u002Fstrong> BM3025-E2W2 for 45cm packaging\u003C\u002Fem> (DN0010301) for this material and setpoints is for sealer \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealer or justification for equipment equivalency.\u003C\u002Fp>\u003Cp>In addition, your procedure \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem> GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, \u003Cem>Process Confirmation for Sterile Barrier Sealing\u003C\u002Fem>, and FM-7.4-3 REV AC, \u003Cem>Sterile Barrier Sealing Confirmation\u003C\u002Fem>, not aligning with GSOP-00002 REV AD, \u003Cem>Validation Program\u003C\u002Fem>, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\u003C\u002Fp>\u003Cp>iii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure \u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem> DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, \u003Cem>Control of Inspection, Measuring, and Test Equipment\u003C\u002Fem>, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB \u003Cem>Completing a Calibration Request Form\u003C\u002Fem>, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\u003C\u002Fp>\u003Cp>b. At the Hinode facility, your firm failed to adequately validate critical process parameters of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute and a higher set value of \u003Cstrong>(b)(4)\u003C\u002Fstrong> liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\u003C\u002Fp>\u003Cp>c. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\u003C\u002Fp>\u003Cp>d. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure \u003Cem>Peel Strength Test Method for Trays and Pouches\u003C\u002Fem> D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “\u003Cem>POWERSEAL MP: Tray Sealer Setup and Peel Test\u003C\u002Fem>” DN0044870 Rev AE states in \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure \u003Cem>Process Monitoring - Packaging Data Review\u003C\u002Fem> D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\u003C\u002Fp>\u003Cp>5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\u003C\u002Fp>\u003Cp>a. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\u003C\u002Fp>\u003Cp>This is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Corrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB \u003Cem>Quality Plans\u003C\u002Fem> to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\u003C\u002Fp>\u003Cp>ii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> and GWI-00014, Rev AB \u003Cem>CAPA Management Work Instruction\u003C\u002Fem> – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\u003C\u002Fp>\u003Cp>iii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\u003C\u002Fp>\u003Cp>c. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 \u003Cstrong>(b)(4)\u003C\u002Fstrong> to address wrinkles but did not investigate why \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified in initial validations. Wrinkle defects may create channels for microbial contamination.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\u003C\u002Fp>\u003Cp>d. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF \u003Cem>Global Corrective Action and Preventive Action Management\u003C\u002Fem> did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\u003C\u002Fp>\u003Cp>ii. Your procedures, \u003Cem>Quality Planning\u003C\u002Fem> QSP-5.5 Rev AL and \u003Cem>Quality Plans\u003C\u002Fem> GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The \u003Cem>Quality Management Review Presentation Template\u003C\u002Fem> GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\u003C\u002Fp>\u003Cp>8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. \u003Cem>Complaint Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. \u003Cem>Trending Attributes, Statistical Method, and Trending Rules\u003C\u002Fem> GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\u003C\u002Fp>\u003Cp>d. At the Aomori facility,\u003C\u002Fp>\u003Cp>i. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\u003C\u002Fp>\u003Cp>ii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Acceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. \u003Cem>Receiving Acceptance\u003C\u002Fem> GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to \u003Cem>Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B\u003C\u002Fem> DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\u003C\u002Fp>\u003Cp>Your inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the \u003Cem>FAI Inspection Request\u003C\u002Fem> for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, \u003Cem>Receiving Acceptance\u003C\u002Fem>, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Purchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility,\u003C\u002Fp>\u003Cp>i. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB \u003Cem>QAA Template for Component Suppliers\u003C\u002Fem> and GTMP-00022 Rev AB \u003Cem>QAA\u003C\u002Fem> \u003Cem>Template for Finished Device Suppliers\u003C\u002Fem> lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\u003C\u002Fp>\u003Cp>ii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA \u003Cem>Global External Product Qualification\u003C\u002Fem> lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\u003C\u002Fp>\u003Cp>iii. Section 3.5 of \u003Cem>First Article Inspection\u003C\u002Fem> GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures \u003Cem>Global Supplier Risk Improvement \u003C\u002Fem>GSOP-00045 Rev AB and \u003Cem>Global Supplier Risk Improvement with Action Plan\u003C\u002Fem> GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB \u003Cem>Global Supplier Risk Improvement\u003C\u002Fem> does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\u003C\u002Fp>\u003Cp>iv. Supplier A has not adequately validated their \u003Cem>Performance Qualification Report\u003C\u002Fem> PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD \u003Cem>Validation Program\u003C\u002Fem> and GWI-00112 Rev AA \u003Cem>Global Standards for External Product Qualification\u003C\u002Fem> for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\u003C\u002Fp>\u003Cp>c. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Records Violations – Brooklyn Park and Shirakawa facilities:\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\u003C\u002Fp>\u003Cp>a. At the Brooklyn Park facility, your firm's procedure, \u003Cem>Complaint Investigation Tiers and Investigation Activities\u003C\u002Fem> GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\u003C\u002Fp>\u003Cp>b. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\u003Cp>For example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\u003C\u002Fp>\u003Cp>Failure to address any violations of the FD&amp;C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&amp;C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\u003Cp>Your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>In addition, we also note the following comments:\u003C\u002Fp>\u003Cp>1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\u003C\u002Fp>\u003Cp>2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to \u003Cstrong>Kristina Donohue\u003C\u002Fstrong> at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS #729208\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: \u003Cstrong>Beckilyn Dorsey\u003C\u002Fstrong> at \u003Cstrong>Rebecca.dorsey@fda.hhs.gov.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Michael J. Hoffmann&nbsp;&nbsp;\u003Cbr>Director&nbsp;&nbsp;\u003Cbr>Office of Health Technologies 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Todd Brill, US Agent, Gyrus ACMI, Inc., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@Olympus.com\u003Cbr>Daniel S. Sampson, Senior Director of Operations, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Richard Reynolds, President, Olympus Corporation of the Americas, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Hiroaki Hosoi, President, Aomori Olympus, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Kota Ishibiki, President, Olympus Medical Systems Corporation \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Shinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Seiji Morishita, President, Shirakawa Olympus Co., Ltd., \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003Cbr>Carl A. Yallop, Vice President OSTE, SIS Operations &amp; ISC and Managing Director, EMEA, \u003Cstrong>(b)(6)\u003C\u002Fstrong>@olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nOlympus Medical Systems Corporation\n\n2951 Ishikawa-machi\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\n(b)(6)@olympus.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #729208\nOctober 7, 2026\nDear Mr. White:\nThe United States Food and Drug Administration (FDA) conducted the following inspections of your firm’s medical device facilities:\nOlympus Medical Systems Corporation, located at 2951 Ishikawa-Cho, Hachioji-Shi, Tokyo, JP 192-8507, FEI 3002807795, November 17, 2025, to November 21, 2025 (“Hachioji”)\nAomori Olympus Co., Ltd., located at 2-248-1 Okkonoki, Kuroishi-shi, Aomori, JP, 036-0357, FEI 3003995201, from November 4, 2025, to November 7, 2025 (“Aomori”)\nOlympus Medical Systems Corp. Hinode Plant, located at 34-3 Hirai, Hinode-Machi, Nishitama-Gun, Tokyo, JP, 190-0182, FEI 3003637092, from November 17, 2025, to November 21, 2025 (“Hinode”)\nShirakawa Olympus Co., Ltd., located at 3-1 Okamiyama, Odakura, Nishigo-Mura, Nishishirakawa-Gun, Fukushima, JP 961-8061, FEI 3002808148, November 10, 2025, to November 14, 2025 (“Shirakawa”)\nOlympus Winter & IBE Gmbh, located at Kuehnstrasse 61, Hamburg, DE 22045, FEI 3002807798, from November 10, 2025, to November 21, 2025 (“Hamburg”)\nGyrus ACMI, Inc. [dba Olympus Surgical Technologies (OSTA)], located at 9600 Louisiana Ave North, Brooklyn Park, MN 55445, FEI 3011050570, from October 6, 2025, to November 12, 2025 (“Brooklyn Park”)\nDuring these inspections, our investigators determined that your firm manufactures a variety of surgical and endotherapy devices, including but not limited to, hemostatic metal clips, sphincterotomes, cystoscopes, bronchoscopes, endoscopic distal covers, valves, and insufflators. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThe above-referenced inspections revealed that the devices manufactured at the Hachioji, Aomori, Hinode, Shirakawa, Hamburg, and Brooklyn Park facilities are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. This nonconformity includes issues across the referenced inspected facilities, resulting in the distribution of nonconforming devices and significant risks to patients.\nA Form FDA 483 (FDA 483), List of Inspectional Observations, was issued to the Aomori facility on November 7, 2025, the Brooklyn Park facility on November 12, 2025, the Shirakawa facility on November 14, 2025, the Hachioji facility on November 21, 2025, the Hinode facility on November 21, 2025, and the Hamburg facility on November 21, 2025. We received responses concerning our investigator’s observations noted on these FDA 483s from Robert A. Fryc, Director, Global Quality Compliance, External Regulatory Communications, Olympus Corporation of the Americas, dated December 22, 2025, February 13, 2026, March 30, 2026, May 28, 2026, and July 31, 2026. We address these responses (collectively referred to as “your firm’s response”) below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\nDesign Control Violations – Shirakawa, Aomori, Hamburg, and Hachioji facilities\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and validation shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g). For example,\na. At the Shirakawa facility, your firm failed to identify and control known catastrophic hazards in your risk management documentation and failed to validate the device design under actual or simulated use conditions for the UHI-4 insufflator. Catastrophic hazards, including air embolism, arrhythmia, and patient death, were identified through Health Hazard Assessments and complaint investigations associated with CAPA-201353; however, your Risk Management Report (DC00067142, dated November 6, 2025) did not reflect these hazards or ensure implementation of appropriate risk control measures, even after a confirmed patient death and Class I recall of UHI-4 units in 2023. Further, your design validation did not simulate actual or worst-case use conditions related to pressure sensor failure or inaccurate pressure measurements to ensure that the device would operate safely. As a result, devices distributed had design deficiencies that contributed to overpressure events during clinical use.\nThe adequacy of your firm’s response cannot be determined. Your response states that design-related deficiencies are being addressed through global CAPAs, including CAPA-204150 (design control) and CAPA-203525 (risk management), and that a traceability matrix for the UHI-4 will be developed to evaluate design requirements, verification, and validation. You also indicate that additional design verification and\u002For validation testing will be performed as needed and that potential design changes will be assessed by the design owner (Olympus Hachioji). However, these activities remain ongoing, and you have not provided objective evidence demonstrating that design validation deficiencies have been corrected or that revised validation activities adequately address identified risks, including overpressure conditions. Additionally, corrective actions have been deferred to global CAPAs and another facility, and no documentation has been provided demonstrating completion or effectiveness of these actions.\nb. At the Aomori facility, your firm failed to identify and assess known hazards in the risk management documentation and failed to establish risk control measures for manufacturing processes for the Sphincterotome. In your risk management report (E_V-KD_Risk Management Report_Rev.27), the corresponding risk line ID (KD-G158-00) identifies the potential patient harm as “Delay in Treatment” for complaints of deformed wires but fails to include the higher risk identified through analysis of Medical Device Reports of unintended cutting of blood vessels leading to patient bleeding. It also fails to identify any risk control measures for the manufacture of the wire for the Sphincterotome. Additionally, the risk management report (DC00609260_20250910) does not include the known hazard of failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes and does not include risk control measures for this hazard, which can lead to tissue damage and procedural complications.\nThe adequacy of your firm’s response cannot be determined at this time. Your firm has not provided an updated Risk Management Report (DC00609260_20250910) to address the hazard and implement risk control measures for failure of the Automated Optical Inspection system to detect nonconforming Sphincterotome products (KD-V400 Series) with burrs and flakes. Additionally, your firm has not provided an updated risk management report (E_V-KD_Risk Management Report) to address the risk of unintended cutting of blood vessels leading to patient bleeding and risk control measures for manufacture of the wire.\nc. At the Hamburg facility, your firm distributed the Continuous Flow Cystoscope (model WA22810A) with instructions for use (IFU) that claimed compatibility with the GreenLight PV ADDstat laser fiber component without conducting design validation testing to ensure compatibility under use conditions. This resulted in two recalls, RES 95584 and RES 98300, due to a risk of damage and\u002For overheating to the tip of the sheath when used together. Unrecognized sheath damage can result in tissue injury or parts of the sheath breaking off into the patient.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response should include a retrospective review of similar devices with IFU compatibility claims to ensure that they are supported by design validation activities to ensure compatibility under use conditions.\nd. At the Hachioji facility:\ni. Your firm distributed the BF-1TH190 bronchoscope with instructions for use (IFU) claiming compatibility with CO2 lasers without conducting design validation testing to ensure compatibility under use conditions. This resulted in a class I recall (RES 93052), due to a risk of endobronchial combustion if high-frequency cauterization is performed while supplying oxygen and\u002For the electrode section of the electrosurgical accessory is too close to the distal end of the endoscope. If endobronchial combustion occurs, the patient may suffer adverse events, including internal burns in their airway or lungs. The related CAPA did not evaluate compatibility claims for all endoscopes and lasers.\nii. Design validation activities were not conducted with an understanding of the actual operating conditions for the Evis Exera Video Imaging System, used with your firm’s endoscopes for processing images. For example, design validation did not consider the conductivity of the electrolyte when it contained dust and moisture, nor did it consider the impact over time of water entering the scope during cleaning. This caused signal transmission problems and resulted in a significant number of complaints and MDRs for image erasure, image transition problems, and poor-quality images.\niii. Your firm failed to complete design verification testing after implementing a change to the 0.2 μm Water Filter (Part MAJ-2318) to demonstrate that the device meets established design requirements and acceptance criteria. This water filter is used in your OER-Elite and OER-Mini Reprocessors for cleaning and high-level disinfection of your flexible endoscopes, their accessories, and endoscope reprocessor accessories. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, requires design verification or validation for all changes. However, ECR ER00006389 (dated December 11, 2024) shows verification testing was incomplete. Document MAJ-318_DC00429244 establishes the requirements and acceptance criteria for the product, including a filter service life of at least one month; however, design verification and validation records did not demonstrate that the filter has a service life of at least one month.\niv. Your firm’s design change control procedure, OMBS_S_7.3.9_01_001, and Traceability Activities (OMBS W_7.3.3_03_002) require documentation of design traceability matrices. However, you have not implemented design traceability matrices for the following products: Evis Exera III Bronchovideoscopes, Evis Exera III Video System Center, Evis X1 Video System Center, Single Use Reloadable Clip Applicator, Endoscope Reprocessor, Evis Exera III Duodenovideoscopes. Without design traceability matrices there is no documentation demonstrating that all design requirements, including safety requirements, were properly verified and validated.\nThe adequacy of your firm’s response for (i) through (iv) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nNonconforming Product Violations – Brooklyn Park and Hinode facilities:\n2. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm reworked and distributed nonconforming Vizishot 2 FLEX (19G) devices without adequate justification that the rework addressed the cause of the nonconformance. NCR-00038111 was opened on July 30, 2025, to disposition nonconforming material subject to recall (RES 97303) for the detachment of the Vizishot 2 Flex 19G needle [laser cut hypotube (LCH)] after reported complaints and MDRs, including where the device may have contributed to a patient death during explant surgery to recover the detached needle. Your firm reworked product under NCR-00038111 and dispositioned passing products using an automated vision system for release, stating this minimized impact on any product safety, efficacy, or performance of the product\u002Fmaterial. However, the primary CAPA for the LCH ejection issues had not identified a root cause, and there were two additional CAPAs open related to the observed complaints (pebax material degradation and sheath snap lock not engaging), indicating other potential contributing factors to nonconformances. Additionally, your firm circumvented the ship hold in place under the NCR by changing the manufacturing date during rework, which allowed the release of those units.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203864 was opened and determined that the issue was linked to global processes GSOP‑00022 Global NC Management and GSOP‑00023 Global CAPA Management. The process related aspects of this observation are being addressed separately under Global CAPAs, CAPA-203799 and CAPA-204047. Your response acknowledged in CAPA 203864 that the eleven lots of product noted in NCR-00038111 underwent rework outside of your procedures. You reinstated the ship hold and quarantined all Vizishot 2 FLEX product. You executed product removal activities separately for Vizishot 2 FLEX (19G) devices, including a global removal decision made on December 11, 2025, with a corresponding 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203864, CAPA-203799 and CAPA-204047.\nii. Your firm failed to control all nonconforming Shockpulse Lithotripsy generators that were subject to recall due to a miswired component (RES 98360). NCR-00000670 was opened on June 1, 2022, to scope the units affected under recall FY23-OSTA-05, for the miswiring of the Shockpulse generator. This NCR did not include a scope of all affected devices, including 2 lots containing 21 and 25 sub-assemblies, 9 finished units, and 2 service units. NCR-00046008 was opened to address the scoping nonconformance.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203777 was opened and the root cause identified the need to evaluate process gaps in Global Nonconformance Management GSOP-00022, specifically related to scoping methodology, alignment with HHA\u002FFCA teams, and decision-making during NCR and Stop Ship activities. A Global Ship Hold for miswired ShockPulse generator units was initiated on November 12, 2025, and the recall scope was expanded on December 9, 2025, with an 806 report submitted to FDA. Your firm’s corrective actions are ongoing under CAPA-203777 and CAPA-204047.\nb. At the Hinode facility,\ni. Your firm failed to control nonconforming MAJ 210 single-use biopsy valves when devices failed durability testing during the investigation of CAPA 203270. This CAPA was initiated after receiving multiple complaints reporting fractures of the device, including MDR reportable events. Although devices failed testing during the complaint investigation, your firm did not initiate a nonconformance for these out-of-specification device failures. Your firm eventually initiated NCR-00030581 for the complaint trend, but not for the identified testing failures.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm has initiated actions to address the MAJ-210 failures, including a shipping hold on the device, a plan to modify the device design, and an investigation into the complaint trend. Your response does not address why a nonconformance was not initiated when testing showed the product\u002Ffailed the durability specification per GSOP-00029 Global Complaint Investigation and was only later opened for the complaint trend. It is unclear if you plan to evaluate whether similar issues occurred for other devices and how you will ensure that complaint investigations result in CAPAs when appropriate.\nii. Your firm failed to control nonconforming devices with sterile barrier seal overlap defects that were found to impact seal integrity. A nonconformance (NCR-00025684) was initiated in March 2025 in response to observed defects in sterile seals from September 2024- January 2025. NCR-00025684 identified overlaps as a novel defect that was not included in your visual inspection procedures. CAPA-202690 concluded that because seal overlaps are a large wrinkle, inspectors trained to visually identify wrinkles would identify seal overlap defects. However, wrinkles and seal overlaps represent distinct sterile barrier defects. CAPA-203907 included a retrospective evaluation to demonstrate that existing visual inspection procedures were likely to identify seal overlaps, based on a blind test of engineers. However, this evaluation does not demonstrate that overlaps were identified at the time of the nonconformances.\nWe reviewed your firm’s response and determined that it is not adequate. You state that you are conducting an investigation and root cause analysis as part of your CAPA; however, this is in progress and the details of this investigation and corrective actions are not clear, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nProduction and Process Controls Violations – Brooklyn Park, Hinode, Aomori, and Shirakawa facilities\n3. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). For example,\na. At the Brooklyn Park facility,\ni. Your firm failed to validate the heat sealing process for the (b)(4) Tray Sealer. The (b)(4) Tray Sealer (P4001467-001 Gyrus ACMI SN:01) Operational Qualification using Universal tray sealing nests, documented in Operational Qualification (OQ) Report D8201348-002 Rev AB, does not contain passing results for the challenge conditions at the high and low setpoints. The validation was intended to cover low setpoints of 200°F, 100 PSI, and 2.0 seconds and high setpoints of 265°F, 125 PSI, and 7.0 seconds. However, visual results showed all failures at the lower setpoints and all failures at the high setpoints for the Universal and PKS Omni products. Only the nominal settings (232°F, 115 PSI, 4.5 seconds) showed passing results, which do not match your current production setpoints (253°F, 118 PSI, 4 seconds).\nDuring the inspection, you re-executed the validation (D8201348-002, Revision AC). While this validation passed seal integrity and seal strength requirements at high and low challenge conditions, the deviation section notes that trays sealed at low settings had spottiness in the seal and trays from high settings had warp that would cause rejection during 100% visual inspection, demonstrating that the process is not capable of consistently producing conforming product throughout the acceptable setpoint ranges.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203841 to address the root cause of inadequate process for assessing procedure revisions that resulted in earlier validations (Operational Qualifications) not being updated to meet regulatory requirements. Specifically, you plan to transition from Process Validation GSOP-7.5-1 to Global Process Validation GSOP-00002. Your response indicates that the retrospective re-validation of the heat sealers is complete except for the (b)(4) sealer for the Universal Tray products and the (b)(4) sealer for the Powerseal vessel sealing product line. You are currently assessing the risks associated with products manufactured and distributed using the (b)(4) Tray Sealer, which failed the retrospective re-validation. Regarding the retrospective revalidation of the (b)(4) heat sealer used for the Powerseal product line you have noted the OQ failed to meet seal width acceptance criteria as detailed in the protocol, however, the OQ\u002FPQ testing will not be repeated at the current process settings (temperature, time, pressure). You have indicated that you will communicate with FDA regarding any actions taken based on the outcome of the completed HHA for distributed product and failed retrospective revalidation.\nii. Your firm failed to validate the heat sealing process for tray material PN0003356 (45cm PETG Tray line) on the (b)(4) sealer SN01. The OQ Report for (b)(4) BM3025-E2W2 for 45cm packaging (DN0010012) and PQ Report for BP (b)(4) BM3025-E2W2 for 45cm packaging (DN0010301) for this material and setpoints is for sealer (b)(4), which was decommissioned and removed from use in 2023. Your firm did not provide documentation showing this material was validated on the (b)(4) sealer or justification for equipment equivalency.\nIn addition, your procedure Process Confirmation for Sterile Barrier Sealing GWI-0704-07 Rev AE dated April 4, 2024, allows for abbreviated validation runs for \"equivalent or duplicate equipment.\" This procedure allows for equipment with the same manufacturer and model number to be considered equivalent, regardless of the year purchased or any other modifications made to the sealers. There is no additional justification or testing required to establish equivalency of the equipment.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. You are in the process of implementing CAPA-203842 to address GWI-0704-07 REV AE, Process Confirmation for Sterile Barrier Sealing, and FM-7.4-3 REV AC, Sterile Barrier Sealing Confirmation, not aligning with GSOP-00002 REV AD, Validation Program, nor GSOP-7.5-1 REV BA, Process Validation. In addition, your response confirmed that the work instructions and form lacked objective evidence to justify equipment equivalency. You are in the process of completing a Health Hazard Assessment (HHA- FY26-071-A) to evaluate any risks associated with sterile barriers for distributed products.\niii. Your firm failed to operate your heat sealers at the validated setpoints used for the Powerseal vessel sealing products. Heat sealer numbers 19-11821 and 23-70915 are only calibrated for time at 5 seconds and 10 seconds, but the nominal setpoint is 3 seconds according to your procedure POWERSEAL MP: Tray Sealer Setup and Peel Test DN0044870 Rev AE. There is no documented justification on why this calibration is acceptable to demonstrate accuracy at the validated setpoint, or potential impact on packaging seal quality and sterile barrier integrity for the Powerseal products.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. For example, GSOP-7.18-1 REV AT, Control of Inspection, Measuring, and Test Equipment, does not ensure consistent implementation of calibration across the intended use range. Additionally, the supporting work instruction, GWI-0718-03 Rev AB Completing a Calibration Request Form, lacked sufficient clarity to implement the requirements of GSOP-7.18-1. Your firm plans to revise GWI-0718-03 to improve clarity, include a requirement to notify external calibration vendors of specification changes, and ensure calibration point selection is documented with clear rationale. The calibration request form (FM 7.18-1) will also be updated to provide traceability, reference the revised work instruction, and ensure alignment with validated set points. GSOP-7.18-1 will be updated to explicitly require calibration points to cover validated set points, document rationale for selected calibration points, and mandate re-evaluation of calibration points when validation parameters or process conditions change.\nb. At the Hinode facility, your firm failed to adequately validate critical process parameters of the (b)(4) to the heat sealing process. An Operational Qualification (OQ) for the heat sealing process for the MAJ-210 Single Use Biopsy valve was conducted in July 2024, after (b)(4) to the heat sealing packaging process to address seal wrinkle defects; however, the process parameters and validation are inadequate. The process parameter range shown in the Operational Qualification lists a lower set value of (b)(4) liters\u002Fminute and a higher set value of (b)(4) liters\u002Fminute, which is flawed because the \"lower\" limit exceeds the \"higher\" limit. The OQ documentation does not detail how the (b)(4).\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm completed an investigation and root cause analysis under CAPA-203908, and as a result, updated GSOP-00002 to provide instruction for how to identify process parameters that require control in a validated process. Your firm is also planning to conduct a review of all validated manufacturing processes in place at the facility to confirm that process parameters are adequately controlled.\nc. At the Aomori facility, your firm failed to validate the cleaning process for metal components used in the production of the HX-610 EZ Clip (hemostasis clip) made according to procedure DC00736661 to remove dirt or other particles. For example, the procedure doesn’t include defining and validating all critical process parameters with acceptable ranges including cleaning solution (type, concentration, temperature), immersion time, drying parameters, and visual inspection criteria.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm initiated a Global Ship Hold (ID.530) and CAPA 203781 as part of your corrective actions.\nd. At the Shirakawa facility, your firm did not adequately validate the testing process used in the production of UHI-4 Insufflation Unit where the results could not be fully verified by subsequent inspection and testing. For example, the software-driven functional testing process used to evaluate device performance was not adequately validated to ensure that it consistently produced devices meeting specifications in that it did not include appropriate test cases to demonstrate user requirements met acceptance criteria.\nThe adequacy of your firm’s response cannot be determined. Your response states that process validation deficiencies are being addressed through ongoing remediation activities and global CAPA efforts, and that validation activities are planned or underway to ensure processes consistently produce conforming devices. You have not provided objective evidence demonstrating that process validation activities have been completed or that affected processes have been validated, including validation protocols, reports, or data demonstrating that processes consistently produce conforming devices.\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). For example,\na. At the Brooklyn Park facility, your firm failed to establish adequate process monitoring to ensure validated sealing processes for the heat sealers used for the Powerseal vessel sealing and Miscellaneous Urology products continue to meet specifications throughout production. Per procedure Peel Strength Test Method for Trays and Pouches D5100327-001 Rev AL, the heat sealer for Powerseal products requires peel strength testing to be completed at the beginning and the end of a lot. The process monitoring does not demonstrate that the heat sealing meets specification throughout the manufacturing operations, nor does the process monitoring demonstrate the machine was fully set up and operational when heat sealing process for a lot occurs over multiple days. The DHR for Lot (b)(4) notes that the sealing took place over two days. However, the process monitoring was conducted according to the procedure and only had a single tray sealing sample for testing at the start of the lot on June 20, 2025, and at shutdown on June 23, 2025. Your firm’s procedure for set-up, “POWERSEAL MP: Tray Sealer Setup and Peel Test” DN0044870 Rev AE states in (b)(4) for the temperature to stabilize prior to use; however, there is no indication that this was done at the start of the second production day. This step is identified as critical, according to your firm’s Symbol Index in DN0044870. Additionally, the sealing procedure, D5100327-001, is also used for the Miscellaneous Urology line and the Cutting Forceps line and requires the pull strength testing be performed at the beginning and end of every day. Your firm has not assessed whether critical parameters remain in control during all production activities, including after equipment set up on subsequent production days and when processing multiple products with different configurations on the same day. Finally, your procedure Process Monitoring - Packaging Data Review D0300188-001 Rev AK states in section 4, step 2 that a process control analysis should include an evaluation of lower and upper control limits. However, these limits are not currently calculated by your firm, and the upper and lower bound specifications are used instead. There is no documented statistical rationale for this decision.\nThe adequacy of your response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203867 to capture corrective actions such as the retraining of employees on process monitoring requirements to include peel testing at the beginning and end of each lot for the affected product lines. You note that you will revise FM-7.5-10, Control Plan requirements with risk assessments to define and align appropriate sample sizes and frequency monitoring. Ongoing actions as part of CAPA-203867 include defining, establishing, and implementing risk-based requirements in Process Controls, GSOP-7.5-4, for ongoing validated process monitoring. You have not performed an assessment of potentially affected units in the field and any ongoing post market monitoring to assess any risks of commercially distributed product. Your firm plans to review all process monitoring plans subject to D0300188-001 Rev AK, to ensure that such plans include justified control limits as well as specification limits. Your firm has not implemented calculated control limits.\n5. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example,\na. At the Hinode facility, your firm failed to revalidate the heat sealing process after implementing process changes in response to seal defects in the MAJ-1555. CAPA-202690 identified the cause of the overlap defects as a misalignment of the bag surfaces when the bag enters the sealing operation to create the sterile barrier. To address this issue, your firm added a sensor to control opening and closing of the extraction arm and receiving arm, which impacts bag surface alignment during sealing. Operational qualification or performance qualification was not performed after these changes to validate that the modified process continued to meet specifications and quality attributes.\nThis is a repeat violation from our 2023 Warning Letter issued to the Hinode facility.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Following an investigation and root cause analysis under CAPA-203919, your firm revised GSOP-00002 to provide additional instruction on how to assess whether a manufacturing change triggers revalidation of the manufacturing process, and your firm established the guidance document GREF-00197 to provide revalidation guidelines. The verification of effectiveness of these actions is not yet complete, and it is unclear whether concerns with process validation have been adequately addressed for other products subject to sealing at your facility. Your response stated that all seals are subject to visual inspection and, therefore, any nonconforming seals would be detected prior to release; however, visual inspection is not a substitute for adequate process validation.\nCorrective and Preventive Action Violations – Brooklyn Park, Shirakawa, Hinode, Hachioji, Hamburg, and Aomori facilities:\n6. Failure to identify the action(s) needed to correct and prevent the recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3). Specifically,\na. At the Brooklyn Park facility,\ni. Your firm failed to identify corrective actions that address the full scope of multiple Line Clearance Control nonconformances on the Miscellaneous Urology Production Line. CAPA-201354 was opened on August 31, 2023, and included automated verification steps and automated inspections on the lines. However, the CAPA only included implementing the automated verifications for the Soltive laser fibers and did not address corrections for any of the other products made on the Miscellaneous Urology production line, including nonconformances associated with missing syringes in the Irri-Flow line or incorrectly labeled RB Electrodes, as listed in the CAPA Initiation Information.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened and is developing an action plan for CAPA-203705, which revealed that the Miscellaneous Urology product line lacks sufficient process controls and robust automation and further noted that this technical gap creates a potential for the recurrence of nonconformances. While a quality plan was developed per GSOP-5.5-1 Rev AB Quality Plans to address the remaining implementation requirements for this line, the execution of these corrective actions occurred outside of the formal CAPA framework and did not include verification of effectiveness.\nii. Your firm failed to identify corrective actions to address ongoing Supplier Quality Performance rate failures for Vizishot endoscopic aspiration needle slider components. CAPA-202086 was opened on August 15, 2024, to address the Supplier Quality Performance rate (SQ3) not meeting the KPI objective for more than three months in a row. The investigation identified root causes related to supplier capability gaps, including inadequate manufacturing processes, insufficient purchase order review, and delayed drawing revisions. A separate NCR-00028865 due to a SQ2 KPI signal (Part Failure Rate) was escalated to CAPA-202086 on May 20, 2025. CAPA-202086 was closed on October 16, 2025, with no corrective or preventive actions taken, and the SQ3 KPI was eliminated without addressing the underlying quality problems or providing a rationale for no action taken.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203869 confirmed that the early closure of CAPA-202086 occurred because GSOP-00023, Rev AF Global Corrective Action and Preventive Action Management and GWI-00014, Rev AB CAPA Management Work Instruction – Agile did not clearly define requirements for early closure rationale or verification of linked records. An action plan is being developed but has not yet been implemented for CAPA-203869.\niii. Your firm identified a root cause for the blue ring on the Powerseal vessel sealing device detaching from the rotation knob during use (operator error during assembly) but failed to implement corrective actions consistent with that root cause. CAPA-200547 was opened on July 22, 2022, for the detachment, which resulted in a recall (RES 90788). The CAPA found the root cause was an operator error during assembly and not the out of specification supplier component originally documented in the HHA FY23-OSTA-07. However, the scope of corrections for the recall were based on supplier component lots and the scope was not expanded to include all devices assembled during the period when the operator error occurred, allowing potentially defective devices to remain in distribution.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm opened CAPA-203868 and noted that the Health Hazard Assessment (HHA) and Field Corrective Action (FCA) for CAPA-200547 were not reassessed after the identified root cause changed, as procedure GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not define requirements for re-evaluation when new investigation findings modify the identified failure mode. Your firm indicated that since the process is shared among sites, the process related aspects of this observation are being addressed separately under Global CAPA-203799. An action plan is being developed but has not yet been implemented for CAPA-203868.\nb. At the Shirakawa facility, your firm failed to identify corrective actions needed to correct and prevent the recurrence of known quality problems associated with the UHI-4 insufflation system. CAPA-200872 identified pressure sensor failures as the root cause of front panel display issues; however, you relied on prior corrective actions (SCAR-Shirakawa-152-06) and concluded that the risk remained acceptable despite 325 complaints. Your firm failed to implement adequate corrective actions to address supplier control failures, complaint trending deficiencies, and design and risk management process gaps that allowed these repeated failures. As a result, your supplier control processes failed to prevent defective components from entering production and your quality system failed to detect and escalate recurring defects.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response noted planned corrective actions, including reliance on global CAPA procedures (GSOP00023) and proposed improvements to complaint trending, supplier controls, and risk management processes. You indicated that CAPA deficiencies continue to be addressed through ongoing local and global CAPAs and that you have initiated additional CAPAs (e.g., CAPA-203879, CAPA-203856, CAPA-203877).\nc. At the Hinode facility, your firm’s CAPA procedures failed to ensure that corrective actions addressed the root causes and prevented recurrence. Between October 2022 and September 2025, three CAPAs (CAPA-200736, CAPA-201399, CAPA-203398) were opened for wrinkle defects in sterile barrier seals across five products (MAJ-2315, MAJ-1555, MAJ-209, MAJ-210, MAJ-287). Each CAPA identified inadequate process validation as a contributing factor, yet none implemented corrective actions to address the underlying validation methodology deficiency that allowed critical process parameters to be missed. For example, CAPA-203398 identified the root cause as \"Method Inadequate validation\" but did not implement corrective actions to address the validation failure. CAPA-201399 identified wrinkles across multiple products but concluded that inspection would remove nonconforming product, without implementing corrective actions to the validated processes producing defects. CAPA-200736 (b)(4) to address wrinkles but did not investigate why (b)(4) identified in initial validations. Wrinkle defects may create channels for microbial contamination.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your firm characterized the pattern of recurring CAPAs for seal defects as representative of continuous improvement, citing decreases in defect rates, and your firm characterized the sealing processes as “under control”. However, ongoing nonconformances were initiated for wrinkles even after CAPAs were initiated. Your responses do not appear to address why your CAPA process allowed the same problem to require three separate CAPAs over three years without implementing corrections to the validation methodology.\nd. At the Hachioji facility, your firm failed to identify corrective actions for CAPA 201212, initiated June 20, 2023, in response to an FDA Additional Information request related to a patient death following use of the Evis Exera III Bronchovideoscope. Your CAPA documented that your firm failed to conduct design verification for use conditions and accessory compatibility claims in your IFU; however, no corrective actions were taken to address these design control deficiencies and the suspension of shipping was lifted on July 28, 2023. Your investigation revealed that your firm received 210 similar complaints and your investigation was not completed until November 14, 2025, over two years after CAPA initiation and your decision to continue shipping the devices.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\n7. Failure to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example,\na. At the Brooklyn Park facility,\ni. Your firm implemented actions to address root causes of a Vizishot II component mix-up without classifying them as corrective actions and verifying their effectiveness. CAPA-203041 was opened on June 30, 2025, for the use of the 21G slider components instead of the 22G on the Vizishot II NA-U401SX-4022 line. The Early Closure memo states that “operators were retrained on the line clearance procedure GWI-0705-16 and (b)(4)” and “the (b)(4) was modified to restrict access to the sides…”. Neither of these actions were considered a corrective action, nor was a verification of effectiveness conducted to ensure these actions prevented recurrence of the component mix-up.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203041 was prematurely closed because actions taken under the NCR were misclassified as corrections, even though they addressed root-cause-level factors that required corrective actions and verification of effectiveness (VOE). GSOP-00023 Rev AF Global Corrective Action and Preventive Action Management did not explicitly distinguish correction from corrective action within the CAPA workflow, which contributed to the omission of VOE. Your firm also indicated an action plan is being developed but has not yet been implemented for CAPA-203705.\nii. Your procedures, Quality Planning QSP-5.5 Rev AL and Quality Plans GSOP-5.5-1 Rev AB, have not adequately defined when quality plans contain corrective or preventive actions and should contain a verification that changes are effective and do not adversely affect devices. These procedures do not adequately define the difference between a quality plan and a corrective or preventive action. Additionally, during the inspection your firm had 54 quality plans open, including multiple plans intended to address backlogs in the complaint system and late MDRs. These quality plans directly address deficiencies in your quality system and are also being referenced within and in conjunction with CAPAs addressing the same issues.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203836 determined that the current procedures lack defined criteria for determining when a Quality Plan is not appropriate and a CAPA is required and does not require oversight to ensure appropriate use and completion tracking of Quality Plans. The Quality Management Review Presentation Template GTMP-00077 was revised to require that quality plans be reviewed as part of the Quality Management Review process. The scope of affected quality plans that lacked VOE was not provided. An action plan is being developed but has not yet been implemented for CAPA-203836.\nb. At the Shirakawa facility, your firm failed to verify that corrective actions implemented for overpressure events for the UHI-4 Insufflator were effective in preventing recurrence. For example, CAPA-200872 (opened February 2023) relied on prior corrective actions related to pressure sensor failures and concluded that these actions were effective without demonstrating that they prevented recurrence of similar defects or adequately mitigated risk in distributed devices. CAPA-201353 (opened August 2023) was subsequently opened to address overpressure events associated with the UHI-4 insufflation system only after significant adverse events occurred, including cardiac arrest and possible gas embolism, and resulted in a Class I recall (RES 92932). Your CAPA activities did not demonstrate that corrective actions were verified or validated to ensure effectiveness in preventing recurrence of overpressure-related failures.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Several CAPAs remain open, and you have not demonstrated that corrective actions have been verified or validated to ensure effectiveness or to prevent recurrence of similar defects, including overpressure-related failures.\n8. Failure to analyze processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example,\na. At the Brooklyn Park facility, your firm is using statistical methods for complaint trending without a documented rationale for the appropriateness of those methods. Complaint Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA defines your complaint quality data analysis method of using median values and recalculating control limits each month. During the inspection your employees noted the calculations used were originally chosen in 2020, due to COVID-related data irregularities. However, you acknowledged that your firm does not still see these data irregularities and confirmed your firm has not documented a re-assessment or other justification for why this analysis method is still appropriate. The use of median values and monthly recalculation of control limits (that may not be appropriate for post-COVID data) may mask trends or delay detection of increasing complaint rates, potentially allowing serious device problems to persist undetected.\nThe adequacy of your firm’s response cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. CAPA-203873 determined that Olympus lacks a global procedure or guidance for statistical techniques, resulting in the absence of defined expectations for the consistent implementation of statistical methods. An action plan is being developed but has not yet been implemented for CAPA-203873.\nb. At the Shirakawa facility, your firm did not adequately analyze quality data, including complaints and adverse event information, to identify causes of quality problems. For example, you received a high volume of complaints related to pressure sensor defects and front panel failures associated with the UHI-4 insufflation system (including 325 complaints between November 2020 and October 2022), yet you did not appropriately trend or escalate these data to identify a cause or initiate CAPA in a timely manner. Additionally, you were aware of pressure sensor defects as early as 2018–2021 but did not reassess risk or investigate the increased occurrence of these defects in distributed devices. A CAPA was not initiated until FDA inquiry, indicating that your quality system did not effectively analyze available data sources, including complaints, supplier information, and risk management records.\nWe reviewed your firm’s response and determined that it is not adequate. Your response states that CAPA deficiencies are being addressed through a combination of local and global CAPAs, including local CAPA-203879, CAPA-203856, CAPA-203850, and global CAPA-203789, CAPA-203525, and CAPA-204150. You indicate that updates to procedures, including GSOP-00023 (CAPA), GSOP-00033 (complaint trending), GSOP-00069 (supplier quality agreement), and GSOP-00079 (supplier corrective action), have been implemented or are in progress. You also state that retrospective reviews of complaint data and supplier corrective action requests have been conducted. Several CAPAs remain open and root cause investigations and corrective actions are ongoing. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific deficiencies have been adequately addressed. Your response further confirms that complaint trend signals were not adequately identified and that supplier-related defects were not appropriately evaluated for field impact at the time they were identified. You have not provided sufficient objective evidence demonstrating implementation or effectiveness of corrective actions, including completion of investigations, verification of corrective actions, or sustained improvements to your CAPA system.\nc. At the Hamburg facility, your firm’s complaint trending failed to include all complaints as required by your procedure. Trending Attributes, Statistical Method, and Trending Rules GREF-00157 Rev AA, section 4.4.2 states “trending will be based on the value of monthly data (i.e. actual number of open complaints per month).” However, trend signal information (TS-1224-WA50042A) for your video telescope (model WA50042A) only includes the trending of MDR reportable complaints and does not include non-reportable complaints.\nWe reviewed your firm’s response and determined that it is not adequate. Your response did not include an assessment of how the lack of trending of non-reportable complaints may impact already distributed product. For example, if the complaints reveal quality problems that may require correction or removal to address.\nd. At the Aomori facility,\ni. Your firm failed to adequately analyze quality data to identify causes of nonconforming product. CAPA-201434, which was initiated to address reports of deformed wires for the Single Use 3-Lumen Sphincterotome, incorrectly identified the root cause as “shortcomings in work procedures” during outsourcing, failing to recognize inadequate design transfer to production specification as the actual cause. Per the CAPA scope, the corrective actions only applied to products distributed to the Japanese market and were not implemented for devices distributed to the U.S. market. It was noted during the inspection that the CAPA task (Task 10012651) assigned to correct the manufacturing process for products destined for the U.S. was cancelled because the products are subject to FDA 510(k) and it would have taken longer to implement the changes which would “prolong the period until the CAPA closes.” Your firm received over 1000 complaints for this device failure, including 24 MDR reportable events.\nii. Your firm failed to conduct a timely and adequate analysis of complaint data related to potential causes of nonconforming product for the Thunderbeat 5 mm Front-actuated Grip Type S. Your firm received over 1900 complaints between September 2021 and September 2024, including 1583 that were MDR reportable. CAPA-201438 was initiated on October 18, 2023, but no action was taken as the Health Hazard Evaluation was canceled on January 31, 2024, because it was deemed not necessary based on complaint incident rates and without considering the potential harm to patients. A recall (RES 95950) was initiated on November 25, 2024, over a year later.\nThe adequacy of your firm’s response for (i) and (ii) above cannot be determined at this time. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness.\nAcceptance Activities Violations – Brooklyn Park and Shirakawa facilities:\n9. Failure to establish and maintain procedures for acceptance of incoming product, as required by 21 CFR 820.80(b). For example,\na. At the Brooklyn Park facility, your firm failed to conduct statistical calculations required to demonstrate lot acceptability in accordance with your procedure. Receiving Acceptance GSOP-7.11-1 Rev AT uses a variable sampling plan for receiving inspection of part number 0000315-TAB, according to Inspection Procedure for 0000315-TAB JAW ASSEMBLY, MACHINED, INNER, POWERSEAL CURVED JAW B DN0040655 Rev AE. However, your receiving inspection for each length of this part (PN 0000315-001, 0000315-002 and 0000315-003) does not include calculation of your standard deviation, kLSL, and kUSL as required by GSOP-7.11-1. Additionally, your acceptance procedure for Powerseal Curved Jaw B only includes a specification for sample calculation for dimension 9 but does not document a calculation of the maximum standard deviation (MSD) for any other dimension as required. Finally, your Supplier D also uses the sampling plan, but does not provide you with their standard deviation, kLSL and kUSL calculations. The calculations for standard deviation, lower controls limits and upper control limits are part of the variable sampling plan that demonstrate the acceptability of the lot.\nYour inspection procedure also allows for CMM measurements to be re-tested by another inspector if they do not pass initially. This was done for 8 of the 10 samples in the FAI Inspection Request for part number 0000315-002, dated March 20, 2025. The only rationale recorded was \"Believed fixture incorrect.\" Our inspection also found that retesting had occurred on all of the most recent receiving records for all sizes of the 000315-TAB. Part Number 0000315-001 was inspected on October 23, 2025, and the record includes failing CMM results for 5 of the 10 parts, as well as the retested data, but the parts were accepted into inventory. When our investigator communicated this to your employee, it was noted that this lot was accepted by mistake and NCR-00048701 was opened to contain the nonconforming material.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 was opened to capture corrective actions and noted that GSOP 7.11-1 Rev. AU, Receiving Acceptance, and the inspection procedures did not define the statistical requirements, resulting in incomplete evaluation of incoming product and acceptance of parts without proper statistical justification. Your response noted that you have updated the inspection procedures for all parts subject to ANSI\u002FASQ Z1.9 to require inclusion of sample size rationale for critical dimensions and to ensure that data is provided by their suppliers. Your firm plans to conduct a retrospective review of inspection records from the past 2 years for failed dimensions without a record of appropriate retest or passing results. Based on the results of the review you will take appropriate action; however, it is not clear what those actions would include, nor if the actions will include a risk assessment for product that has been distributed.\nb. At the Shirakawa facility, your firm failed to identify defective components used in the UHI-4 insufflation system during acceptance activities. For example, defective pressure sensor components were not identified through incoming inspection or acceptance testing prior to use in manufacturing. As a result, nonconforming components were incorporated into finished devices, contributing to reports of device malfunctions and adverse events received by your firm.\nThe adequacy of your firm’s response cannot be determined. Your corrections remain ongoing, and you have not yet provided objective evidence demonstrating completion or effectiveness. Your response states that improvements to incoming acceptance activities will be implemented as part of broader corrective actions, including updates to ensure that purchased materials meet specifications. However, you have not provided sufficient detail demonstrating that revised acceptance activities have been implemented or are effective in detecting nonconforming components.\nPurchasing Controls Violations – Brooklyn Park, Shirakawa and Hamburg facilities:\n10. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product, and services conform to specified requirements, as required by 21 CFR 820.50. For example,\na. At the Brooklyn Park facility,\ni. Your firm’s supplier controls procedure (GQS-00013) does not ensure that supplied product that cannot be fully verified by subsequent inspection and test is validated with a high degree of assurance and conforms to specified requirements. On December 4, 2023, your firm issued SCR-0000649 for an increased rate of complaints for broken welds in the ESG PK Cutting Forceps (model PK-CF0533), occurring in the supplied bottom and top jaw assemblies (part numbers P5700259-001 and P5700260-001, respectively). Supplier A determined the cause of the weld breaking was a sub-supplier, Supplier B. In SCR-0000649, Supplier A documented that Supplier B stated the welding process \"could not be controlled or validated.\" Your firm established increased inspection rather than requiring validation or changing suppliers. This complaint trend resulted in a recall (RES 93842) in December 2023. This unvalidated welding process has resulted in weld failures during patient use, creating risk of foreign bodies in patients assessed at Critical (S4) severity and High (S5) probability. Similar welds are also performed by Supplier B for your Halo and Cutting Forceps. Approximately 4,600 units with similar unvalidated welds have been distributed. During the inspection, your firm initiated an NCR and a Global Ship Hold.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened to address the failure to ensure welding performed by the supplier was validated. The CAPA root cause investigation identified that the QAA template used to finalize the Supplier Agreement back in 2014 did not incorporate process validation requirements for suppliers and their Sub-Tier suppliers. Moreover, the Global QAA templates GTMP-00021 Rev AB QAA Template for Component Suppliers and GTMP-00022 Rev AB QAA Template for Finished Device Suppliers lack specificity on sub-tier control for process validation. All impacted product remains on Global Ship Hold (ID 476), and you have halted the manufacture of affected product. The FCA board reviewed and decided to conduct a removal of the impacted products. Your response stated you would submit a Correction and Removal report in compliance with 21 CFR Part 806 requirements. Although an expansion of the recall is being performed, it has been over 2 years between awareness (December 4, 2023) and recall decision (February 3, 2026). Your firm has not explained the delay or assessed patient harm during this period.\nii. Your firm accepted failing process capability data after components were remeasured without justification. SCR-0000166 was issued to Supplier C for out of specification components. The investigation led to two design changes to the mating parts used in the Powerseal vessel sealing device: the blue ring (part PN0013810) and the overmolded rotation knob (part PN0013804) and resulted in a class II recall (RES 90788). You accepted first article inspection that included Supplier C “Validation Documents Submission” where parts were remeasured with passing results, “Ppk’s for Cav 2 on PQ1 was right at 1.39 and PQ2 was 1.36 failing the Ppk requirement per protocol of 1.39. 2 parts were remeasured and Ppk came into requirement.” There is no justification for why these remeasurements were considered appropriate.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203872 is ongoing, and the root cause investigation identified that the supplier procedure permitted data remeasurement without documented justification and did not define requirements for documenting the rationale or controls associated with remeasurement activities. In addition, GSOP-00086 Rev AA Global External Product Qualification lacked requirements for justification of remeasurement. Your firm’s response notes that you have planned the process to requalify Supplier C against new global procedure requirements by March 27, 2026, including a new Quality Agreement. The impact on released product has not been evaluated since this will involve the remeasurement at incoming testing after you have updated GSOP-00086 that governs the conditions and permissibility for remeasurement. Your firm has not provided interim results or identified how many additional components may be affected. Your response should also include a retrospective review of similar supplier processes that pose a potential for patient safety risk.\niii. Section 3.5 of First Article Inspection GSOP-7.11-2 Rev AG, allows suppliers on risk improvement plans with documented quality concerns to conduct first article inspections without additional verification by your firm. For example, Supplier D has been on a risk improvement plan since January 21, 2025, but a \"Supplier conducted FAI\" for part number 0000315-002, delivered on or before March 5, 2025, and used in the Powerseal vessel sealing device. The process is currently controlled by the two procedures Global Supplier Risk Improvement GSOP-00045 Rev AB and Global Supplier Risk Improvement with Action Plan GWI-00002 Rev AB. Despite the supplier providing out-of-specification components and being on a supplier risk improvement plan, your firm failed to consider the appropriateness of the supplier performing first article inspection measurements following a design change or when implementing a new component.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203866 identified that GSOP-00045 Rev AB Global Supplier Risk Improvement does not require evaluation of internal inspection plans when supplier risk improvement plans are issued or revised in response to changes in part failure rate. Additionally, the procedure lacks defined linkage between supplier risk improvement plans and corresponding receiving inspection requirements. It is not clear from your response whether there is nonconforming product in the field associated with suppliers who are on a heightened inspection status or risk improvement plan and who conducted their own supplier first article inspections.\niv. Supplier A has not adequately validated their Performance Qualification Report PQR-10774 Rev A for part number P5700138-001, used to support the weld tensile strength in your legacy Cutting Forceps. According to your firm’s Engineer, the worst-case weld is considered the shortest weld of the group, as the welds all have to meet a minimum weld pull strength of 30 lbs. However, part P5700138-001 has a weld length specification of 0.10 ± 0.02 inches, while parts P5700211-002 and P5700210-002 have a shorter weld length specification of 0.081 ± 0.02 inches.\nWe reviewed your firm’s response and determined that it is not adequate. CAPA-203871 was opened and a Health Hazard Assessment (HHA) FY26-062 was conducted to evaluate potential field action. On February 3, 2026, the FCA board reviewed and decided to conduct a removal of the impacted products in the Cutting Forceps product line (RES 98454). Olympus completed the review of validations for Supplier A to determine conformance with Global GSOP-00002 Rev AD Validation Program and GWI-00112 Rev AA Global Standards for External Product Qualification for worst-case trials with documented rationale. The review determined that three (3) components manufactured by Supplier A require additional process validation. The review, however, was limited to products with an active production schedule. Products that have reached end-of-life and are in the process to be discontinued were excluded from the scope (jaw assemblies, ESG Cutting Forceps, Halo, Everest 5mm Cutting Forceps, and PKS Cutting Forceps). It is not clear from your response whether there is product within expiry date that is still in commercial distribution. Your firm will complete a review of applicable supplier-manufactured components documentation, through collaboration with suppliers to identify potential validation gaps.\nb. At the Shirakawa facility, your firm did not adequately control suppliers to ensure that components used in the UHI-4 insufflation system met specified requirements. For example, pressure sensor defects associated with supplier-provided components were identified; however, your supplier control processes did not prevent nonconforming components from being incorporated into finished devices. Your CAPA investigations did not adequately evaluate why supplier controls were ineffective or ensure that appropriate corrective actions were implemented to prevent recurrence of similar supplier-related defects. Root cause analysis identified gaps in supplier change control procedures and audit processes, including lack of mechanisms to verify supplier changes against specifications.\nThe adequacy of your firm’s response cannot be determined. Your response states that supplier control deficiencies are being addressed through local and global CAPAs, including CAPA-203856 and CAPA-203789, and that supplier oversight processes will be enhanced through updated supplier quality agreements and risk-based supplier requalification activities. You also indicate that procedures, including GSOP-00079, have been updated to require assessment of field impact for supplier-related defects. However, investigations into supplier-related root causes remain ongoing, and corrective actions have not been fully implemented. Additionally, you indicate that certain local CAPAs will be closed early and that corrective actions will be addressed under global CAPAs, which limits the ability to assess whether site-specific supplier control deficiencies have been adequately addressed. You have not provided objective evidence demonstrating that revised supplier controls are effective in preventing recurrence of nonconforming components.\nc. At the Hamburg facility, your firm failed to ensure that purchased services conform to specified requirements. Your firm hired HCL Technologies as part of “(b)(4)” to reduce the backlog of complaint investigation and closures; however, your firm did not evaluate HCL Technologies on the basis of their ability to provide contract services to meet specified quality requirements, including their ability to provide qualified staff to perform quality assurance responsibilities. Your firm’s contract services included approximately (b)(4) temporary personnel to investigate and close complaint files. Your firm was unable to demonstrate that the contract personnel received product specific training.\nWe reviewed your firm’s response and determined that it is not adequate. Your firm initiated CAPA-204033 and CAPA-204034. Your firm indicated that your root cause investigation determined that there was no central governance defining shared services requirements within the Quality Management System (QMS) and that as a result, roles and responsibilities between Legal Manufacturers, Global QMS functions, and shared service owners were not consistently defined or understood, leading to fragmented accountability for end-to-end oversight. Your firm is developing a corrective action plan; however, you have not provided corrective actions demonstrating how you will ensure contract personnel are qualified and trained in the services they will perform.\nRecords Violations – Brooklyn Park and Shirakawa facilities:\n11. Failure to review, evaluate and investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, as required by 21 CFR 820.198(c). For example,\na. At the Brooklyn Park facility, your firm's procedure, Complaint Investigation Tiers and Investigation Activities GWI-0809-10 Rev BB, does not require investigations to be completed on complaints in investigation Tier 3. For example, complaints C22097460, C22184070, C22248777, C22249599, C22259835, C22279317, C22332770, and C22387391 all state in the investigation summary that the complaints are “non-PAE, Tier 3 codes. No investigation is required,” in the “Evaluation Result” section (PAE stands for potential adverse event). There is no documentation of a complaint investigation or reference to where an investigation for this failure has previously been investigated or other similar rationale for why this investigation is not required. Lack of investigation only allows trending on this subset of complaints based on date of receipt and device model. After transitioning to your current Trackwise system in November 2024, you indicate you no longer use a tier system; however, your trending is based on 24 months of historical data which is still limited by the lack of investigation results on potential device performance issues.\nWe reviewed your firm’s response and determined that it is not adequate. Your response does not address the failure to investigate complaints.\nb. At the Shirakawa facility, your firm failed to adequately investigate complaints involving serious adverse events to determine whether device malfunction contributed to the reported outcomes. For example, complaints associated with UHI-4 insufflation systems, including reports of overpressure events and serious adverse outcomes such as cardiac arrest and possible gas embolism, were not fully evaluated to determine whether device malfunction contributed to the reported events. Your complaint investigations did not consistently incorporate available device performance data to determine whether the device met specifications during use. For example, complaint CN-249953 reported a death due to gas embolism during use and included the device event log retrieved by the Field Service Engineer; however, this log was not reviewed as part of the investigation.\nWe reviewed your firm’s response and determined that it is not adequate. You state that complaint handling and trending processes have been improved through implementation of GSOP-00033 and that retrospective reviews of complaint data have been conducted to assess whether complaint signals were appropriately escalated. You also indicate that CAPA-203879 was initiated to address missed complaint trend signals. However, CAPA-203879 and related investigations remain ongoing, and you have not provided sufficient objective evidence demonstrating that complaint investigations are comprehensive or that systemic issues are consistently identified and escalated.\nMedical Device Reporting (MDR) Violations\nOur inspection at your Hamburg facility also revealed that your firm’s resection sets are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n12. Failure to report the information required by 21 CFR 803.52 in accordance with the requirements of 21 CFR 803.12(a), no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that the firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\nFor example, the information included in Complaints CN-182867 and CN-184790 reasonably suggests that your firm’s resection set malfunctioned (e.g., broken ceramic insulation) while in use. A serious injury MDR 2951238-2019-00404, submitted by your firm on February 1, 2019, documents a serious injury resulting from the same malfunction involving the same device. That malfunction would be likely to cause or contribute to a death or serious injury if it were to recur, as evidenced by the serious injury MDR 2951238-2019-00404. Accordingly, the referenced adverse events represent MDR-reportable malfunctions as defined under 21 CFR 803.3. Your firm became aware of complaint CN-182867 on February 13, 2025, and submitted the corresponding MDR 9610773-2025-06509 on October 20, 2025; and became aware of CN-184790 on February 12, 2025, and submitted the corresponding MDR 9610773-2025-04016 on June 16, 2025. These two MDRs were submitted beyond the required 30-calendar-day reporting timeframe.\nThe adequacy of your firm’s response cannot be determined at this time. The response states that your firm initiated CAPA-204035 to address late reporting, including revising procedures to correctly document event dates and the dates your firm became aware of the events. However, supporting evidence demonstrating completion of these corrective actions was not provided because the corrective actions are still ongoing.\nFailure to address any violations of the FD&C Act may result in the FDA refusing admission of the devices manufactured by your firm into the United States under section 801(a) of the FD&C Act, 21 U.S.C. § 381(a). Devices under this authority that appear to be adulterated may be detained or refused admission.\nYour firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facilities to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspections conducted between October 2025 and December 2025 were conducted pursuant to the QS Regulation, which was in effect at the time of the inspections. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nIn addition, we also note the following comments:\n1. In response to three prior warning letters issued to your firm in 2022 and 2023 (including the Hachioji and Hinode facilities), your firm implemented new global procedures, including complaint handling, MDR, and CAPA procedures. Review of these procedures found the roles and responsibilities of manufacturing sites versus your global remote corporate entity have not been clearly defined, including, for example, how your firm will assess that site specific quality issues have been resolved, and how your global CAPA process will provide oversight and ensure correction and prevention of repetitive quality issues within and across your global facilities that follow these procedures.\n2. Regarding the inspection of Olympus Corporation of the Americas, located at 3500 Corporate Pkwy, Center Valley, PA 18034, FEI 2429304, from November 18, 2025, to December 16, 2025: Multiple complaint files reviewed during the inspection were found to contain insufficient documentation of complaint intake, evaluation, and investigation conclusions. Complete complaint files provide your firm with critical information to detect and trend medical device failures and to make reportability decisions.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Kristina Donohue at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS #729208” when replying. If you have any questions about the contents of this letter, please contact: Beckilyn Dorsey at Rebecca.dorsey@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technologies 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nTodd Brill, US Agent, Gyrus ACMI, Inc., (b)(6)@Olympus.com\nDaniel S. Sampson, Senior Director of Operations, (b)(6)@olympus.com\nRichard Reynolds, President, Olympus Corporation of the Americas, (b)(6)@olympus.com\nHiroaki Hosoi, President, Aomori Olympus, (b)(6)@olympus.com\nKota Ishibiki, President, Olympus Medical Systems Corporation (b)(6)@olympus.com\nShinji Egami, Senior Director, Olympus Medical Systems Corporation, Hinode, (b)(6)@olympus.com\nSeiji Morishita, President, Shirakawa Olympus Co., Ltd., (b)(6)@olympus.com\nCarl A. Yallop, Vice President OSTE, SIS Operations & ISC and Managing Director, EMEA, (b)(6)@olympus.com","Olympus Medical Systems Corporation","olympus-medical-systems-corporation-729208-10072026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-729208-10072026","2026-10-20","729208","2026-10-27T01:19:05.406+00:00","2026-10-07",{"id":147,"raw":148,"subject":116,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":157,"fei_number":20,"letter_url":158,"updated_at":159,"action_type":23,"case_status":66,"posted_date":160,"marcs_cms_no":161,"product_type":27,"closeout_date":20,"issuing_office":162,"recipient_name":163,"body_fetched_at":164,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":165,"medical_device_id":20,"response_letter_date":20},2105,[149,150,151,152,116,13,13,13],"\u003Ctime datetime=\"2023-05-16T13:20:00Z\">05\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-04T04:00:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsea-long-medical-systems-llc-647320-04042023\">Sea-Long Medical Systems, LLC\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mrs. Valarie A. Austin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO) and Co-owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sea-Long Medical Systems, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2498 FM 66, Building 1021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waxahachie\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75167\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vaustin@sea-long.com\"> vaustin@sea-long.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 647320\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 4, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mrs. &amp; Mr. Austin,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 2498 FM 66, Building 1021, Waxahachie, TX 75167 on 08\u002F22\u002F2022 through 09\u002F08\u002F2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of a latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5012, 5015, 5002 and 5005), a non-latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5035, 5025, 5022 and 5000), a non-latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5335, 5325, 5322, and 5300) and a latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5312, 5315, 5302 and 5305), hereafter referred to as Sea-Long Medical Treatment Hoods. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Quality System Regulation Provisions and Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response from your firm on 09\u002F21\u002F2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your complaint handling procedures, “Customer Complaint - (MDR) Medical Device Reporting and Recall” (OP-85-01, dated 09\u002F08\u002F2017) and “How to process a Customer Complaint Procedure” do not adequately include requirements to document the nature and details of the complaint and the dates and results for any investigation. Your firm is missing this information in the five (5) complaint records listed below:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Customer complaint record dated 12\u002F07\u002F2020 related to “hood with a hole”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 03\u002F04\u002F2021 related to “damage hoods”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 12\u002F07\u002F2021 related to “hood defect”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 07\u002F13\u002F2022 related to “bad weld on hoods and small hole in neck seals”\u003C\u002Fli>\n\t\u003Cli>Customer complaint record dated 02\u002F08\u002F2022 related to “neck seals ripped”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm also determined that the devices involved in the complaint records above failed to meet specification and are manufacturing defects, and at least three (3) complaint events involved a device that was used during treatment or analysis. However, all five (5) complaint\u003Cbr>\nrecords did not contain a “Corrective Action\u002FPreventive Action form” and “Root Cause Analysis form” as required by your complaint handling procedure. Also, there was no rationale why no investigation was necessary and the name of the person(s) responsible for the decision not to investigate in any of the records.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your firm is missing a complaint log as acknowledged by your management and product IDs for all 5 complaint records above as required by your complaint handling procedures. Your firm is missing device serial numbers (complaint record dated 12\u002F07\u002F2021, 07\u002F13\u002F2022, and 02\u002F28\u002F2022) as required by your complaint handling procedures.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures for process validation where the results of a process cannot be fully verified by subsequent inspection and test; failure to validate the process with a high degree of assurance; and failure to approve the process according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not conduct process validation per your established procedure, “Verification and Validation” (SP-000004, dated 08\u002F22\u002F2022), for the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> welding process used to manufacture the Treatment Hoods (hyperbaric chambers). Your firm utilizes \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;welding machines (serial numbers: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for manufacturing of your Treatment Hoods. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> welding machines utilize various welding parameters such as seal time, cooling time, and power.\u003C\u002Fli>\n\t\u003Cli>The cleaning process used in cleaning of your Treatment Hoods (specifically the hood component) that are reusable on multiple patients. Your firm’s “Sea-Long Product Cleaning Guideline” (with no document number, dated 2020) for your Treatment Hoods (consisting of the hood and neck seal) provides information on the use of EPA registered hospital disinfectants (Sanizide Pro or Plus). The cleaning guidelines provide a contact time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for most EPA-registered hospital disinfectants as well as at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on multiple scientific studies on hospital disinfectants against pathogens.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish and maintain procedures for design change to ensure the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, as acknowledged by your management, your firm has not established design change procedures for your Treatment Hoods (hyperbaric chambers).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish a procedure for implementing corrective and preventive actions. During the inspection, your management stated that your firm has not established any quality system procedures including CAPA procedures. Also, the “Masterlist of Operating Procedures” (print dated 08\u002F21\u002F2022) directs firm personnel to use the old CAPA procedure (SP-000022, dated 09\u002F02\u002F2005) from the firm’s previous quality management system. Review of the old procedure directs the person to an electronic file; however, the file path was corrupt, and the file was unable to open or unretrievable.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not adequately establish your nonconforming procedure, “Non-Conforming Material” (OP-83-00, dated 03\u002F14\u002F2021). For example, your management stated that your firm is utilizing the “Inspection Specification Sheet” (created on 04\u002F08\u002F2004) to document leaks, scratches, and dents during the hood quality checks. The “Inspection Specification Sheet” is not referenced or captured in your nonconforming material procedure. Also, your firm does not store or maintain records of completed Inspection Specification Sheets and was unable to provide the investigator with records from 2021.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for finished device acceptance, to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not have written procedures for finished Treatment Hood device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria. During the inspection, your management stated that you had not established any procedure addressing finished device acceptance. Also, during the inspection, your firm created and provided the “Treatment Hood Inspection Process” procedure (OP-85- 02 version 1.0, effective 08\u002F26\u002F2022). This new procedure did not address requirements for completing and retaining your “Inspection Specification Sheet” (no form number and created on 04\u002F08\u002F2004) and “Quality Control \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tracking Report” (no form number or date). The “Inspection Specification Sheet” requires recording pass\u002Ffail results during hood inspections for criteria such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Assurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\u003C\u002Fli>\n\t\u003Cli>Assurance that the weld of the ring is secure and completely sealed\u003C\u002Fli>\n\t\u003Cli>Assurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\u003C\u002Fli>\n\t\u003Cli>Assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is completely sealed around the ports to prevent leaks\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and maintain procedures for acceptance of incoming product to ensure acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish your Inspection and Testing procedure (SP-000028, dated 09\u002F19\u002F2017) and “Warehouse Receiving Inspection” (OP-74-03, no date). For example, your firm did not document incoming inspections for at least 12 out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> product shipments from supplier of latex neck seals and \u003Cstrong>(b)(4)\u003C\u002Fstrong> neck seals that you received between July 2020 to August 2022.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to maintain device master records (DMRs), as required by 21 CFR 820.181.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not maintain device master records (DMRs) for the Treatment Hood (hyperbaric chamber), to include or refer to the location of current device specifications (e.g., drawings and component specifications), production and process specifications, quality assurance procedures, and packaging and labeling specifications to ensure that each DMR is prepared and approved in accordance with document controls.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish and maintain procedures for device history records (DHRs) to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR part 820, as required by 21 CFR 820.184.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish a procedure for creating and adequately documenting device history records (DHR) for the Treatment Hoods (hyperbaric chambers). For example, your firm's last documented DHR for the Treatment Hoods using manufacturing procedure router was in 2018 and your Office Manager indicated that your firm has been manufacturing Treatment Hoods (including hood and neck seals) after 2018.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for quality audits and to conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish your Internal Audits Procedure (OP-82-02, dated 08\u002F22\u002F2022). According to your procedure, “Quality Manager will plan and determine the audit schedule on an ongoing basis.” Your procedure failed to define and document what “ongoing basis” means in the procedure. Also, your firm did not have any documented evidence of audits being conducted or documentation of review of any audit reports since 2018, and your management stated that the firm had not conducted any quality audit since 2016.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>11. Failure to establish procedures for management review to ensure that management with executive responsibility shall review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency, as required by 21 CFR 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm failed to establish your “Management Review” procedure (OP-56-01, version 1.2). Your procedure requires management reviews to be conducted at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, your firm did not have any documented evidence of any annual management review meetings since 2018.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Other Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm currently holds a 510(k) clearance (K010659) for the “Sea-Long Medical Treatment Hood,” which was issued on May 16, 2001. The device was classified under regulation number 21 CFR 868.5470, \u003Cem>Hyperbaric chamber\u003C\u002Fem>, with the following Indications for Use statement: “The Treatment Hood is intended to: provide the use any place that a clinician would normally use a mask for medical purposes of supplying gas\u002Foxygen\u002Fair. There is a connector attachment on the hood to allow the Treatment Hood to be connected to a standard gas\u002Foxygen\u002Fair supply source.”\u003C\u002Fp>\n\n\u003Cp>However, statements on your firm’s website\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and in materials collected during the inspection indicate that the device is also intended for noninvasive ventilation (NIV), respiratory distress\u002Fillness, acute respiratory distress syndrome (ARDS), pressure support ventilation (PSV)\u002Fpositive end-expiratory pressure (PEEP), COVID-19 treatment, and other additional uses, which constitute major changes or modifications to its intended use for which your firm lacks clearance or approval. Examples include the following:\u003C\u002Fp>\n\n\u003Cp>Your website (https:\u002F\u002Fwww.sea-long.com) promotes the following new intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your “About” page states, “Second Study by pulmonologist John P. Kress, MD showing the helmet ‘confers several advantages over the face mask’. Check out the study here” and includes a link that takes the viewer to an article on The University of Chicago Medicine’s website dated March 25, 2020, and titled, “Helmet-based ventilation is superior to face mask for patients with respiratory distress.” The article indicates that “In a second study published in 2018, the researchers followed up with the same patients after one year. The patients who received helmet ventilation were more likely to be functionally independent than those given a face mask and spent more days living at home. The initial study, published in JAMA, followed 83 patients with ARDS, a severe and often lethal injury to the lungs. ARDS causes fluid to accumulate in the lungs' microscopic air sacs. It can lead to partial collapse of the lungs, dangerously low blood-oxygen levels and death.” [ARDS]\u003C\u002Fli>\n\t\u003Cli>Your “Media” page includes excerpts from and links to various media articles and videos, including:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o An NBC news article and video titled, “Texas ‘mom and pop’ business flooded with orders for helmet-style ventilation device,” dated March 31, 2020. The description under the title states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating patients suffering with respiratory illness amid a ventilator shortage during the pandemic.” The link takes you to the NBC news article with video. The description under the title of the NBC news article states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating COVID-19 patients amid a ventilator shortage.” The article states that the “helmet was originally designed to supply oxygen to patients receiving treatment in hyperbaric chambers. But doctors in Italy, where a version of the helmet has long been used to treat people experiencing breathing problems, found it to be effective in helping some COVID-19 patients […] Dr. Bhakti Patel, who has been studying the devices for six years, said they hold promise as an early intervention that could spare respiratory patients the need to be put on the more traditional — and costly and invasive — ventilators. […] The original devices were made to run through ventilators. But working with Patel and her mentor, Dr. John Kress, Sea-Long has modified the helmets so they can be hooked up to a hospital’s regular oxygen supply, keeping the ventilators free for those who need them most. They have also made another significant modification, adding a viral filter to prevent possible COVID-19 exposure to others. […] Other companies make similar ventilator helmets, but Sea-Long’s is the only helmet available in the U.S. that meets requirements of the Food and Drug Administration and has been validated in a clinical study for acute respiratory syndrome. No studies have yet been done, however, examining the effectiveness of the devices in treating COVID-19 patients.” [COVID-19 and ARDS]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o A Fox News article with the description, “Company flooded with orders for helmet ventilators calls for government assistance to ‘scale up’ production,” published April 2, 2020. The article states that “[t]he owner of Sea Long Medical Systems said on Thursday that the flood of ventilator mask orders at his company requires a ‘scaling up’ of production to meet the demand from hospitals fighting the coronavirus outbreak. ‘We’re just completely inundated with phone calls from all over the world from India to anywhere you can think of plus the majority of the hospitals in the United States,’ Chris Austin told ‘America’s Newsroom’. […] Austin said that the masks are used in hospitals at the University of Chicago, University of Pennsylvania, a ‘few’ veterans' hospitals and others.” [COVID-19]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o A Fox News video titled, “Company demonstrates how helmet ventilation device works amid pandemic,” and a video with a chyron at the bottom of the screen that states, “CHRIS AUSTIN | SEA-LONG MEDICAL SYSTEMS OWNER” and “HELMET VENTILATORS COULD HELP EASE SHORTAGE OF TRADITIONAL VENTILATORS AMID PANDEMIC.” The video shows a snapshot of Sea-Long Medical System’s website stating “COVID - 19 Update: Please contact us for updated information and break thru uses for our products with CPAP, BIPAP and NON-INVASIVE VENTILATION. Check out the information from the Helmet Based Ventilation website-based ventilation is a solution for COVID-19 treatment.” [Ventilator, CPAP, and BIPAP]\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your “Media” page has an embedded link to a video from the CBS DFW YouTube channel uploaded March 27, 2020 with the description, “Family-Owned Business Making Medical Devices that Can Ease the Ventilator Shortage: A small family-owned business is making medical devices to help fight the shortage of ventilators during the pandemic.” The video narration introduces a small family own business in Waxahachie and states that “Christopher Austin is the owner of Sea-Long Medical Systems.” The narration states that “once used to supply oxygen to patients receiving treatment in hyperbaric chambers. The device now called the COVID-19 helmet.” [Ventilator and COVID-19]\u003C\u002Fp>\n\n\u003Cp>Your YouTube Channel (https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCQ2YgVWpxMr8gYyMlaWhBA\u002Ffeatured) promotes the following intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Watch this video to learn how to install a Sea-Long Covid 19 kit. www.sea-long.com.” Also, the YouTube channel directly links (1-click away) to the Sea-Long Medical Systems, LLC’s website. [COVID-19]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The Directions for Use (DFU) promotes the following intended uses:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“One-Piece Neck Seal &amp; Heat Tent […] Non-Invasive Ventilation (NIV)” [NIV]\u003C\u002Fli>\n\t\u003Cli>“Start the ventilator in Pressure Support Ventilation with a PEEP of 5-7 cmH20 at least switching off the alarms for 2 minutes. [PSV]\u003C\u002Fli>\n\t\u003Cli>“Use the device only with devices and appliances suitable to the Non-Invasive Ventilation (NIV) and Pressure Support Ventilation (PSV).” [PSV]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You have not submitted any new 510(k) in association with the statements made in the labeling of the Treatment Hood describing these new intended uses. The Treatment Hood as currently labeled is therefore misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified MCH Devices, as required by section 510(k) of the Act. Our inspection, including our review of your website, revealed that the Treatment Hood (hyperbaric chamber) is also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>The inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Sea-Long Medical Treatment Hood devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\n\n\u003Cp>In addition, your Sea-Long Medical Treatment Hood devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, Subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 647320 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh N. Adams, Compliance Officer, at (916) 930-3674 ext. 1111 or lindalinh.adams@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Regards,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nShari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Malvina Eydelman\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\u003Cbr>\nENT &amp; Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc: Mr. Christopher L. Austin, President and Co-owner (via UPS)\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Website content last verified on March 30, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMrs. Valarie A. Austin\n\nRecipient Title\n\nChief Executive Officer (CEO) and Co-owner\n\nSea-Long Medical Systems, LLC\n\n2498 FM 66, Building 1021\n\nWaxahachie, TX 75167\n\nUnited States\n\nvaustin@sea-long.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS 647320\n\nApril 4, 2023\n\nDear Mrs. & Mr. Austin,\n\nDuring an inspection of your firm located at 2498 FM 66, Building 1021, Waxahachie, TX 75167 on 08\u002F22\u002F2022 through 09\u002F08\u002F2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of a latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5012, 5015, 5002 and 5005), a non-latex single use neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5035, 5025, 5022 and 5000), a non-latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5335, 5325, 5322, and 5300) and a latex multi-patient neck seal plus small\u002Flarge hood with\u002Fwithout port (P\u002FN: 5312, 5315, 5302 and 5305), hereafter referred to as Sea-Long Medical Treatment Hoods. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nObservations Pertaining to Quality System Regulation Provisions and Regulations\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from your firm on 09\u002F21\u002F2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nSpecifically, your complaint handling procedures, “Customer Complaint - (MDR) Medical Device Reporting and Recall” (OP-85-01, dated 09\u002F08\u002F2017) and “How to process a Customer Complaint Procedure” do not adequately include requirements to document the nature and details of the complaint and the dates and results for any investigation. Your firm is missing this information in the five (5) complaint records listed below:\n\nCustomer complaint record dated 12\u002F07\u002F2020 related to “hood with a hole”\n\nCustomer complaint record dated 03\u002F04\u002F2021 related to “damage hoods”\n\nCustomer complaint record dated 12\u002F07\u002F2021 related to “hood defect”\n\nCustomer complaint record dated 07\u002F13\u002F2022 related to “bad weld on hoods and small hole in neck seals”\n\nCustomer complaint record dated 02\u002F08\u002F2022 related to “neck seals ripped”\n\nYour firm also determined that the devices involved in the complaint records above failed to meet specification and are manufacturing defects, and at least three (3) complaint events involved a device that was used during treatment or analysis. However, all five (5) complaint\n\nrecords did not contain a “Corrective Action\u002FPreventive Action form” and “Root Cause Analysis form” as required by your complaint handling procedure. Also, there was no rationale why no investigation was necessary and the name of the person(s) responsible for the decision not to investigate in any of the records.\n\nFurthermore, your firm is missing a complaint log as acknowledged by your management and product IDs for all 5 complaint records above as required by your complaint handling procedures. Your firm is missing device serial numbers (complaint record dated 12\u002F07\u002F2021, 07\u002F13\u002F2022, and 02\u002F28\u002F2022) as required by your complaint handling procedures.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\n\n2. Failure to establish procedures for process validation where the results of a process cannot be fully verified by subsequent inspection and test; failure to validate the process with a high degree of assurance; and failure to approve the process according to established procedures, as required by 21 CFR 820.75(a).\n\nSpecifically, your firm did not conduct process validation per your established procedure, “Verification and Validation” (SP-000004, dated 08\u002F22\u002F2022), for the following:\n\nThe (b)(4) welding process used to manufacture the Treatment Hoods (hyperbaric chambers). Your firm utilizes (b)(4) welding machines (serial numbers: (b)(4), and (b)(4)) for manufacturing of your Treatment Hoods. The (b)(4) welding machines utilize various welding parameters such as seal time, cooling time, and power.\n\nThe cleaning process used in cleaning of your Treatment Hoods (specifically the hood component) that are reusable on multiple patients. Your firm’s “Sea-Long Product Cleaning Guideline” (with no document number, dated 2020) for your Treatment Hoods (consisting of the hood and neck seal) provides information on the use of EPA registered hospital disinfectants (Sanizide Pro or Plus). The cleaning guidelines provide a contact time of (b)(4) for most EPA-registered hospital disinfectants as well as at least (b)(4) based on multiple scientific studies on hospital disinfectants against pathogens.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates were made, but no documentation or evidence was provided.\n\n3. Failure to establish and maintain procedures for design change to ensure the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\n\nSpecifically, as acknowledged by your management, your firm has not established design change procedures for your Treatment Hoods (hyperbaric chambers).\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n4. Failure to establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\n\nSpecifically, your firm failed to establish a procedure for implementing corrective and preventive actions. During the inspection, your management stated that your firm has not established any quality system procedures including CAPA procedures. Also, the “Masterlist of Operating Procedures” (print dated 08\u002F21\u002F2022) directs firm personnel to use the old CAPA procedure (SP-000022, dated 09\u002F02\u002F2005) from the firm’s previous quality management system. Review of the old procedure directs the person to an electronic file; however, the file path was corrupt, and the file was unable to open or unretrievable.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n5. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a).\n\nSpecifically, your firm did not adequately establish your nonconforming procedure, “Non-Conforming Material” (OP-83-00, dated 03\u002F14\u002F2021). For example, your management stated that your firm is utilizing the “Inspection Specification Sheet” (created on 04\u002F08\u002F2004) to document leaks, scratches, and dents during the hood quality checks. The “Inspection Specification Sheet” is not referenced or captured in your nonconforming material procedure. Also, your firm does not store or maintain records of completed Inspection Specification Sheets and was unable to provide the investigator with records from 2021.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n6. Failure to establish and maintain procedures for finished device acceptance, to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\n\nSpecifically, your firm did not have written procedures for finished Treatment Hood device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria. During the inspection, your management stated that you had not established any procedure addressing finished device acceptance. Also, during the inspection, your firm created and provided the “Treatment Hood Inspection Process” procedure (OP-85- 02 version 1.0, effective 08\u002F26\u002F2022). This new procedure did not address requirements for completing and retaining your “Inspection Specification Sheet” (no form number and created on 04\u002F08\u002F2004) and “Quality Control (b)(4) Tracking Report” (no form number or date). The “Inspection Specification Sheet” requires recording pass\u002Ffail results during hood inspections for criteria such as:\n\nAssurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\n\nAssurance that the weld of the ring is secure and completely sealed\n\nAssurance that there are no holes, gaps, or tears\u002Fcuts in the hood material\n\nAssurance that the (b)(4) is completely sealed around the ports to prevent leaks\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n7. Failure to establish and maintain procedures for acceptance of incoming product to ensure acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\n\nSpecifically, your firm did not establish your Inspection and Testing procedure (SP-000028, dated 09\u002F19\u002F2017) and “Warehouse Receiving Inspection” (OP-74-03, no date). For example, your firm did not document incoming inspections for at least 12 out of (b)(4) product shipments from supplier of latex neck seals and (b)(4) neck seals that you received between July 2020 to August 2022.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n8. Failure to maintain device master records (DMRs), as required by 21 CFR 820.181.\n\nSpecifically, your firm did not maintain device master records (DMRs) for the Treatment Hood (hyperbaric chamber), to include or refer to the location of current device specifications (e.g., drawings and component specifications), production and process specifications, quality assurance procedures, and packaging and labeling specifications to ensure that each DMR is prepared and approved in accordance with document controls.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n9. Failure to establish and maintain procedures for device history records (DHRs) to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR part 820, as required by 21 CFR 820.184.\n\nSpecifically, your firm did not establish a procedure for creating and adequately documenting device history records (DHR) for the Treatment Hoods (hyperbaric chambers). For example, your firm's last documented DHR for the Treatment Hoods using manufacturing procedure router was in 2018 and your Office Manager indicated that your firm has been manufacturing Treatment Hoods (including hood and neck seals) after 2018.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n10. Failure to establish procedures for quality audits and to conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\n\nSpecifically, your firm failed to establish your Internal Audits Procedure (OP-82-02, dated 08\u002F22\u002F2022). According to your procedure, “Quality Manager will plan and determine the audit schedule on an ongoing basis.” Your procedure failed to define and document what “ongoing basis” means in the procedure. Also, your firm did not have any documented evidence of audits being conducted or documentation of review of any audit reports since 2018, and your management stated that the firm had not conducted any quality audit since 2016.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\n11. Failure to establish procedures for management review to ensure that management with executive responsibility shall review the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency, as required by 21 CFR 820.20(c).\n\nSpecifically, your firm failed to establish your “Management Review” procedure (OP-56-01, version 1.2). Your procedure requires management reviews to be conducted at least (b)(4); however, your firm did not have any documented evidence of any annual management review meetings since 2018.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response indicated procedural updates will be made, but no documentation or evidence was provided.\n\nObservations Pertaining to Other Regulations\n\nYour firm currently holds a 510(k) clearance (K010659) for the “Sea-Long Medical Treatment Hood,” which was issued on May 16, 2001. The device was classified under regulation number 21 CFR 868.5470, Hyperbaric chamber, with the following Indications for Use statement: “The Treatment Hood is intended to: provide the use any place that a clinician would normally use a mask for medical purposes of supplying gas\u002Foxygen\u002Fair. There is a connector attachment on the hood to allow the Treatment Hood to be connected to a standard gas\u002Foxygen\u002Fair supply source.”\n\nHowever, statements on your firm’s website1 and in materials collected during the inspection indicate that the device is also intended for noninvasive ventilation (NIV), respiratory distress\u002Fillness, acute respiratory distress syndrome (ARDS), pressure support ventilation (PSV)\u002Fpositive end-expiratory pressure (PEEP), COVID-19 treatment, and other additional uses, which constitute major changes or modifications to its intended use for which your firm lacks clearance or approval. Examples include the following:\n\nYour website (https:\u002F\u002Fwww.sea-long.com) promotes the following new intended uses:\n\nYour “About” page states, “Second Study by pulmonologist John P. Kress, MD showing the helmet ‘confers several advantages over the face mask’. Check out the study here” and includes a link that takes the viewer to an article on The University of Chicago Medicine’s website dated March 25, 2020, and titled, “Helmet-based ventilation is superior to face mask for patients with respiratory distress.” The article indicates that “In a second study published in 2018, the researchers followed up with the same patients after one year. The patients who received helmet ventilation were more likely to be functionally independent than those given a face mask and spent more days living at home. The initial study, published in JAMA, followed 83 patients with ARDS, a severe and often lethal injury to the lungs. ARDS causes fluid to accumulate in the lungs' microscopic air sacs. It can lead to partial collapse of the lungs, dangerously low blood-oxygen levels and death.” [ARDS]\n\nYour “Media” page includes excerpts from and links to various media articles and videos, including:\n\no An NBC news article and video titled, “Texas ‘mom and pop’ business flooded with orders for helmet-style ventilation device,” dated March 31, 2020. The description under the title states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating patients suffering with respiratory illness amid a ventilator shortage during the pandemic.” The link takes you to the NBC news article with video. The description under the title of the NBC news article states that “Sea-Long Medical Systems has drawn huge interest from hospitals and foreign countries seeking alternatives in treating COVID-19 patients amid a ventilator shortage.” The article states that the “helmet was originally designed to supply oxygen to patients receiving treatment in hyperbaric chambers. But doctors in Italy, where a version of the helmet has long been used to treat people experiencing breathing problems, found it to be effective in helping some COVID-19 patients […] Dr. Bhakti Patel, who has been studying the devices for six years, said they hold promise as an early intervention that could spare respiratory patients the need to be put on the more traditional — and costly and invasive — ventilators. […] The original devices were made to run through ventilators. But working with Patel and her mentor, Dr. John Kress, Sea-Long has modified the helmets so they can be hooked up to a hospital’s regular oxygen supply, keeping the ventilators free for those who need them most. They have also made another significant modification, adding a viral filter to prevent possible COVID-19 exposure to others. […] Other companies make similar ventilator helmets, but Sea-Long’s is the only helmet available in the U.S. that meets requirements of the Food and Drug Administration and has been validated in a clinical study for acute respiratory syndrome. No studies have yet been done, however, examining the effectiveness of the devices in treating COVID-19 patients.” [COVID-19 and ARDS]\n\no A Fox News article with the description, “Company flooded with orders for helmet ventilators calls for government assistance to ‘scale up’ production,” published April 2, 2020. The article states that “[t]he owner of Sea Long Medical Systems said on Thursday that the flood of ventilator mask orders at his company requires a ‘scaling up’ of production to meet the demand from hospitals fighting the coronavirus outbreak. ‘We’re just completely inundated with phone calls from all over the world from India to anywhere you can think of plus the majority of the hospitals in the United States,’ Chris Austin told ‘America’s Newsroom’. […] Austin said that the masks are used in hospitals at the University of Chicago, University of Pennsylvania, a ‘few’ veterans' hospitals and others.” [COVID-19]\n\no A Fox News video titled, “Company demonstrates how helmet ventilation device works amid pandemic,” and a video with a chyron at the bottom of the screen that states, “CHRIS AUSTIN | SEA-LONG MEDICAL SYSTEMS OWNER” and “HELMET VENTILATORS COULD HELP EASE SHORTAGE OF TRADITIONAL VENTILATORS AMID PANDEMIC.” The video shows a snapshot of Sea-Long Medical System’s website stating “COVID - 19 Update: Please contact us for updated information and break thru uses for our products with CPAP, BIPAP and NON-INVASIVE VENTILATION. Check out the information from the Helmet Based Ventilation website-based ventilation is a solution for COVID-19 treatment.” [Ventilator, CPAP, and BIPAP]\n\no Your “Media” page has an embedded link to a video from the CBS DFW YouTube channel uploaded March 27, 2020 with the description, “Family-Owned Business Making Medical Devices that Can Ease the Ventilator Shortage: A small family-owned business is making medical devices to help fight the shortage of ventilators during the pandemic.” The video narration introduces a small family own business in Waxahachie and states that “Christopher Austin is the owner of Sea-Long Medical Systems.” The narration states that “once used to supply oxygen to patients receiving treatment in hyperbaric chambers. The device now called the COVID-19 helmet.” [Ventilator and COVID-19]\n\nYour YouTube Channel (https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCQ2YgVWpxMr8gYyMlaWhBA\u002Ffeatured) promotes the following intended uses:\n\n“Watch this video to learn how to install a Sea-Long Covid 19 kit. www.sea-long.com.” Also, the YouTube channel directly links (1-click away) to the Sea-Long Medical Systems, LLC’s website. [COVID-19]\n\nThe Directions for Use (DFU) promotes the following intended uses:\n\n“One-Piece Neck Seal & Heat Tent […] Non-Invasive Ventilation (NIV)” [NIV]\n\n“Start the ventilator in Pressure Support Ventilation with a PEEP of 5-7 cmH20 at least switching off the alarms for 2 minutes. [PSV]\n\n“Use the device only with devices and appliances suitable to the Non-Invasive Ventilation (NIV) and Pressure Support Ventilation (PSV).” [PSV]\n\nYou have not submitted any new 510(k) in association with the statements made in the labeling of the Treatment Hood describing these new intended uses. The Treatment Hood as currently labeled is therefore misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify FDA of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the Modified MCH Devices, as required by section 510(k) of the Act. Our inspection, including our review of your website, revealed that the Treatment Hood (hyperbaric chamber) is also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g).\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThe inspection revealed that your devices are also misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Sea-Long Medical Treatment Hood devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\n\nIn addition, your Sea-Long Medical Treatment Hood devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, Subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 647320 when replying. If you have any questions about the contents of this letter, please contact: Linda Linh N. Adams, Compliance Officer, at (916) 930-3674 ext. 1111 or lindalinh.adams@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nRegards,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest\n\n\u002FS\u002F\n\nDr. Malvina Eydelman\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia, Respiratory,\n\nENT & Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc: Mr. Christopher L. Austin, President and Co-owner (via UPS)\n\n_____________________\n\n1 Website content last verified on March 30, 2023.","Sea-Long Medical Systems, LLC","sea-long-medical-systems-llc-647320-04042023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsea-long-medical-systems-llc-647320-04042023","2026-10-26T08:09:54.778439+00:00","2023-05-16","647320","Division of Medical Device and Radiological Health Operations West","Mrs. Valarie A. Austin","2026-08-20T01:07:14.815+00:00","2023-04-04",{"id":167,"raw":168,"subject":172,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":157,"fei_number":20,"letter_url":177,"updated_at":178,"action_type":23,"case_status":66,"posted_date":179,"marcs_cms_no":180,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":181,"body_fetched_at":182,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":183,"medical_device_id":20,"response_letter_date":20},2160,[169,170,171,11,172,13,13,13],"\u003Ctime datetime=\"2023-03-17T15:00:00Z\">03\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-15T04:00:00Z\">03\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023\">Olympus Medical Systems Corp.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Seiji Morishita\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-3 Hirai Hinode-machi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nishitama-gun\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>190-0182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 15, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Morishita:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>A. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\u003C\u002Fp>\n\n\u003Cp>B. The process flow diagram of Procedure for Complaint Handling\u002FOMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\u003C\u002Fp>\n\n\u003Cp>C. Non-Conformances \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance \u003Cstrong>(b)(4)\u003C\u002Fstrong> was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Process Validation and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\u003C\u002Fp>\n\n\u003Cp>Your firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>For example, Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\u003C\u002Fp>\n\n\u003Cp>Your firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\u003C\u002Fp>\n\n\u003Cp>However, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>A. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>B. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\u003C\u002Fp>\n\n\u003Cp>a. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\u003C\u002Fp>\n\n\u003Cp>C. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\u003Cbr>\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information included for Complaints \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong> reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Seiji Morishita\n\nRecipient Title\n\nDirector\n\nOlympus Medical Systems Corp.\n\n34-3 Hirai Hinode-machi\n\nNishitama-gun, Tokyo\n\n190-0182\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nMarch 15, 2023\n\nWARNING LETTER\n\nDear Mr. Morishita:\n\nDuring an inspection of your firm located in Tokyo, Japan on November 7, 2022, through November 10, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures endoscopes and endoscope accessories including, Single-Use Distal Covers for Duodenoscopes and Single-Use Suction Valve Accessories for Bronchoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are accessories intended to be used with endoscopes for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Mr. Seiji Morishita, Director of Olympus Medical Systems Corp, Hinode dated December 5, 2022, January 10, 2023, and February 13, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, including analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a)(1). For example:\n\nA. Since November 2020, Olympus Medical has received approximately 160 complaints describing the “distal end cover” model number MAJ-2315 has “dropped out.” Your firm performed trending and identified that number of complaints was above the expected numbers for that type of complaint. However, your firm did not consider this increasing trend of complaints to be a quality data input to initiate a corrective and preventive action.\n\nB. The process flow diagram of Procedure for Complaint Handling\u002FOMBS (b)(4) describes that complaint investigations that would require evaluation for reportability would not be considered for Corrective and Preventive Action. Complaints are specifically required to be analyzed for inclusion into the CAPA subsystem and complaints that are deemed reportable are of the highest risk complaints and therefore especially important to be considered for corrective and preventive action implementation.\n\nC. Non-Conformances (b)(4) and (b)(4) were opened for observed wrinkles in the package seal of Distal End Cap\u002FMAJ-2315 between October 13 to October 23, 2022. Your firm stated that yield control may be appropriate for some low risk nonconformances instead of using its Nonconforming Product procedure. Yield control allows for an acceptable level of package seal defects, even though there is no assurance that visually observed seal defects would not compromise the sterile barrier. Package sealing is a validated process, which results cannot be verified when the validated requirements of the seal are not met. A potential breach of sterility in the packaging seal would not be considered a low risk nonconformance. Because yield control was inappropriately applied to the package seal defect, the nonconformances were not considered as nonconforming product and not included as quality data for the corrective and preventive actions.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200735 to investigate complaints of MAJ-2315 “dropped out” and after conducting a Health Hazard Analysis (HHA), concluded that no additional action is required and they will continue to monitor complaints for the distal cap falling off in the patient. However, FDA does not agree that the risk to the patient is of a low enough risk to not warrant further action at this time. The HHA conducted does not discuss how\u002Fwhy the risk to the patient is not increased by exposure to the uncovered endoscope during the procedure as it is removed. The HHA does not consider the risk of tissue injury from navigating the gastrointestinal tract with an uncovered scope tip. Further, your firm’s documentation concludes that the distal cap is unlikely to fall off if the user has applied it correctly. CAPA-200735 does not consider whether the device actually meets user needs as required by 21 CFR 820.30(g), including the ability to recognize imperfections in the cap and attach it to the scope correctly without damaging it. While your firm did initiate a systemic corrective and preventive action to determine why this complaint trend was not escalated to a CAPA, the investigation into the issue itself, the cap falling off the scope in the patient, appears to be inadequate.\n\n2. Failure to ensure that when changes or process deviations occur, the manufacturer shall review and evaluate the process and perform revalidation where appropriate, as required by 21 CFR 820.75(c). For example, Nonconformance (b)(4) was opened due to wrinkles and air bubbles in the package seal of MAJ-210\u002FLot H2410 a sterile product. Your firm made a modification to the manufacturing equipment to increase the cooling rate of the package after sealing. While some testing was performed to demonstrate seal integrity, no re-validation of the process was made. Because sterility of the product is a critical requirement and the process cannot be fully verified by subsequent inspection and test, the process must be validated and re-validated when a modification such as this is made.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm identified its plan to perform revalidation for MAJ-201 sealing operation by January 31, 2023. Also, your firm stated that it will revise (b)(4), Process Validation and (b)(4), Conduct of Process Validation by February 23, 2023, to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made; and revise (b)(4) Assembly\u002FProcessing Equipment Control by February 28, 2023, to ensure that the change control process is followed when process or equipment changes are made.\n\nYour firm reviewed complaints and MDRs from the last two years associated with all products distributed to the US to determine if any signals exist to suggest sterility was compromised as a result of the modification made to the sealing process. It is not clear whether your firm evaluated devices shipped to other markets as well that would have the same concern or could possibly be imported into the US by a third party. Your firm should clarify this. Your firm performed a retrospective review of all changes for all products marketed in the US since each product’s last full validation to determine if any other changes have been made to any products marketed in the US that should have prompted a full or partial revalidation and opened several nonconformances for changes without adequate documentation of necessity for revalidation to investigate impact to product and revalidation requirements. Your firm completed its revalidation of MAJ-210 sealing process on January 31, 2023. Your firm has additional corrective actions planned, including revising its Process Validation procedures to clarify when revalidation is necessary and to specify who is necessary to review and approve changes to ensure revalidation decisions are appropriately made. Your firm also plans to implement a change to its Assembly\u002FProcessing Equipment Control procedure to ensure that the change control process is followed when process or equipment changes are made. However, your firm did not mention a plan to train its personnel on these new procedures, nor did it clarify that the retrospective reviews that were done were in line with the new requirements of its procedures. Your firm should provide clarification to these two points and provide documentation of implementation.\n\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198.\n\nFor example, Complaint (b)(4) was received by Olympus Medical on November 21, 2020. The complaint described that \"a patient sustained esophageal trauma\" and \"tissue from the esophagus was caught up in the distal tip of the device.\" The complaint also stated that the \"customer attributes these events to cracked caps\" and that they noticed a \"few already cracked when coming out of the packaging.\" Your firm’s complaint handling procedure, OMBS (b)(4) requires investigations of complaints to be made within 30 days. The investigation of the complaint was not made until 2022.\n\nWe reviewed your firm’s responses and concluded that they are not adequate. Your firm initiated CAPA-200739 to determine the root cause of Observation 4a of the FDA-483. It appears your firm identified the root cause to be related to be a lack of linkage between the scopes and the caps within their system. Your firm completed a retrospective review of all complaints associated with MAJ-2315, expanding the search to other scopes that use the distal cap in addition to TJF-Q190V. Your firm found that there were 98 complaints not initiated according to their procedure during this retrospective review. Your firm stated that it will conduct the necessary investigation and submit MDRs as needed by February 28, 2023.\n\nYour firm revised (b)(4) Complaint Handling, which included instructions for ensuring individual complaints are opened for all related\u002Fconcomitant devices. Your firm revised (b)(4) Complaint Investigation Work Instruction, which included detailed instruction for ensuring individual complaints are opened for all related\u002Fconcomitant devices while performing complaint investigation. Your firm confirmed in its plan that personnel have been trained on the new procedures.\n\nYour firm plans to do a retrospective review of complaint records in the past two years related to the issue of cracked caps coming out of the packaging by February 28, 2023.\n\nHowever, it is not clear based on your firm’s CAPA and documentation whether they have investigated why the investigation into the complaint did not occur for two years, while your firm’s procedure requires it to be made within 30 days.\n\nOur inspection also revealed that your firm’s Single-Use Distal Cover (MAJ-2315) devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a).\n\nFor example, during the inspection, your firm identified the document titled “Medical Device Reporting Work Instruction”, OMBS (b)(4), dated 10\u002F26\u002F2022, as its MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\nA. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure includes definitions from 21 CFR 803.3 for the terms “become aware”, “malfunction”, “MDR reportable event”, and the definition of the term “reasonably suggest” found in 803.20(c)(1). However, the procedure omits definitions of the terms “caused or contributed” and “serious injury” from the 21 CFR Part 803.3. The exclusion of the definitions for those terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nB. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2).\n\na. For example, there are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The MDR Decision Tree in your firm’s MDR procedure does not reference a process for investigating events identified as MDRs to ensure that MDRs are submitted to FDA within the required reporting timeframes, as required under 21 CFR 803.17(a)(1).\n\nC. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review, and archive in accordance with 21 CFR 803.12(a).\n\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within the firm.\n\nYour firm’s response did not address the procedural deficiencies noted above, as they were not identified in the FDA-483.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information included for Complaints (b)(4) and (b)(4) reasonably suggests your firm’s duodenovideoscope with a distal cover MAJ-2315 malfunctioned (e.g., cracked cap) while in use, leading to potential mucosal tissue damage. Your firm initiated recall Z-1292-2021 for the referenced malfunction. Per the Preamble, in Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (December 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information included for the complaints that rules out that the referenced device malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Although your firm submitted the MDRs (MDR# 8010047-2021-03794, 8010047-2022-02861, 8010047-2021-03786, 8010047-2022-02867, 8010047-2021-03796, 8010047-2022-02865) corresponding to each of the referenced events, the MDRs were not received by FDA within the required 30 calendar day timeframe.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm initiated a series of CAPAs to investigate the root cause of the cracked cap problem and have plans to address it accordingly. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm is in the process of completing CAPAs to address the referenced malfunction and updating the complaint handling process. Additionally, your firm conducted a retrospective review of all complaints associated with MAJ-2315 and complaints for the endoscopes (TJF-Q190V, TJF-Q290V, TJF-Q170V), which are used in conjunction with MAJ-2315. As a result, 98 complaints were identified for further investigation and your firm is evaluating them for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including a retrospective review for reportability, as these actions are still ongoing.\n\nYour firm completed the update of its complaint handling procedures and is evaluating newly identified events related to cracked caps for reportability. However, your firm has not provided documentation or evidence that the systemic corrective actions have been fully implemented, including the submission of newly identified reportable events, as these actions are still ongoing.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\n\nWe will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #654013 when replying. If you have any questions about the contents of this letter, please contact: Shanil Haugen, Ph.D., at Shanil.Haugen@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nDirector\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\ncc:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.com","Olympus Medical Systems Corp.","olympus-medical-systems-corp-654013-03152023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corp-654013-03152023","2026-10-26T08:09:37.557484+00:00","2023-03-17","654013","Mr. Seiji Morishita","2026-08-20T01:11:43.772+00:00","2023-03-15",{"id":185,"raw":186,"subject":190,"body_html":191,"body_text":192,"firm_name":138,"letter_id":193,"created_at":157,"fei_number":20,"letter_url":194,"updated_at":195,"action_type":23,"case_status":66,"posted_date":196,"marcs_cms_no":197,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":198,"body_fetched_at":199,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":200,"medical_device_id":20,"response_letter_date":20},2263,[187,188,189,11,190,13,13,13],"\u003Ctime datetime=\"2023-01-10T14:20:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-12T05:00:00Z\">12\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022\">Olympus Medical Systems Corporation\u003C\u002Fa>","Medical Device Reporting\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tomohisa Sakurai\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Olympus Medical Systems Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2951, Ishikawa-cho\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hachioji-shi\u003C\u002Fspan>, \u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>192-8507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Tomohisa Sakurai:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\u003C\u002Fp>\n\n\u003Cp>For example, the information in complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-02641), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-07387), complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-11050), and complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\u003C\u002Fp>\n\n\u003Cp>U.S. federal agencies may take your compliance history into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 478315\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nTodd Brill\u003Cbr>\nGyrus ACMI Inc.\u003Cbr>\n800 West Park Drive\u003Cbr>\nWestborough, MA US 01581\u003Cbr>\nPhone: 508 8042600 Ext\u003Cbr>\nEmail: Todd.Brill@Olympus.Com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTomohisa Sakurai\n\nRecipient Title\n\nPresident\n\nOlympus Medical Systems Corporation\n\n2951, Ishikawa-cho\n\nHachioji-shi, Tokyo\n\n192-8507\n\nJapan\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDecember 12, 2022\n\nDear Tomohisa Sakurai:\n\nDuring an inspection of your firm located in Hachioji-shi, Tokyo, Japan, on September 6, 2022, through September 9, 2022, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures gastrointestinal and surgical endoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nOur inspection revealed that your firm's gastrointestinal and surgical endoscopes are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. We received a response from your firm, dated September 30, 2022, to the Form FDA 483 (FDA 483). We address this response below, in relation to each of the noted violation(s). These violation(s) include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2).\n\nFor example, the information in complaint (b)(4) (MDR# 8010047-2021-02641), complaint (b)(4) (MDR# 8010047-2021-07387), complaint (b)(4) (MDR# 8010047-2021-11050), and complaint (b)(4) (MDR# 8010047-2021-09059), reasonably suggests that your firm’s Uretero-Reno Fiberscope and Uretero-Reno Videoscope malfunctioned (e.g., device breakage or rupture) while in use. Your firm failed to submit an MDR for each of the referenced complaints within the required 30-calendar day timeframe. As a result of these complaints, your firm conducted recall Z-2518-2018, for the Uretero-reno fiberscope URF-P6, where it was established that such events could result in potential perforation of a patient’s organs. Per 21 CFR 803.3, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the Act as a result of the malfunction of the device or other similar devices. As such, each of the referenced complaints represents an MDR-reportable malfunction, as defined in 21 CFR 803.3.\n\nThe adequacy of your firm’s response dated September 30, 2022, cannot be determined at this time as the response notes that your firm is continuing to implement its systemic corrective actions, including optimizing the MDR reporting process and staff training. However, the adequacy of your firm’s response cannot be determined because your firm’s actions are presently ongoing. When your firm’s corrective actions are completed, please provide documentation or evidence of the systemic corrective actions, including a copy of your revised MDR procedure and a retrospective review of complaints for reportability.\n\nU.S. federal agencies may take your compliance history into account when considering the award of contracts.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violation, as well as an explanation of how your firm plans to prevent the violation, or similar violation, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violation included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 478315\n\nIf you have any questions about the contents of this letter, please contact: Mark Antonino at Mark.Antonino@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violation at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nTodd Brill\n\nGyrus ACMI Inc.\n\n800 West Park Drive\n\nWestborough, MA US 01581\n\nPhone: 508 8042600 Ext\n\nEmail: Todd.Brill@Olympus.Com","olympus-medical-systems-corporation-649726-12122022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Folympus-medical-systems-corporation-649726-12122022","2026-10-26T08:09:37.595173+00:00","2023-01-10","649726","Tomohisa Sakurai","2026-08-20T01:19:56.315+00:00","2022-12-12",{"id":202,"raw":203,"subject":116,"body_html":207,"body_text":208,"firm_name":209,"letter_id":210,"created_at":42,"fei_number":20,"letter_url":211,"updated_at":212,"action_type":23,"case_status":66,"posted_date":213,"marcs_cms_no":214,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":215,"body_fetched_at":216,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":217,"medical_device_id":20,"response_letter_date":20},1879,[204,205,206,11,116,13,13,13],"\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-31T04:00:00Z\">08\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaltag-medsystems-ltd-662115-08312023\">Caltag Medsystems Ltd\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tim Almond, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Caltag Medsystems Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Whiteleaf Business Centre, 11 Little Balmer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buckingham\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Buckingshire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>MK18 1TF\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@caltagmedsystems.co.uk\"> (b)(6)@caltagmedsystems.co.uk\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 31, 2023\u003Cbr>\n\u003Cbr>\nDear Dr. Tim Almond:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Buckingham, United Kingdom on May 2 through May 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the TransFix\u002FEDTA Vacuum Blood Collection Tubes (TVTs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Nicki Kaenzig, Chief Scientific Officer, and Quality Manager\u002FManagement Representative, dated May 26, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspection Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100. For example, SOP10-001, Version 6 (v6), titled “Corrective and Preventive Action (CAPA)” dated, February 2, 2023, describes the procedures and documentation for implementing preventive actions. In the “CAPA Effectiveness” section of the SOP10-001 v6, it states “The CAPA is approved and closed by a member of the Management Team.” However, CP2019\u002F017 lacked documentation of verification or validation of effectiveness. Specifically, CP2019\u002F017 was not reviewed and signed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm states that the CAP SOP (SOP10-001 v7) has been updated and a new investigation report template has been created (10-008.01 v1) and a new Quality Review Form (01-011.02v1) has been created for review of non-conformances, complaints &amp; CAPA which is signed by the CAPA Leader\u002FNon- Conformance Lead and the Reviewer which is attached to all the documents. However, no documents were provided as evidence that the three CAPAs noted during the inspection were corrected nor were evidence or training provided to ensure that the procedures for implementing corrective and preventive actions are adequate or have been implemented. Also, your firm did not indicate whether there are plans to perform a retrospective review. Your firm should provide evidence that CAPA record CP2019\u002F017 was corrected and that the corrective actions were verified or validated. Your firm should also provide a copy of their revised and new documents and evidence of training. Further, your firm should perform a retrospective review to ensure that other CAPAs were appropriately handled.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the device's design development, as required by 21 CFR 820.30(e). For example:\u003C\u002Fp>\n\n\u003Cp>a. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design review. However, the procedure does not define how your firm will ensure that the results of a design review, including identification of the design, the date, and the individual(s) performing the review, will be documented in the design history file (DHF). Nor does this procedure ensure that all of the functions and people involved with the stage under design review are included in the design review.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection records of design reviews for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that the results of the design review have not been maintained.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, including how they plan to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF or perform a systemic review of other DHFs to ensure they are complete. Your firm also states that they plan to revise SOP12-002 to ensure that design review is adequately covered. However, no documents were provided. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF and their plan to ensure other DHFs are complete.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain adequate procedures to ensure that the device design is correctly translated into production specification, as required by 21 CFR 820.30(h). For example:\u003C\u002Fp>\n\n\u003Cp>a. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design transfer. However, this procedure does not explain how your firm will conduct the final review and approval of design and development activities in order to transfer the design to manufacturing. Nor does it describe what design documents comprise the device master record.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection, design transfer records for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that no design transfer records were created as part of the Design History File.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm states that they plan to revise SOP12-002 with design transfer procedures and ensure that the design transfer procedure is followed by the contract manufacturer. However, no documents were provided as evidence. Also, your firm’s proposal to revise their SOP did not address how they plan to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly transferred into production nor did your firm indicate whether there are plans to perform a systemic review of other products. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly translated into production and their plan to ensure other devices were correctly translated in addition to evidence of implementation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, that the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). Specifically, your firm uses a \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for packing and labeling of TransFix Vacuum Blood Collection Tubes. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a process for which the results cannot be fully verified and your firm failed to validate this packing and labeling process, as there were no process validation record and no record of the parameter settings. During the inspection, the process validation records were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that you have chosen to verify the process via a visual check.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. This is a repeat violation from the 2019 inspection which has not been adequately corrected. Your firm stated “that they performed validation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, no documentation of the validation procedure(s) or individual validation plan(s) for each process that will be validated for the device under review or the results were provided. Your firm did not address the corrective action to ensure future processes which cannot be verified are validated nor did the firm conduct a systemic review of other processes. Your firm should include the validation protocols and final reports for the heat sealing process. The protocols should contain or refer to objective and measurable acceptance criteria and describe how appropriate statistical method for data collection and analysis are used. Your firm should provide documentation and evidence of their corrective action as well as perform a systemic review to ensure all process which cannot be fully verified are appropriately validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained. These activities shall be documented, as required by 21 CFR 820.72(a). For example:\u003C\u002Fp>\n\n\u003Cp>a. PLAN-VAL-005v3, titled “Validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flow Cytometer for use in the QC of CE\u002FIVD TVTs and FDA cleared TVTs for the US Market”, dated Feb 2020, describes procedures to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Flow Cytometer for use the Quality Control testing of CE\u002FIVD TVTs and FDA-cleared TVTs. However, your firm has not adequately documented, reviewed and approved the procedures. Specifically, your firm’s Installation Qualification (IQ) phase of Flow Cytometer was not adequately reviewed and approved. During the inspection, validation records were requested, and the records showed that the “Reviewer\u002FApprover” signatures had not been signed. Further, on May 8, 2014 \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed onsite maintenance of instrument and reported to your firm that the instrument is run in a room with “no or little air conditioning” which may affect the instrument.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection the procedures were requested and reviewed; however, there was not record of performance qualification (PQ) phase. Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative had agreed to correct the deficiency.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that we could not determine the adequacy at this time. Your firm plans to perform IQ\u002FPQ validation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> flow cytometer. However no documentation was provided nor did your firm include a corrective action or systemic corrective action. Your firm should provide a copy of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flow Cytometer qualification protocol and report. Your firm should also provide their corrective action to ensure that all equipment will be suitable for its intended purpose and capable of producing valid results. Your firm should also conduct a systemic review to determine if other equipment has been appropriately qualified.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain adequate procedures to control labeling activities, including ensuring that labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, among other things, the correct unique device identifier (UDI) or universal product code (UPC), as required by 21 CFR 820.120(b). For example, SOP07-009 Version 12 (v12), titled “Dispensing and Packaging Cytomark Products Containing TransFix” dated January 15, 2021, describes your firm’s process for labeling and packaging the product. SOP07-009 v12 includes steps to verify and check for accuracy and completion before use of labeling. However, your procedures do not describe the process of examining the labeling for accuracy. Specifically, Manufacturing Batch Record of Transfix for lots 29985.33, 29985.34, 29990 and 29943 show no record of UDI compliant labels.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, in that they did not indicate whether there are plans to perform a systemic review of other device labeling. Your firm states that they plan to perform the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Prevent any more TVT 3ml IVD products entering the USA. Email all staff with immediate message to this effect.\u003C\u002Fli>\n\t\u003Cli>Ensure UDI information on EUDAMED and GUDID is the same to enable a single harmonised label for TVT-03-50 and TVT-03-2 pouch label.\u003C\u002Fli>\n\t\u003Cli>Master new labels with barcode to replace existing stock immediately.\u003C\u002Fli>\n\t\u003Cli>Review Form 01-013.03 Label CE Marking Checklist to ensure FDA requirements are fully included.\u003C\u002Fli>\n\t\u003Cli>Prepare new Technical Sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and ensure transfer conducted properly.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, no documents were provided for review. Your firm should provide copies of their revised procedures and evidence of training and their plans to review all device labeling practices to ensure that all devices conform to the UDI requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov.&nbsp;\u003Cstrong>Refer to CMS case #662115 when replying.\u003C\u002Fstrong> If you have any questions about the contents of this letter, please contact: Christopher Blackwood, Ph.D. at +1 (240)-402-1665 or Christopher.blackwood@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, MD, PhD\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nNadine Shabat\u003Cbr>\nBion Enterprises, Ltd.\u003Cbr>\nUS Agent\u003Cbr>\nNadine.Shabat@Aesku-Bion.Com\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTim Almond, PhD\n\nRecipient Title\n\nCEO\u002FFounder\n\nCaltag Medsystems Ltd\n\nWhiteleaf Business Centre, 11 Little Balmer\n\nBuckingham\n\nBuckingshire\n\nMK18 1TF\n\nUnited Kingdom\n\n(b)(6)@caltagmedsystems.co.uk\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nAugust 31, 2023\n\nDear Dr. Tim Almond:\n\nDuring an inspection of your firm located in Buckingham, United Kingdom on May 2 through May 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the TransFix\u002FEDTA Vacuum Blood Collection Tubes (TVTs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Nicki Kaenzig, Chief Scientific Officer, and Quality Manager\u002FManagement Representative, dated May 26, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspection Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100. For example, SOP10-001, Version 6 (v6), titled “Corrective and Preventive Action (CAPA)” dated, February 2, 2023, describes the procedures and documentation for implementing preventive actions. In the “CAPA Effectiveness” section of the SOP10-001 v6, it states “The CAPA is approved and closed by a member of the Management Team.” However, CP2019\u002F017 lacked documentation of verification or validation of effectiveness. Specifically, CP2019\u002F017 was not reviewed and signed.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm states that the CAP SOP (SOP10-001 v7) has been updated and a new investigation report template has been created (10-008.01 v1) and a new Quality Review Form (01-011.02v1) has been created for review of non-conformances, complaints & CAPA which is signed by the CAPA Leader\u002FNon- Conformance Lead and the Reviewer which is attached to all the documents. However, no documents were provided as evidence that the three CAPAs noted during the inspection were corrected nor were evidence or training provided to ensure that the procedures for implementing corrective and preventive actions are adequate or have been implemented. Also, your firm did not indicate whether there are plans to perform a retrospective review. Your firm should provide evidence that CAPA record CP2019\u002F017 was corrected and that the corrective actions were verified or validated. Your firm should also provide a copy of their revised and new documents and evidence of training. Further, your firm should perform a retrospective review to ensure that other CAPAs were appropriately handled.\n\n2. Failure to establish and maintain adequate procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the device's design development, as required by 21 CFR 820.30(e). For example:\n\na. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design review. However, the procedure does not define how your firm will ensure that the results of a design review, including identification of the design, the date, and the individual(s) performing the review, will be documented in the design history file (DHF). Nor does this procedure ensure that all of the functions and people involved with the stage under design review are included in the design review.\n\nb. During the inspection records of design reviews for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that the results of the design review have not been maintained.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, including how they plan to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF or perform a systemic review of other DHFs to ensure they are complete. Your firm also states that they plan to revise SOP12-002 to ensure that design review is adequately covered. However, no documents were provided. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to remediate the TransFix\u002FEDTA Vacuum Blood Collection Tubes DHF and their plan to ensure other DHFs are complete.\n\n3. Failure to establish and maintain adequate procedures to ensure that the device design is correctly translated into production specification, as required by 21 CFR 820.30(h). For example:\n\na. SOP12-002 Version 7 (v7), titled “New Product Design and Development” dated May 2022, describes your firm’s procedures for design transfer. However, this procedure does not explain how your firm will conduct the final review and approval of design and development activities in order to transfer the design to manufacturing. Nor does it describe what design documents comprise the device master record.\n\nb. During the inspection, design transfer records for the TransFix\u002FEDTA Vacuum Blood Collection Tubes were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that no design transfer records were created as part of the Design History File.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm states that they plan to revise SOP12-002 with design transfer procedures and ensure that the design transfer procedure is followed by the contract manufacturer. However, no documents were provided as evidence. Also, your firm’s proposal to revise their SOP did not address how they plan to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly transferred into production nor did your firm indicate whether there are plans to perform a systemic review of other products. Your firm should provide a copy of the revised procedure for review and evidence of training. Your firm should provide their plans to ensure that the TransFix\u002FEDTA Vacuum Blood Collection Tubes were correctly translated into production and their plan to ensure other devices were correctly translated in addition to evidence of implementation.\n\n4. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, that the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). Specifically, your firm uses a (b)(4) process for packing and labeling of TransFix Vacuum Blood Collection Tubes. (b)(4) is a process for which the results cannot be fully verified and your firm failed to validate this packing and labeling process, as there were no process validation record and no record of the parameter settings. During the inspection, the process validation records were requested; however, Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative, stated that you have chosen to verify the process via a visual check.\n\nWe reviewed your firm’s response and concluded that it is not adequate. This is a repeat violation from the 2019 inspection which has not been adequately corrected. Your firm stated “that they performed validation of (b)(4)”. However, no documentation of the validation procedure(s) or individual validation plan(s) for each process that will be validated for the device under review or the results were provided. Your firm did not address the corrective action to ensure future processes which cannot be verified are validated nor did the firm conduct a systemic review of other processes. Your firm should include the validation protocols and final reports for the heat sealing process. The protocols should contain or refer to objective and measurable acceptance criteria and describe how appropriate statistical method for data collection and analysis are used. Your firm should provide documentation and evidence of their corrective action as well as perform a systemic review to ensure all process which cannot be fully verified are appropriately validated.\n\n5. Failure to establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained. These activities shall be documented, as required by 21 CFR 820.72(a). For example:\n\na. PLAN-VAL-005v3, titled “Validation of the (b)(4) Flow Cytometer for use in the QC of CE\u002FIVD TVTs and FDA cleared TVTs for the US Market”, dated Feb 2020, describes procedures to validate the (b)(4) Flow Cytometer for use the Quality Control testing of CE\u002FIVD TVTs and FDA-cleared TVTs. However, your firm has not adequately documented, reviewed and approved the procedures. Specifically, your firm’s Installation Qualification (IQ) phase of Flow Cytometer was not adequately reviewed and approved. During the inspection, validation records were requested, and the records showed that the “Reviewer\u002FApprover” signatures had not been signed. Further, on May 8, 2014 (b)(4) performed onsite maintenance of instrument and reported to your firm that the instrument is run in a room with “no or little air conditioning” which may affect the instrument.\n\nb. During the inspection the procedures were requested and reviewed; however, there was not record of performance qualification (PQ) phase. Mrs. Nicki Kaenzig, Chief Scientific Officer\u002FManagement Representative had agreed to correct the deficiency.\n\nWe reviewed your firm’s response and concluded that we could not determine the adequacy at this time. Your firm plans to perform IQ\u002FPQ validation of (b)(4) flow cytometer. However no documentation was provided nor did your firm include a corrective action or systemic corrective action. Your firm should provide a copy of the (b)(4) Flow Cytometer qualification protocol and report. Your firm should also provide their corrective action to ensure that all equipment will be suitable for its intended purpose and capable of producing valid results. Your firm should also conduct a systemic review to determine if other equipment has been appropriately qualified.\n\n6. Failure to establish and maintain adequate procedures to control labeling activities, including ensuring that labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, among other things, the correct unique device identifier (UDI) or universal product code (UPC), as required by 21 CFR 820.120(b). For example, SOP07-009 Version 12 (v12), titled “Dispensing and Packaging Cytomark Products Containing TransFix” dated January 15, 2021, describes your firm’s process for labeling and packaging the product. SOP07-009 v12 includes steps to verify and check for accuracy and completion before use of labeling. However, your procedures do not describe the process of examining the labeling for accuracy. Specifically, Manufacturing Batch Record of Transfix for lots 29985.33, 29985.34, 29990 and 29943 show no record of UDI compliant labels.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm’s response did not include a systemic corrective action, in that they did not indicate whether there are plans to perform a systemic review of other device labeling. Your firm states that they plan to perform the following corrective actions:\n\n“Prevent any more TVT 3ml IVD products entering the USA. Email all staff with immediate message to this effect.\n\nEnsure UDI information on EUDAMED and GUDID is the same to enable a single harmonised label for TVT-03-50 and TVT-03-2 pouch label.\n\nMaster new labels with barcode to replace existing stock immediately.\n\nReview Form 01-013.03 Label CE Marking Checklist to ensure FDA requirements are fully included.\n\nPrepare new Technical Sheet for (b)(4) and ensure transfer conducted properly.”\n\nHowever, no documents were provided for review. Your firm should provide copies of their revised procedures and evidence of training and their plans to review all device labeling practices to ensure that all devices conform to the UDI requirements.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #662115 when replying. If you have any questions about the contents of this letter, please contact: Christopher Blackwood, Ph.D. at +1 (240)-402-1665 or Christopher.blackwood@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, MD, PhD\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nNadine Shabat\n\nBion Enterprises, Ltd.\n\nUS Agent\n\nNadine.Shabat@Aesku-Bion.Com","Caltag Medsystems Ltd","caltag-medsystems-ltd-662115-08312023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcaltag-medsystems-ltd-662115-08312023","2026-10-26T08:08:10.563662+00:00","2023-09-05","662115","Tim Almond, PhD","2026-08-20T00:42:49.102+00:00","2023-08-31",{"id":219,"raw":220,"subject":224,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":157,"fei_number":20,"letter_url":229,"updated_at":230,"action_type":23,"case_status":66,"posted_date":196,"marcs_cms_no":231,"product_type":232,"closeout_date":20,"issuing_office":233,"recipient_name":234,"body_fetched_at":235,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":236,"medical_device_id":20,"response_letter_date":20},2261,[187,221,222,223,224,13,13,13],"\u003Ctime datetime=\"2022-12-20T05:00:00Z\">12\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fauto-chlor-system-llc-641808-12202022\">Auto-Chlor System LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Johnathan Koth\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manufacturing Plant Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Auto-Chlor System LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3045 Commerce Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hapeville\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30354-1240\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 12\u002F20\u002F2022\u003C\u002Fp>\n\n\u003Cp>Case #: 641808\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Koth:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Auto-Chlor System LLC, FEI 3010164603, at 3045 Commerce Way, Hapeville, from July 5 to 18, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, HAND KLEEN FOAMING INSTANT HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your August 8, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is currently registered as a drug manufacturer and manufactures over-the-counter (OTC) hand rub\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> drug products (also referred to as a consumer hand sanitizer) including HAND KLEEN FOAMING INSTANT HAND SANITIZER, as well as non-drug products including industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial cleaners or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment.\u003C\u002Fp>\n\n\u003Cp>Inadequate removal of active ingredients and drug product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to test your incoming components for identity before using the components to manufacture your drug products. This includes not testing incoming ethanol, used as an active ingredient, for methanol. Additionally, you relied on certificates of analyses from unqualified suppliers for specifications such as purity, strength, and quality. By not analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>In addition, you confirmed that your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as a component for manufacturing drug products. Your firm has not shown that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>water that you use for component water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP purified water monograph and appropriate microbial limits. You confirmed to our investigators that no testing of this \u003Cstrong>(b)(4)\u003C\u002Fstrong> water has been performed, and you also lack procedures regarding water specifications, testing, or handling of water.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has not established that your processes used to manufacture hand sanitizer drug products are validated. In addition, you could not provide evidence that equipment qualification had been performed on your equipment.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Employees are trained and remain familiar with CGMPs (21 CFR 211.25(a)).\u003C\u002Fli>\n\t\u003Cli>Appropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\u003C\u002Fli>\n\t\u003Cli>Appropriate testing of each batch of drug product to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Performance of annual product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\t\u003Cli>To prepare adequate batch control and production records for your hand sanitizer drug products (21 CFR 211.188).\u003C\u002Fli>\n\t\u003Cli>Thorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the HAND KLEEN FOAMING INSTANT HAND SANITIZER label that provide evidence of the intended uses\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND KLEEN FOAMING INSTANT HAND SANITIZER . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Active Ingredient . . . Benzethonium Chloride 0.20% w\u002Fw . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antiseptic handwash. . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For handwashing to decrease bacteria on the skin. . .&nbsp;\u003Cstrong>Directions \u003C\u002Fstrong>. . . Apply a small amount to palm · Briskly rub, covering hands with product until dry. . .” [from your HAND KLEEN FOAMING INSTANT HAND SANITIZER label]\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HAND KLEEN FOAMING INSTANT HAND SANITIZER product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that OTC topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that the active ingredient benzethonium chloride was classified as Category III for use as an active ingredient in a consumer antiseptic wash. However, benzethonium chloride was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic rubs.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, HAND KLEEN FOAMING INSTANT HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>As previously noted, statements on the product label for HAND KLEEN FOAMING INSTANT HAND SANITIZER suggest that this product is intended to be both a consumer antiseptic wash and consumer antiseptic rub. However, benzethonium chloride (in any concentration) is not an active ingredient permitted for use in consumer antiseptic rubs under the 1994 TFM. A product cannot also be labeled as a handwash with directions in the labeling that pertain to use as a hand rub under the 1994 TFM.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because HAND KLEEN FOAMING INSTANT HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Outsourcing to Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility, to outsource the manufacturing of all FDA products to a private labeling company, and to ensure appropriate corrections are completed at the new manufacturer. If you plan to resume or outsource the manufacturing of drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to Jose R. Lopez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to joser.lopez@fda.hhs.gov and ronda.loyd-jones@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>641808\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Jose R. Lopez via (787) 729-8603 or joser.lopez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Auto-Chlor System LLC hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your HAND KLEEN FOAMING INSTANT HAND SANITIZER drug product’s labeling contains conflicting information regarding whether it should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e.,&nbsp;“Apply a small amount to palm · Briskly rub, covering hands with product until dry”). This product, however, does not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Johnathan Koth\n\nRecipient Title\n\nManufacturing Plant Manager\n\nAuto-Chlor System LLC\n\n3045 Commerce Way\n\nHapeville, GA 30354-1240\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 12\u002F20\u002F2022\n\nCase #: 641808\n\nWARNING LETTER\n\nDear Mr. Koth:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Auto-Chlor System LLC, FEI 3010164603, at 3045 Commerce Way, Hapeville, from July 5 to 18, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, HAND KLEEN FOAMING INSTANT HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your August 8, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm is currently registered as a drug manufacturer and manufactures over-the-counter (OTC) hand rub1 drug products (also referred to as a consumer hand sanitizer) including HAND KLEEN FOAMING INSTANT HAND SANITIZER, as well as non-drug products including industrial cleaners. It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture industrial cleaners or other non-pharmaceutical products due to the risk of cross-contamination. Our investigator also observed inadequate cleaning and maintenance of your drug manufacturing equipment.\n\nInadequate removal of active ingredients and drug product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to test your incoming components for identity before using the components to manufacture your drug products. This includes not testing incoming ethanol, used as an active ingredient, for methanol. Additionally, you relied on certificates of analyses from unqualified suppliers for specifications such as purity, strength, and quality. By not analyzing your components for identity, purity, strength, and quality, you failed to ensure that your incoming components meet appropriate specifications.\n\nIn addition, you confirmed that your firm uses (b)(4) water as a component for manufacturing drug products. Your firm has not shown that the (b)(4) water that you use for component water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP purified water monograph and appropriate microbial limits. You confirmed to our investigators that no testing of this (b)(4) water has been performed, and you also lack procedures regarding water specifications, testing, or handling of water.\n\nFurthermore, you manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nAs a manufacturer, you have a responsibility to sample, test, and examine drug components before use to assure adequate quality, including testing for the presence of methanol in ethanol, before use in production.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm has not established that your processes used to manufacture hand sanitizer drug products are validated. In addition, you could not provide evidence that equipment qualification had been performed on your equipment.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nEmployees are trained and remain familiar with CGMPs (21 CFR 211.25(a)).\n\nAppropriate testing for the identity and strength of the active ingredients was performed and reviewed before release for each batch of drug product (21 CFR 211.165(a)).\n\nAppropriate testing of each batch of drug product to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nEstablishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\n\nPerformance of annual product reviews (21 CFR 211.180(e)).\n\nTo prepare adequate batch control and production records for your hand sanitizer drug products (21 CFR 211.188).\n\nThorough investigations for out-of-specifications results, complaints, deviations, and other discrepant results per an adequate written and approved procedure (21 CFR 211.192).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nUnapproved New Drug and Misbranding Violations\n\nExamples of claims observed on the HAND KLEEN FOAMING INSTANT HAND SANITIZER label that provide evidence of the intended uses2 (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“HAND KLEEN FOAMING INSTANT HAND SANITIZER . . . Drug Facts . . . Active Ingredient . . . Benzethonium Chloride 0.20% w\u002Fw . . . Purpose . . . Antiseptic handwash. . . Uses . . . For handwashing to decrease bacteria on the skin. . . Directions . . . Apply a small amount to palm · Briskly rub, covering hands with product until dry. . .” [from your HAND KLEEN FOAMING INSTANT HAND SANITIZER label]\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your HAND KLEEN FOAMING INSTANT HAND SANITIZER product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that OTC topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that the active ingredient benzethonium chloride was classified as Category III for use as an active ingredient in a consumer antiseptic wash. However, benzethonium chloride was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic rubs.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, HAND KLEEN FOAMING INSTANT HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule [and the 2013 Consumer Antiseptic Washes Proposed Rule], nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAs previously noted, statements on the product label for HAND KLEEN FOAMING INSTANT HAND SANITIZER suggest that this product is intended to be both a consumer antiseptic wash and consumer antiseptic rub. However, benzethonium chloride (in any concentration) is not an active ingredient permitted for use in consumer antiseptic rubs under the 1994 TFM. A product cannot also be labeled as a handwash with directions in the labeling that pertain to use as a hand rub under the 1994 TFM.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because HAND KLEEN FOAMING INSTANT HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, if your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of any identified corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nOutsourcing to Contract Manufacturers\n\nWe acknowledge your commitment to cease production of drugs at this facility, to outsource the manufacturing of all FDA products to a private labeling company, and to ensure appropriate corrections are completed at the new manufacturer. If you plan to resume or outsource the manufacturing of drugs, notify this office before resuming your operations.\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to Jose R. Lopez, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to joser.lopez@fda.hhs.gov and ronda.loyd-jones@fda.hhs.gov.\n\nYour written notification should refer to case # 641808.\n\nIf you have questions regarding the contents of this letter, you may contact Jose R. Lopez via (787) 729-8603 or joser.lopez@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n_______________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Auto-Chlor System LLC hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n2 We note that your HAND KLEEN FOAMING INSTANT HAND SANITIZER drug product’s labeling contains conflicting information regarding whether it should be used as consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs, and the Drug Facts Label of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “Apply a small amount to palm · Briskly rub, covering hands with product until dry”). This product, however, does not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash, as further described below.","Auto-Chlor System LLC","auto-chlor-system-llc-641808-12202022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fauto-chlor-system-llc-641808-12202022","2026-10-26T08:07:59.371651+00:00","641808","Drugs","Division of Pharmaceutical Quality Operations II","Mr. Johnathan Koth","2026-08-20T01:19:41.201+00:00","2022-12-20",{"id":238,"raw":239,"subject":246,"body_html":247,"body_text":248,"firm_name":249,"letter_id":250,"created_at":251,"fei_number":20,"letter_url":252,"updated_at":253,"action_type":23,"case_status":24,"posted_date":254,"marcs_cms_no":255,"product_type":256,"closeout_date":257,"issuing_office":243,"recipient_name":258,"body_fetched_at":259,"delivery_method":260,"recipient_title":20,"reference_number":20,"action_taken_date":261,"medical_device_id":20,"response_letter_date":20},2523,[240,241,242,243,244,13,245,13],"\u003Ctime datetime=\"2022-08-09T13:20:00Z\">08\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-08032022\">Valley Biosystems\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Bioresearch Monitoring Program\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-10142022\">\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Bioresearch Monitoring Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Granger G. C. Hwa, M.D. Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Valley Biosystems\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1265 Triangle Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Sacramento\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER-22-002\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Hwa:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during a Food and Drug Administration (FDA) inspection conducted at Valley Biosystems, West Sacramento, California between August 26 and October 8, 2021. FDA investigators met with your staff during the inspection to review your firm’s conduct of the following nonclinical Good Laboratory Practice (GLP) studies:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>FDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to review the conduct of research involving investigational products and to help ensure that the data are scientifically valid and accurate, in accordance with Title 21 of the Code of Federal Regulations (CFR), Part 58 – Good Laboratory (GLP) regulations (available at \u003Cstrong>eCFR :: 21 CFR Part 58 -- Good Laboratory Practice for Nonclinical Laboratory Studies\u003C\u002Fstrong>), which are requirements promulgated under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262, and section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355, among other provisions. You were not present in person during the inspection but were available via Zoom on September 2, 2021, and October 8, 2021. At the end of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) and discussed the listed observations with you and your staff.\u003C\u002Fp>\n\n\u003Cp>Based on our review of the Establishment Inspection Report (EIR), the documents submitted with that report, and your firm’s response dated November 1, 2021, to the Form FDA 483 (“Response Letter”), signed by Mr. Cello, we determined that you violated GLP regulations in 21 CFR Part 58. The violations include, but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to ensure that each individual engaged in the conduct of or responsible for the supervision of a nonclinical laboratory study has education, training, and experience, or a combination thereof, to enable that individual to perform the assigned functions; that each testing facility maintains a current summary of training and experience and job description for each individual engaged in or supervising the conduct of a nonclinical laboratory study; and that for each nonclinical laboratory study, a scientist or other professional of appropriate education, training, and experience, or combination thereof, shall be identified as the study director. [21 CFR §§ 58.29(a), 58.29(b), and 58.33].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to maintain records of trainings that your staff had received to adequately assess their competency and qualifications to perform their assigned tasks for Studies&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Examples, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. There is no documentation of protocol-specific trainings for the following individuals who participated in these studies:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Dr. GGCH, the Chairman of the Board, and Test Facility Management who was involved in editing and reviewing the final reports for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Three (3) Veterinarians\u003C\u002Fli>\n\t\u003Cli>Gross Pathologist\u003C\u002Fli>\n\t\u003Cli>Operations Manager\u003C\u002Fli>\n\t\u003Cli>Director of Animal Program &amp; Facilities &amp; Chief Operating Officer\u003C\u002Fli>\n\t\u003Cli>QA Manager\u003C\u002Fli>\n\t\u003Cli>Nine (9) Research Technicians\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. Your firm failed to adequately fulfill your regulatory responsibilities by assuring that your study director is qualified and appointed to be the single point of control for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your QA Manager (hereafter referred to as the Quality Assurance Unit (QAU)) stated that your firm’s study director is not a position and is a title on an “as needed” basis.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you expanded your pre-project planning meetings and required Read Only Trainings for all protocols and protocol amendments. We also reviewed your SOP QA25.4, submitted with your Response Letter, and it appears adequate, if properly implemented.\u003C\u002Fp>\n\n\u003Cp>Your firm has also assigned the supplemental GLP training CAPA PA-21-072-01, which was expected to be completed on or before January 31, 2021. We request that you provide all documentation of the GLP training that you have stated to be completed on or before January 31, 2022, including the materials used for the trainings.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you restated your position that the study director is a title at Valley Biosystems, but not a position, and that you therefore do not plan to create a Study Director position description. This approach is not compliant with the applicable requirements. In response to this letter, please review 21 CFR § 58.33, which sets forth the regulatory requirements for the role of the study director, and inform FDA how you intend to comply with this and the other GLP requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The study director failed to assure that the protocol, including any change, is approved as provided by 21 CFR § 58.120 and is followed; that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented. Additionally, all data entries shall be dated on the date of entry and signed or initialed by the person entering the data. Any change in entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change. [21 CFR § 58.33 (a)(b)(c) and 21 CFR 58.130(e)]\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>a. The study director failed to assure that the study was conducted according to the protocol and was accurately recorded. Specifically, the section of the study #\u003Cstrong>(b)(4)\u003C\u002Fstrong> protocol entitled, “Monitoring of Animal Welfare” required that “signs of animal illness, injury, or pain and distress will be communicated to the Study Director and Sponsor Monitor” and “Recommendations for the treatment of the animals must be approved by the Study Director and Sponsor Monitor.” However, it was not documented that these requirements were met for the following animals:\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – hemorrhagic diarrhea on 3\u002F2\u002F19 – 3\u002F4\u002F19 and treatment with&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> on 3\u002F2\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> –treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 5\u002F9\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 1\u002F2\u002F19.\u003C\u002Fli>\n\t\u003Cli>Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong> – treatment with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for trichuris infection on 1\u002F2\u002F19.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>b. A review of 12 of 12 of the Test Article (TA)\u002FControl Article (CA) Preparation Forms revealed that the name, lot number, and expiration date of reagents and solutions used in preparation of test and control articles were preprinted as opposed to being documented contemporaneously. The documents revealed that the preprinted expiration dates were crossed out and changed, without explanation, by the study director to reflect different expiration dates over a month after the actual date of preparation. This occurred for the following animal source records:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal ID\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date of TA\u002FCA Preparation&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Completed\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>of change\u002Ffootnote\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F3\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F5\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F4\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F10\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F6\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F9\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F12\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F16\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F11\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>10\u002F2\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F17\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F18\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>(b)(4)\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F19\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>11\u002F7\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>Because you failed to ensure that all experimental data were accurately recorded and verified, and that all entries and changes in entries were properly documented, FDA has concerns about the integrity of the data generated from the nonclinical toxicity studies conducted at your testing facility.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you listed SOPs that were revised or are being developed since the inspection, including the revised SOP PA01.7. In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs not already provided, and documentation of any related trainings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure of the QAU to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection. [21 CFR § 58.35(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The QAU is responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the GLP regulations. 21 CFR § 58.35(a).\u003C\u002Fp>\n\n\u003Cp>a. Your QAU failed to maintain a complete copy of the audit schedule sheet to inspect studies at intervals adequate to assure the integrity of the studies.\u003C\u002Fp>\n\n\u003Cp>b. Your QAU failed to maintain contemporaneously signed and dated documentation or reports of the Critical Phase inspections. Your QAU stated that the Critical Phase inspection results were written directly on the Protocols or on scratch pieces of paper that were thrown away after summarizing the results on the monthly Quality Assurance Status Reports.\u003C\u002Fp>\n\n\u003Cp>Your QAU was not able to provide any source documents of the schedule nor reports for the Critical Phase inspections that were performed for the two GLP studies. We are unable to verify that your QAU audits were adequately conducted according to your SOPs and are in compliance with applicable GLP regulations.\u003C\u002Fp>\n\n\u003Cp>A reliable QAU is integral to the successful completion of any GLP study. Without appropriate QAU oversight, the sponsor and FDA reviewers have no assurance that what is reported in the final study report is accurate. Failure to perform QAU functions calls into question the integrity of both studies.\u003C\u002Fp>\n\n\u003Cp>Your Response Letter explains that you revised SOP QA 10.4 and the accompanying forms; however, you have not developed effective, contemporaneous audit documents that will serve as source documentation of the audits performed by your QAU, for each Critical Phase defined by your SOP. In your response to this letter, please provide audit document templates to accompany your SOP that will serve to demonstrate full compliance with the regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to retain all raw data, documentation, protocols, final reports, and specimens (except those specimens obtained from (b)(4)\u003C\u002Fstrong>\u003Cstrong>&nbsp;tests and (b)(4)\u003C\u002Fstrong>\u003Cstrong>) generated as a result of a nonclinical laboratory study. [ 21 CFR § 58.190(a)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>a. Twelve (12) of 48 animals surgically treated with the test or control article were missing original source Laboratory Animal Anesthesia Records, which contain details of the surgical procedure for test or control article administration. According to your QAU, the original paper records were discarded once they were scanned and saved electronically.\u003C\u002Fp>\n\n\u003Cp>b. Your firm failed to preserve any source records demonstrating your study director’s adherence to the GLP requirements in regard to his conduct of writing the final reports for Studies \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm was not able to provide the redline copies of the draft reports, and your QAU stated that the documents had all been deleted.\u003C\u002Fp>\n\n\u003Cp>In your Response Letter, you stated that your SOPs are being revised following the inspection, but you did not provide supporting documentation of your corrective and preventive actions. Please note that good record keeping and an organized archive that allows for the expedient retrieval of raw data are ways in which your firm can ensure the quality and integrity of the data generated from your GLP nonclinical studies.\u003C\u002Fp>\n\n\u003Cp>Incorrect archiving of study materials affects the integrity and reliability of study data as it prevents accurate retrieval of such data for review, analysis, and verification. Also, failure to have an index prevents data from being readily available, located expeditiously, analyzed, and reconciled when necessary.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs for archiving source documents, and documentation of any trainings related to this violation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to include in the final report a description of all circumstances that may have affected the quality or integrity of the data for each nonclinical laboratory study. [21 CFR § 58.185(a)(9)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to include all data observed for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the final Study Report. Data that were not included in the final report include, but are not limited to:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Number\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Source Document\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Assessment\u002FComment\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Assessment&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Daily Clinical&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Observations\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Nervous tapping\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>9\u002F20\u002F19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Functional&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Observation&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Battery&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Evaluation\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Day 122 post-dose “Out-of Cage”&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>assessment documented abnormal&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>dysmetria, specifically a new&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>comment of “mild crouching of torso&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>when walking tripedally.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>1\u002F16\u002F20\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>\u003Cspan>(b)(4)\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Animal Health&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Record\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Acute emesis\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>02\u002F19\u002F20\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>We acknowledge in your Response Letter that you plan to revise SOP QA08.4, Preparation, Review and Approval of Nonclinical Laboratory Study Reports. However, your response cannot be evaluated due to lack of supporting documentation. Please provide a copy of the revised SOP, which you stated will be completed before December 03, 2021, along with documentation of any corrective actions you have implemented thus far.\u003C\u002Fp>\n\n\u003Cp>The records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents form the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\u003C\u002Fp>\n\n\u003Cp>We further note during the inspection that the FDA investigators found five (5) reports, “Project Observation Note” (PON), from \u003Cstrong>(b)(4)\u003C\u002Fstrong> was the laboratory that you contracted to perform histopathology and immunohistochemical analysis for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These records revealed numerous comments of poor-quality and insufficient tissue collections received from your firm. Examples of these deviations noted in the PON report from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>For Week-5 Animals, various deficiencies were noted for all spinal cords, all eye tissues, all kidney tissues, all heart tissues, and all larynx tissues.\u003C\u002Fli>\n\t\u003Cli>For unscheduled death Animal \u003Cstrong>(b)(4)\u003C\u002Fstrong>, various observations were noted for ureters, salivary gland, adrenal, heart, femur\u002Fsternum bone and marrow, and kidneys.\u003C\u002Fli>\n\t\u003Cli>For the animals sacrificed at 13 weeks, all brain \u003Cstrong>(b)(4)\u003C\u002Fstrong> were received with a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, except for a few animals. It appears the \u003Cstrong>(b)(4)\u003C\u002Fstrong> after processing. In addition, for a certain group of four animals, only one liver was received with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> (i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response to this letter, we request that you provide all documentation and reports, including any corrective action taken that will demonstrate your firm’s investigation and corrective actions taken regarding the numerous tissue sample collection deviations reported to you by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of your violations and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies conducted at your GLP nonclinical laboratory.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your nonclinical studies of investigational new drugs. It is your responsibility to ensure full compliance with the law, including all applicable requirements of the FD&amp;C Act, the PHS Act, and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct the noted violations and to prevent the recurrence of similar violations in current and future nonclinical laboratory studies.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. Failure to respond to this letter and to take appropriate corrective action could result in FDA taking regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8038.\u003C\u002Fp>\n\n\u003Cp>We also request that you send a copy of your response to the FDA Office listed below.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza, JD\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nEric Pittman, Director\u003Cbr>\nFDA ORA-BIMO West\u003Cbr>\n550 West Jackson Street, Suite 1500\u003Cbr>\nChicago, Illinois 60661\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that the FDA investigator was only able to review the conduct of the study by searching through your study director’s email account for the records.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS and Electronic Mail\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nGranger G. C. Hwa, M.D. Ph.D.\n\nRecipient Title\n\nChairman\n\nValley Biosystems\n\n1265 Triangle Court\n\nWest Sacramento, CA 95605\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nCBER-22-002\n\nAugust 3, 2022\n\nDear Dr. Hwa:\n\nThis Warning Letter informs you of objectionable conditions observed during a Food and Drug Administration (FDA) inspection conducted at Valley Biosystems, West Sacramento, California between August 26 and October 8, 2021. FDA investigators met with your staff during the inspection to review your firm’s conduct of the following nonclinical Good Laboratory Practice (GLP) studies:\n\n(b)(4)\n\n(b)(4)\n\nFDA conducted this inspection under the Bioresearch Monitoring Program, which includes inspections designed to review the conduct of research involving investigational products and to help ensure that the data are scientifically valid and accurate, in accordance with Title 21 of the Code of Federal Regulations (CFR), Part 58 – Good Laboratory (GLP) regulations (available at eCFR :: 21 CFR Part 58 -- Good Laboratory Practice for Nonclinical Laboratory Studies), which are requirements promulgated under section 351 of the Public Health Service Act (PHS Act), 42 U.S.C. § 262, and section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355, among other provisions. You were not present in person during the inspection but were available via Zoom on September 2, 2021, and October 8, 2021. At the end of the inspection, the FDA investigator presented a Form FDA 483, List of Inspectional Observations (Form FDA 483) and discussed the listed observations with you and your staff.\n\nBased on our review of the Establishment Inspection Report (EIR), the documents submitted with that report, and your firm’s response dated November 1, 2021, to the Form FDA 483 (“Response Letter”), signed by Mr. Cello, we determined that you violated GLP regulations in 21 CFR Part 58. The violations include, but are not limited to the following:\n\n1. Failure to ensure that each individual engaged in the conduct of or responsible for the supervision of a nonclinical laboratory study has education, training, and experience, or a combination thereof, to enable that individual to perform the assigned functions; that each testing facility maintains a current summary of training and experience and job description for each individual engaged in or supervising the conduct of a nonclinical laboratory study; and that for each nonclinical laboratory study, a scientist or other professional of appropriate education, training, and experience, or combination thereof, shall be identified as the study director. [21 CFR §§ 58.29(a), 58.29(b), and 58.33].\n\nYour firm failed to maintain records of trainings that your staff had received to adequately assess their competency and qualifications to perform their assigned tasks for Studies (b)(4). Examples, include, but are not limited to, the following:\n\na. There is no documentation of protocol-specific trainings for the following individuals who participated in these studies:\n\nDr. GGCH, the Chairman of the Board, and Test Facility Management who was involved in editing and reviewing the final reports for Study (b)(4) and Study (b)(4)\n\nThree (3) Veterinarians\n\nGross Pathologist\n\nOperations Manager\n\nDirector of Animal Program & Facilities & Chief Operating Officer\n\nQA Manager\n\nNine (9) Research Technicians\n\nb. Your firm failed to adequately fulfill your regulatory responsibilities by assuring that your study director is qualified and appointed to be the single point of control for Studies (b)(4) and Study (b)(4). Your QA Manager (hereafter referred to as the Quality Assurance Unit (QAU)) stated that your firm’s study director is not a position and is a title on an “as needed” basis.\n\nIn your Response Letter, you expanded your pre-project planning meetings and required Read Only Trainings for all protocols and protocol amendments. We also reviewed your SOP QA25.4, submitted with your Response Letter, and it appears adequate, if properly implemented.\n\nYour firm has also assigned the supplemental GLP training CAPA PA-21-072-01, which was expected to be completed on or before January 31, 2021. We request that you provide all documentation of the GLP training that you have stated to be completed on or before January 31, 2022, including the materials used for the trainings.\n\nIn your Response Letter, you restated your position that the study director is a title at Valley Biosystems, but not a position, and that you therefore do not plan to create a Study Director position description. This approach is not compliant with the applicable requirements. In response to this letter, please review 21 CFR § 58.33, which sets forth the regulatory requirements for the role of the study director, and inform FDA how you intend to comply with this and the other GLP requirements.\n\n2. The study director failed to assure that the protocol, including any change, is approved as provided by 21 CFR § 58.120 and is followed; that all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented. Additionally, all data entries shall be dated on the date of entry and signed or initialed by the person entering the data. Any change in entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change. [21 CFR § 58.33 (a)(b)(c) and 21 CFR 58.130(e)]\n\na. The study director failed to assure that the study was conducted according to the protocol and was accurately recorded. Specifically, the section of the study #(b)(4) protocol entitled, “Monitoring of Animal Welfare” required that “signs of animal illness, injury, or pain and distress will be communicated to the Study Director and Sponsor Monitor” and “Recommendations for the treatment of the animals must be approved by the Study Director and Sponsor Monitor.” However, it was not documented that these requirements were met for the following animals:1\n\nAnimal (b)(4) – hemorrhagic diarrhea on 3\u002F2\u002F19 – 3\u002F4\u002F19 and treatment with (b)(4) on 3\u002F2\u002F19.\n\nAnimal (b)(4) –treatment with (b)(4) for trichuris infection on 5\u002F9\u002F19.\n\nAnimal (b)(4) – treatment with (b)(4) for trichuris infection on 1\u002F2\u002F19.\n\nAnimal (b)(4) – treatment with (b)(4) for trichuris infection on 1\u002F2\u002F19.\n\nb. A review of 12 of 12 of the Test Article (TA)\u002FControl Article (CA) Preparation Forms revealed that the name, lot number, and expiration date of reagents and solutions used in preparation of test and control articles were preprinted as opposed to being documented contemporaneously. The documents revealed that the preprinted expiration dates were crossed out and changed, without explanation, by the study director to reflect different expiration dates over a month after the actual date of preparation. This occurred for the following animal source records:\n\nAnimal ID\n\nDate of TA\u002FCA Preparation Completed\n\nDate of change\u002Ffootnote\n\n(b)(4)\n\n9\u002F3\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F5\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F4\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F10\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F6\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F9\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F12\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F16\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F11\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n10\u002F2\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F17\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F18\u002F19\n\n11\u002F7\u002F19\n\n(b)(4)\n\n9\u002F19\u002F19\n\n11\u002F7\u002F19\n\nBecause you failed to ensure that all experimental data were accurately recorded and verified, and that all entries and changes in entries were properly documented, FDA has concerns about the integrity of the data generated from the nonclinical toxicity studies conducted at your testing facility.\n\nIn your Response Letter, you listed SOPs that were revised or are being developed since the inspection, including the revised SOP PA01.7. In your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs not already provided, and documentation of any related trainings.\n\n3. Failure of the QAU to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection. [21 CFR § 58.35(b)(3)].\n\nThe QAU is responsible for monitoring each study to assure management that the facilities, equipment, personnel, methods, practices, records, and controls are in conformance with the GLP regulations. 21 CFR § 58.35(a).\n\na. Your QAU failed to maintain a complete copy of the audit schedule sheet to inspect studies at intervals adequate to assure the integrity of the studies.\n\nb. Your QAU failed to maintain contemporaneously signed and dated documentation or reports of the Critical Phase inspections. Your QAU stated that the Critical Phase inspection results were written directly on the Protocols or on scratch pieces of paper that were thrown away after summarizing the results on the monthly Quality Assurance Status Reports.\n\nYour QAU was not able to provide any source documents of the schedule nor reports for the Critical Phase inspections that were performed for the two GLP studies. We are unable to verify that your QAU audits were adequately conducted according to your SOPs and are in compliance with applicable GLP regulations.\n\nA reliable QAU is integral to the successful completion of any GLP study. Without appropriate QAU oversight, the sponsor and FDA reviewers have no assurance that what is reported in the final study report is accurate. Failure to perform QAU functions calls into question the integrity of both studies.\n\nYour Response Letter explains that you revised SOP QA 10.4 and the accompanying forms; however, you have not developed effective, contemporaneous audit documents that will serve as source documentation of the audits performed by your QAU, for each Critical Phase defined by your SOP. In your response to this letter, please provide audit document templates to accompany your SOP that will serve to demonstrate full compliance with the regulations.\n\n4. Failure to retain all raw data, documentation, protocols, final reports, and specimens (except those specimens obtained from (b)(4) tests and (b)(4)) generated as a result of a nonclinical laboratory study. [ 21 CFR § 58.190(a)].\n\nFor example:\n\na. Twelve (12) of 48 animals surgically treated with the test or control article were missing original source Laboratory Animal Anesthesia Records, which contain details of the surgical procedure for test or control article administration. According to your QAU, the original paper records were discarded once they were scanned and saved electronically.\n\nb. Your firm failed to preserve any source records demonstrating your study director’s adherence to the GLP requirements in regard to his conduct of writing the final reports for Studies (b)(4). Your firm was not able to provide the redline copies of the draft reports, and your QAU stated that the documents had all been deleted.\n\nIn your Response Letter, you stated that your SOPs are being revised following the inspection, but you did not provide supporting documentation of your corrective and preventive actions. Please note that good record keeping and an organized archive that allows for the expedient retrieval of raw data are ways in which your firm can ensure the quality and integrity of the data generated from your GLP nonclinical studies.\n\nIncorrect archiving of study materials affects the integrity and reliability of study data as it prevents accurate retrieval of such data for review, analysis, and verification. Also, failure to have an index prevents data from being readily available, located expeditiously, analyzed, and reconciled when necessary.\n\nIn your response to this letter, please provide documentation of the corrective and preventive actions you have implemented to prevent these types of deviations from recurring in future GLP studies, including a copy of all new or revised SOPs for archiving source documents, and documentation of any trainings related to this violation.\n\n5. Failure to include in the final report a description of all circumstances that may have affected the quality or integrity of the data for each nonclinical laboratory study. [21 CFR § 58.185(a)(9)].\n\nYou failed to include all data observed for Study (b)(4) in the final Study Report. Data that were not included in the final report include, but are not limited to:\n\nAnimal Number\n\nSource Document\n\nAssessment\u002FComment\n\nAssessment Date\n\n(b)(4)\n\nDaily Clinical Observations\n\nNervous tapping\n\n9\u002F20\u002F19\n\n(b)(4)\n\nFunctional Observation Battery Evaluation\n\nDay 122 post-dose “Out-of Cage” assessment documented abnormal dysmetria, specifically a new comment of “mild crouching of torso when walking tripedally.”\n\n1\u002F16\u002F20\n\n(b)(4)\n\nAnimal Health Record\n\nAcute emesis\n\n02\u002F19\u002F20\n\nWe acknowledge in your Response Letter that you plan to revise SOP QA08.4, Preparation, Review and Approval of Nonclinical Laboratory Study Reports. However, your response cannot be evaluated due to lack of supporting documentation. Please provide a copy of the revised SOP, which you stated will be completed before December 03, 2021, along with documentation of any corrective actions you have implemented thus far.\n\nThe records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents form the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\n\nWe further note during the inspection that the FDA investigators found five (5) reports, “Project Observation Note” (PON), from (b)(4) was the laboratory that you contracted to perform histopathology and immunohistochemical analysis for Study (b)(4). These records revealed numerous comments of poor-quality and insufficient tissue collections received from your firm. Examples of these deviations noted in the PON report from (b)(4), include, but are not limited to, the following:\n\nFor Week-5 Animals, various deficiencies were noted for all spinal cords, all eye tissues, all kidney tissues, all heart tissues, and all larynx tissues.\n\nFor unscheduled death Animal (b)(4), various observations were noted for ureters, salivary gland, adrenal, heart, femur\u002Fsternum bone and marrow, and kidneys.\n\nFor the animals sacrificed at 13 weeks, all brain (b)(4) were received with a (b)(4), except for a few animals. It appears the (b)(4) after processing. In addition, for a certain group of four animals, only one liver was received with a (b)(4) (i.e., (b)(4)).\n\nIn your response to this letter, we request that you provide all documentation and reports, including any corrective action taken that will demonstrate your firm’s investigation and corrective actions taken regarding the numerous tissue sample collection deviations reported to you by (b)(4).\n\nThis letter notifies you of your violations and provides you an opportunity to address the above deficiencies. You should investigate and determine the causes of any violations and take prompt actions to implement corrections to prevent the recurrence of similar violations in current and future studies conducted at your GLP nonclinical laboratory.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with your nonclinical studies of investigational new drugs. It is your responsibility to ensure full compliance with the law, including all applicable requirements of the FD&C Act, the PHS Act, and FDA regulations.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter. In your response, please provide written documentation of additional actions you have taken or will take to correct the noted violations and to prevent the recurrence of similar violations in current and future nonclinical laboratory studies.\n\nFailure to adequately address this matter may lead to regulatory action. Failure to respond to this letter and to take appropriate corrective action could result in FDA taking regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to me at the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., WO71-G112, Silver Spring, MD 20993-0002. If you have any questions regarding this letter, please contact the Division of Inspections and Surveillance, CBER at 240-402-8038.\n\nWe also request that you send a copy of your response to the FDA Office listed below.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza, JD\n\nActing Director\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\ncc:\n\nEric Pittman, Director\n\nFDA ORA-BIMO West\n\n550 West Jackson Street, Suite 1500\n\nChicago, Illinois 60661\n\n______________________\n\n1 We note that the FDA investigator was only able to review the conduct of the study by searching through your study director’s email account for the records.","Valley Biosystems","valley-biosystems-632553-08032022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalley-biosystems-632553-08032022","2026-10-26T08:10:19.180269+00:00","2022-08-09","632553","Biologics","2022-10-18","Granger G. C. Hwa, M.D. Ph.D.","2026-08-20T01:41:07.432+00:00","UPS and Electronic Mail","2022-08-03",{"id":263,"raw":264,"subject":224,"body_html":268,"body_text":269,"firm_name":270,"letter_id":271,"created_at":272,"fei_number":20,"letter_url":273,"updated_at":274,"action_type":23,"case_status":66,"posted_date":275,"marcs_cms_no":276,"product_type":232,"closeout_date":20,"issuing_office":80,"recipient_name":277,"body_fetched_at":278,"delivery_method":128,"recipient_title":20,"reference_number":279,"action_taken_date":280,"medical_device_id":20,"response_letter_date":20},42,[265,266,267,80,224,13,13,13],"\u003Ctime datetime=\"2026-07-14T04:00:00Z\">07\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-02T04:00:00Z\">07\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-medication-systems-limited-727560-07022026\">International Medication Systems Limited\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-99\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Jack Y. Zhang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>International Medication Systems Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1886 Santa Anita Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South El Monte\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91733\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-99\u003C\u002Fp>\u003Cp>July 2, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Zhang:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Medication System Limited, FEI 2016148, at 1886 Santa Anita Avenue, South El Monte, from December 9 to 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your January 15, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures active pharmaceutical ingredients and sterile injectable drug products. The sterile injectable products include aseptically filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm failed to conduct adequate investigations. For example, you inadequately investigated multiple too-numerous-to-count (TNTC) microbial findings during the manufacture of epinephrine injection, lot EA038A5. Specifically, a viable air environmental monitoring plate, located next to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your ISO 5 aseptic filling area, yielded a too-numerous-to-count result with confluent bacterial growth and numerous insect larvae. On the same day, personnel monitoring plates for an individual in the adjacent ISO 7 \u003Cstrong>(b)(4)\u003C\u002Fstrong> also yielded TNTC results and contained insect larvae.\u003C\u002Fp>\u003Cp>Your investigation failed to identify a scientifically-supported root cause, instead attributing these exceedingly high environmental monitoring findings to an unsubstantiated hypothesis involving insect infiltration of sealed monitoring plates. Notably, written procedures require inspection of plates before use to ensure they are not contaminated or defective, and also require very strict handling measures following sampling (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags, sterile tape). The microbiological growth media batch also passed negative control testing. Although your deviation report lacked evidence of defects or sampling error, you assessed the contamination risk as “low” based on overreliance on passing sterility test results, and the quality unit approved the release of epinephrine injection, lot EA038A5.\u003C\u002Fp>\u003Cp>The presence of insect larvae and gross microbial contamination in your aseptic processing area demonstrates a critical failure of your contamination control program. The decision to release a lot manufactured under these conditions also demonstrates that your quality unit failed to exercise its responsibility to ensure drug products are manufactured under appropriate conditions and to reject any lot produced under conditions that compromise its quality.\u003C\u002Fp>\u003Cp>In your response, you reiterate that your investigation concluded the contamination was “post-exposure adventitious contamination external to the filling suite,” based on mostly acceptable environmental monitoring data in other locations that day. Using this rationale, you determined the two environmental contamination events were isolated incidents and the risk to the product was low. You also determined that no corrective actions were needed.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your investigation outcome based on a “post-exposure” hypothesis remains poorly supported by data. The occurrence of two severe contamination events on the same day in adjacent rooms indicates a significant breakdown in contamination control. Additionally, your failure to implement corrective actions reflects a critical deficiency in your investigation and indicates inadequate oversight of the state of control of the aseptic processing operation.\u003C\u002Fp>\u003Cp>We also note that, between March 2021 and March 2026, your firm filed three field alert reports for contamination issues with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Since December 2023, you received over 90 customer complaints, many related to container-closure deficiencies such as glass breakage\u002Fvial cracking, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Many of your investigations were closed without identifying a root cause.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, third-party assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A comprehensive, independent review and update of all field alert reports and customer complaints for drug products within expiry, including scientifically sound root cause analyses, corrective actions implemented, and timelines for completion of the investigations. This review should include, where applicable, re-investigation of all complaints involving potential contamination and container-closure deficiencies. Include documentation of all investigative steps taken, potential root causes considered and those systematically ruled out, and any interim controls or preventive measures implemented. Include your corrective action plan based on this in-depth review and trend analysis.\u003C\u002Fli>\u003Cli>A comprehensive, third-party assessment and remediation plan for your pest control program. The assessment should include, but not be limited to, a review of facility design and maintenance, effectiveness of monitoring program, investigation procedures, historical findings, and personnel training.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.42(c)(10) and 21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s aseptic processing lines and operations were inadequately designed, controlled, and monitored to prevent microbiological contamination.\u003C\u002Fp>\u003Cp>Your firm refers to your aseptic processing lines as restricted access barrier systems (RABS). However, your equipment lacks fundamental design elements of a RABS, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Without this basic feature, as well as other design provisions, your processing lines cannot be categorized as RABS.\u003C\u002Fp>\u003Cp>In addition to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, RABS include various design elements that are essential for minimizing or eliminating direct gowned personnel interventions (\u003Cstrong>(b)(4)\u003C\u002Fstrong> interactions) into the critical (ISO 5) area during batch manufacturing.\u003C\u002Fp>\u003Cp>Your current process requires an operator to stand within a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 5 area. The operator manually cuts open numerous (e.g., approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>) stopper bags per batch and transfers stoppers using a \u003Cstrong>(b)(4)\u003C\u002Fstrong> scoop. These manually-intensive interventions pose a significant and repeated risk of microbial contamination. Despite the critical nature of this activity, your firm failed to conduct environmental monitoring in this area to evaluate its impact on the aseptic environment. This represents a serious gap in environmental control oversight.\u003C\u002Fp>\u003Cp>Your firm also failed to adequately evaluate unidirectional airflow in the critical area, as the smoke studies conducted were fundamentally flawed. The placement and movement of the wand as well as other factors precluded meaningful assessment of airflow directionality.\u003C\u002Fp>\u003Cp>The design of your aseptic filling line presents inherent contamination risks that are exacerbated by inadequate controls. These conditions are insufficient to ensure robust aseptic production of sterile drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you added a new environmental monitoring location in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and conducted airflow studies in the ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. You claim that operator movement has “no impact to 1st air, maintaining unidirectional airflow and minimal turbulence.” You also propose a long-term plan to upgrade the facility within two years, including upgrading the adjacent \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ISO 5.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposal does not address the fundamental design flaws of your aseptic processing lines, as the primary contamination risks stem from extensive manual interventions within the ISO 5 processing area itself. Additionally, a long-term plan to upgrade the facility in two years is inadequate because it does not address how you will mitigate the immediate and ongoing risk to product quality posed by your current operations.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fsterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow – movement throughout all rooms used to conduct and support sterile operations, and all material transfers\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\u003Cli>A retrospective review and risk assessment for drug product batches within expiry that were manufactured in the affected aseptic processing area. Provide a formal risk assessment evaluating the potential for non-sterility hazards for each batch, along with a report detailing your subsequent actions, such as customer notifications or product recalls.\u003C\u002Fli>\u003Cli>Perform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system was inadequately designed, monitored, and maintained.\u003C\u002Fp>\u003Cp>You use \u003Cstrong>(b)(4)\u003C\u002Fstrong> for cleaning drug manufacturing equipment, and the same system feeds your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. During the inspection, we observed gross contamination in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> storage tank feeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system with interior surfaces coated in dark-colored plaques. Further compounding these concerns, investigators observed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been repaired with \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealant material, and that threaded connections with seal tape were used in place of sanitary fittings. These systems failed to adhere to appropriate \u003Cstrong>(b)(4) \u003C\u002Fstrong>system design and maintenance standards.\u003C\u002Fp>\u003Cp>In your response, you identify the observed dark-colored plaques in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, non-sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank as \u003Cstrong>(b)(4)\u003C\u002Fstrong> biofilm, characterizing the contamination as “predictable and environmentally normal.” You add that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank was \u003Cstrong>(b)(4)\u003C\u002Fstrong> allowed transmission of ambient light, which enabled photosynthesis and extensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> growth on the tank walls. You assert that there was no impact on the quality of the downstream \u003Cstrong>(b)(4)\u003C\u002Fstrong>, relying on passing test results to support this claim. The primary corrective action you reported was cleaning the affected tank.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposed corrective action of simply cleaning the storage tank is insufficient because it fails to address the fundamental design and maintenance flaws that allowed unchecked \u003Cstrong>(b)(4)\u003C\u002Fstrong> growth and gross contamination. A source \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank should be designed and maintained to prevent it from becoming a reservoir for biological contamination as the resulting bioburden can potentially overwhelm downstream \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps. Furthermore, your rationale of using passing downstream test results to justify the use of a grossly contaminated source tank is not in accord with basic system design and control standards. It is your responsibility to ensure that all equipment used in the manufacture of your drug products is appropriately designed, maintained, and controlled.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive third-party assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, including:\u003Cbr>o A comprehensive evaluation of vulnerabilities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design and control and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system \u003Cstrong>(b)(4)\u003C\u002Fstrong>, materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\u003Cbr>o Your interim plans for assuring the quality of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> during your remediation.\u003Cbr>o A validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system obtained after an appropriately designed system has been installed. Include the system validation protocol (installation qualification, operational qualification, and performance qualification), complete test results, and the final validation report.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On March 26, 2026, FDA held a teleconference with you recommending you recall epinephrine injection USP 0.1 mg\u002FmL lot EA038A5 from the U.S. market. On April 1, 2026, you initiated a voluntary recall of epinephrine injection USP 0.1 mg\u002FmL, lot EA038A5, due to lack of sterility assurance. The recall was posted to the FDA’s Enforcement Report website at:\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219475\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Assurance of Sterility – Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>It should be noted that a sterility test, while a critical final quality control for all aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Finished product testing alone does not establish sterility of all units because contamination is typically episodic and not uniformly distributed. Product contamination may go undetected for substantial periods if your firm is placing too much reliance on the final quality control test for sterility to become aware of a problem in aseptic manufacturing. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem and a prompt review of the qualification status of your aseptic process.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2016148 and ATTN: Emily Wu.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003Cbr>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-26-99\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Jack Y. Zhang\n\nRecipient Title\n\nChief Executive Officer\n\nInternational Medication Systems Limited\n\n1886 Santa Anita Avenue\n\nSouth El Monte, CA 91733\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-99\nJuly 2, 2026\nDear Dr. Zhang:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Medication System Limited, FEI 2016148, at 1886 Santa Anita Avenue, South El Monte, from December 9 to 19, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your January 15, 2026, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures active pharmaceutical ingredients and sterile injectable drug products. The sterile injectable products include aseptically filled (b)(4).\nYour firm failed to conduct adequate investigations. For example, you inadequately investigated multiple too-numerous-to-count (TNTC) microbial findings during the manufacture of epinephrine injection, lot EA038A5. Specifically, a viable air environmental monitoring plate, located next to the (b)(4) in your ISO 5 aseptic filling area, yielded a too-numerous-to-count result with confluent bacterial growth and numerous insect larvae. On the same day, personnel monitoring plates for an individual in the adjacent ISO 7 (b)(4) also yielded TNTC results and contained insect larvae.\nYour investigation failed to identify a scientifically-supported root cause, instead attributing these exceedingly high environmental monitoring findings to an unsubstantiated hypothesis involving insect infiltration of sealed monitoring plates. Notably, written procedures require inspection of plates before use to ensure they are not contaminated or defective, and also require very strict handling measures following sampling (e.g., (b)(4) bags, sterile tape). The microbiological growth media batch also passed negative control testing. Although your deviation report lacked evidence of defects or sampling error, you assessed the contamination risk as “low” based on overreliance on passing sterility test results, and the quality unit approved the release of epinephrine injection, lot EA038A5.\nThe presence of insect larvae and gross microbial contamination in your aseptic processing area demonstrates a critical failure of your contamination control program. The decision to release a lot manufactured under these conditions also demonstrates that your quality unit failed to exercise its responsibility to ensure drug products are manufactured under appropriate conditions and to reject any lot produced under conditions that compromise its quality.\nIn your response, you reiterate that your investigation concluded the contamination was “post-exposure adventitious contamination external to the filling suite,” based on mostly acceptable environmental monitoring data in other locations that day. Using this rationale, you determined the two environmental contamination events were isolated incidents and the risk to the product was low. You also determined that no corrective actions were needed.\nYour response is inadequate. Your investigation outcome based on a “post-exposure” hypothesis remains poorly supported by data. The occurrence of two severe contamination events on the same day in adjacent rooms indicates a significant breakdown in contamination control. Additionally, your failure to implement corrective actions reflects a critical deficiency in your investigation and indicates inadequate oversight of the state of control of the aseptic processing operation.\nWe also note that, between March 2021 and March 2026, your firm filed three field alert reports for contamination issues with sterile (b)(4) drug products. Since December 2023, you received over 90 customer complaints, many related to container-closure deficiencies such as glass breakage\u002Fvial cracking, (b)(4). Many of your investigations were closed without identifying a root cause.\nIn response to this letter, provide:\nA comprehensive, third-party assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA third-party assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\nA comprehensive, independent review and update of all field alert reports and customer complaints for drug products within expiry, including scientifically sound root cause analyses, corrective actions implemented, and timelines for completion of the investigations. This review should include, where applicable, re-investigation of all complaints involving potential contamination and container-closure deficiencies. Include documentation of all investigative steps taken, potential root causes considered and those systematically ruled out, and any interim controls or preventive measures implemented. Include your corrective action plan based on this in-depth review and trend analysis.\nA comprehensive, third-party assessment and remediation plan for your pest control program. The assessment should include, but not be limited to, a review of facility design and maintenance, effectiveness of monitoring program, investigation procedures, historical findings, and personnel training.\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.42(c)(10) and 21 CFR 211.113(b)).\nYour firm’s aseptic processing lines and operations were inadequately designed, controlled, and monitored to prevent microbiological contamination.\nYour firm refers to your aseptic processing lines as restricted access barrier systems (RABS). However, your equipment lacks fundamental design elements of a RABS, including (b)(4). Without this basic feature, as well as other design provisions, your processing lines cannot be categorized as RABS.\nIn addition to (b)(4), RABS include various design elements that are essential for minimizing or eliminating direct gowned personnel interventions ((b)(4) interactions) into the critical (ISO 5) area during batch manufacturing.\nYour current process requires an operator to stand within a (b)(4) ISO 5 area. The operator manually cuts open numerous (e.g., approximately (b)(4)) stopper bags per batch and transfers stoppers using a (b)(4) scoop. These manually-intensive interventions pose a significant and repeated risk of microbial contamination. Despite the critical nature of this activity, your firm failed to conduct environmental monitoring in this area to evaluate its impact on the aseptic environment. This represents a serious gap in environmental control oversight.\nYour firm also failed to adequately evaluate unidirectional airflow in the critical area, as the smoke studies conducted were fundamentally flawed. The placement and movement of the wand as well as other factors precluded meaningful assessment of airflow directionality.\nThe design of your aseptic filling line presents inherent contamination risks that are exacerbated by inadequate controls. These conditions are insufficient to ensure robust aseptic production of sterile drug products.\nIn your response, you state that you added a new environmental monitoring location in the (b)(4) area and conducted airflow studies in the ISO 5 (b)(4) area. You claim that operator movement has “no impact to 1st air, maintaining unidirectional airflow and minimal turbulence.” You also propose a long-term plan to upgrade the facility within two years, including upgrading the adjacent (b)(4) to ISO 5.\nYour response is inadequate. Your proposal does not address the fundamental design flaws of your aseptic processing lines, as the primary contamination risks stem from extensive manual interventions within the ISO 5 processing area itself. Additionally, a long-term plan to upgrade the facility in two years is inadequate because it does not address how you will mitigate the immediate and ongoing risk to product quality posed by your current operations.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fsterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel flow and material flow – movement throughout all rooms used to conduct and support sterile operations, and all material transfers\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\nA retrospective review and risk assessment for drug product batches within expiry that were manufactured in the affected aseptic processing area. Provide a formal risk assessment evaluating the potential for non-sterility hazards for each batch, along with a report detailing your subsequent actions, such as customer notifications or product recalls.\nPerform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\n3. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour (b)(4) system was inadequately designed, monitored, and maintained.\nYou use (b)(4) for cleaning drug manufacturing equipment, and the same system feeds your (b)(4) system. During the inspection, we observed gross contamination in the (b)(4) storage tank feeding the (b)(4) system with interior surfaces coated in dark-colored plaques. Further compounding these concerns, investigators observed that (b)(4) had been repaired with (b)(4) sealant material, and that threaded connections with seal tape were used in place of sanitary fittings. These systems failed to adhere to appropriate (b)(4) system design and maintenance standards.\nIn your response, you identify the observed dark-colored plaques in your (b)(4), non-sterile (b)(4) tank as (b)(4) biofilm, characterizing the contamination as “predictable and environmentally normal.” You add that the (b)(4) tank was (b)(4) allowed transmission of ambient light, which enabled photosynthesis and extensive (b)(4) growth on the tank walls. You assert that there was no impact on the quality of the downstream (b)(4), relying on passing test results to support this claim. The primary corrective action you reported was cleaning the affected tank.\nYour response is inadequate. Your proposed corrective action of simply cleaning the storage tank is insufficient because it fails to address the fundamental design and maintenance flaws that allowed unchecked (b)(4) growth and gross contamination. A source (b)(4) tank should be designed and maintained to prevent it from becoming a reservoir for biological contamination as the resulting bioburden can potentially overwhelm downstream (b)(4) steps. Furthermore, your rationale of using passing downstream test results to justify the use of a grossly contaminated source tank is not in accord with basic system design and control standards. It is your responsibility to ensure that all equipment used in the manufacture of your drug products is appropriately designed, maintained, and controlled.\nIn response to this letter, provide:\nA comprehensive third-party assessment of your (b)(4) system design, control, and maintenance.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system, including:\no A comprehensive evaluation of vulnerabilities of (b)(4) system design and control and summarize all deficiencies found in the system. The summary should, at minimum, describe various system characteristics that were assessed for adequacy (system (b)(4), materials of construction, slope, any identified dead-legs, any stagnant locations, any unsanitary fittings, flow velocity, etc.)\no Your interim plans for assuring the quality of your (b)(4) during your remediation.\no A validation report for the (b)(4) system obtained after an appropriately designed system has been installed. Include the system validation protocol (installation qualification, operational qualification, and performance qualification), complete test results, and the final validation report.\nDrug Recall\nOn March 26, 2026, FDA held a teleconference with you recommending you recall epinephrine injection USP 0.1 mg\u002FmL lot EA038A5 from the U.S. market. On April 1, 2026, you initiated a voluntary recall of epinephrine injection USP 0.1 mg\u002FmL, lot EA038A5, due to lack of sterility assurance. The recall was posted to the FDA’s Enforcement Report website at:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=219475\nQuality Unit Authority\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nAssurance of Sterility – Aseptic Processing\nIt should be noted that a sterility test, while a critical final quality control for all aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Finished product testing alone does not establish sterility of all units because contamination is typically episodic and not uniformly distributed. Product contamination may go undetected for substantial periods if your firm is placing too much reliance on the final quality control test for sterility to become aware of a problem in aseptic manufacturing. It should also be noted that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem and a prompt review of the qualification status of your aseptic process.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.2 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2016148 and ATTN: Emily Wu.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","International Medication Systems Limited","international-medication-systems-limited-727560-07022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finternational-medication-systems-limited-727560-07022026","2026-10-26T08:09:00.176574+00:00","2026-07-14","727560","Dr. Jack Y. Zhang","2026-08-19T04:29:55.749+00:00","320-26-99","2026-07-02",{"id":282,"raw":283,"subject":101,"body_html":286,"body_text":287,"firm_name":288,"letter_id":289,"created_at":19,"fei_number":20,"letter_url":290,"updated_at":291,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":292,"product_type":27,"closeout_date":293,"issuing_office":11,"recipient_name":294,"body_fetched_at":295,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":25,"medical_device_id":20,"response_letter_date":20},3484,[99,9,284,11,101,13,285,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-system-limited-613565-03042021\">Thermoteknix System Limited\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-systems-ltd-613565-03252025\">\u003Ctime datetime=\"2025-03-28T04:00:00Z\">03\u002F28\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Sydney Salisbury and Geraldine Anne Salisbury\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Thermoteknix System Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Teknix House, 2 Pembroke Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waterbeach, Cambridge\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>CB25 9QR\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Richard Sydney Salisbury\u003Cbr>\nGeraldine Anne Salisbury\u003Cbr>\nThermoteknix Systems Ltd\u003Cbr>\nTeknix House, 2 Pembroke Avenue\u003Cbr>\nWaterbeach, Cambridge\u003Cbr>\nCB25 9QR\u003Cbr>\nUNITED KINGDOM\u003C\u002Fp>\n\n\u003Cp>richard.salisbury@thermoteknix.com\u003Cbr>\ng.salisbury@thermoteknix.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;&nbsp;\u003Cbr>\nRE:&nbsp;&nbsp;&nbsp;&nbsp; Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Mr. and Ms,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address (http:\u002F\u002Fwww.thermoteknix.com\u002F) on February 22, 2021.&nbsp; We have also reviewed your social media pages at https:\u002F\u002Ftwitter.com\u002FThermoteknix, https:\u002F\u002Fvimeo.com\u002Fthermoteknix, and https:\u002F\u002Fwww.facebook.com\u002FThermoteknix where you direct consumers to your website, https:\u002F\u002Fwww.thermoteknix.com. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “FevIR Scan 2”, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca id=\"footnoteref1_zsxk64p\" href=\"#footnote1_zsxk64p\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; in people, and thus is a device under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the FevIR Scan 2 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“#COVID19 temperature screening &amp; face mask detection technology (FevIR Scan 2) from UK-based @Thermoteknix is helping keep American Bank customers &amp; staff safe during the pandemic.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1356643033559797761]\u003Cbr>\n•&nbsp;“FevIR Scan 2 has been specially engineered and developed in the UK by Cambridge-based thermal imaging experts Thermoteknix to help fight the spread of coronavirus and help businesses and industries around the world to stay open safely during the pandemic.” [Published on a blog post linked in http:\u002F\u002Fwww.thermoteknix.com\u002Fthermoteknix-temperature-screening-technology-becomes-american-banks-newest-front-line-defence-in-coronavirus-covid-19-fight\u002F]\u003Cbr>\n•&nbsp;“Face mask detection &amp; temperature screening. At the forefront during SARS &amp; Ebola viruses – now @Thermoteknix technology is helping curb the spread of #COVID19. Tech is helping us get back to the office safely &amp; back to doing business.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1352554113515577347]\u003C\u002Fp>\n\n\u003Cp>The FevIR Scan 2 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA.&nbsp; Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Ca id=\"footnoteref2_td9e6xe\" href=\"#footnote2_td9e6xe\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Ca id=\"footnoteref3_umdf6sn\" href=\"#footnote3_umdf6sn\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, \u003Ca href=\"http:\u002F\u002Fwww.thermoteknix.com\u002F\">http:\u002F\u002Fwww.thermoteknix.com\u002F\u003C\u002Fa>, includes statements that indicate that the FevIR Scan 2 is intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“On-screen and audible alerts identify one or more individuals in a large crowd situation with visible temperature tracking” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>•&nbsp;“FevIR Scan Fever Screening System is a skin temperature measurement system for mass screening of high pedestrian areas such as airports, train stations, factories and other public places” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Ca id=\"footnoteref4_0k8yac2\" href=\"#footnote4_0k8yac2\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa> provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to \u003C\u002Fstrong>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa> describing the specific steps you have taken to address these violations, using CMS # 613565 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at \u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fa>.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp;&nbsp;&nbsp; General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_zsxk64p\">\u003Ca href=\"#footnoteref1_zsxk64p\">1\u003C\u002Fa>As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_td9e6xe\">\u003Ca href=\"#footnoteref2_td9e6xe\">2\u003C\u002Fa>Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_umdf6sn\">\u003Ca href=\"#footnoteref3_umdf6sn\">3\u003C\u002Fa>President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_0k8yac2\">\u003Ca href=\"#footnoteref4_0k8yac2\">4\u003C\u002Fa>Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload. \u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRichard Sydney Salisbury and Geraldine Anne Salisbury\n\nThermoteknix System Limited\n\nTeknix House, 2 Pembroke Avenue\n\nWaterbeach, Cambridge\n\nCB25 9QR\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nRichard Sydney Salisbury\n\nGeraldine Anne Salisbury\n\nThermoteknix Systems Ltd\n\nTeknix House, 2 Pembroke Avenue\n\nWaterbeach, Cambridge\n\nCB25 9QR\n\nUNITED KINGDOM\n\nrichard.salisbury@thermoteknix.com\n\ng.salisbury@thermoteknix.com\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Mr. and Ms,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address (http:\u002F\u002Fwww.thermoteknix.com\u002F) on February 22, 2021. We have also reviewed your social media pages at https:\u002F\u002Ftwitter.com\u002FThermoteknix, https:\u002F\u002Fvimeo.com\u002Fthermoteknix, and https:\u002F\u002Fwww.facebook.com\u002FThermoteknix where you direct consumers to your website, https:\u002F\u002Fwww.thermoteknix.com. The FDA has observed that your website offers a product for measuring human body temperature, specifically the “FevIR Scan 2”, for sale in the United States. Based on our review, this product is intended to mitigate, prevent, treat, diagnose or cure COVID-191 in people, and thus is a device under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the FevIR Scan 2 is intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\n• “#COVID19 temperature screening & face mask detection technology (FevIR Scan 2) from UK-based @Thermoteknix is helping keep American Bank customers & staff safe during the pandemic.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1356643033559797761]\n\n• “FevIR Scan 2 has been specially engineered and developed in the UK by Cambridge-based thermal imaging experts Thermoteknix to help fight the spread of coronavirus and help businesses and industries around the world to stay open safely during the pandemic.” [Published on a blog post linked in http:\u002F\u002Fwww.thermoteknix.com\u002Fthermoteknix-temperature-screening-technology-becomes-american-banks-newest-front-line-defence-in-coronavirus-covid-19-fight\u002F]\n\n• “Face mask detection & temperature screening. At the forefront during SARS & Ebola viruses – now @Thermoteknix technology is helping curb the spread of #COVID19. Tech is helping us get back to the office safely & back to doing business.” [Published on https:\u002F\u002Ftwitter.com\u002FThermoteknix\u002Fstatus\u002F1352554113515577347]\n\nThe FevIR Scan 2 is offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the product into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, http:\u002F\u002Fwww.thermoteknix.com\u002F, includes statements that indicate that the FevIR Scan 2 is intended to scan multiple individuals simultaneously, including:\n\n• “On-screen and audible alerts identify one or more individuals in a large crowd situation with visible temperature tracking” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\n\n• “FevIR Scan Fever Screening System is a skin temperature measurement system for mass screening of high pedestrian areas such as airports, train stations, factories and other public places” [Published on http:\u002F\u002Fwww.thermoteknix.com\u002Fproducts\u002Foem-thermal-imaging\u002Ffevir-scan-fever-screening-system\u002F]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”4 provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613565 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n1As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.","Thermoteknix System Limited","thermoteknix-system-limited-613565-03042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthermoteknix-system-limited-613565-03042021","2026-10-26T08:10:11.437986+00:00","613565","2025-03-28","Richard Sydney Salisbury and Geraldine Anne Salisbury","2026-08-20T03:19:37.367+00:00",{"id":297,"raw":298,"subject":116,"body_html":303,"body_text":304,"firm_name":305,"letter_id":306,"created_at":251,"fei_number":20,"letter_url":307,"updated_at":308,"action_type":23,"case_status":24,"posted_date":309,"marcs_cms_no":310,"product_type":27,"closeout_date":311,"issuing_office":11,"recipient_name":312,"body_fetched_at":313,"delivery_method":50,"recipient_title":20,"reference_number":20,"action_taken_date":314,"medical_device_id":20,"response_letter_date":20},2802,[299,300,301,11,116,13,302,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-06T05:00:00Z\">01\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022\">Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-05182023\">\u003Ctime datetime=\"2023-05-31T04:00:00Z\">05\u002F31\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roly Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Unimicro Medical Systems-Shenzhen Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>201, Bldg 38 101 Heshui Kou\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gongmingzhen Longgang\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>518106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Roly Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your firm noted \u003Cstrong>(b)(4)\u003C\u002Fstrong> package heat sealing nonconformances. For these \u003Cstrong>(b)(4)\u003C\u002Fstrong> nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), Sealing Machine Sealing Effect Re-Verification Report (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>), UV Curing Re-Verification Program (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Your firm also did not have personnel familiar with process validation.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Model MND11500 and Model MND11200).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push &amp; pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push &amp; Pull Tester, your firm was unable to provide calibration documentation and data.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&amp;Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&amp;Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\u003C\u002Fp>\n\n\u003Cp>For example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\u003C\u002Fp>\n\n\u003Cp>7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\u003C\u002Fp>\n\n\u003Cp>For example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Ver. \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case #424228 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely Yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nZeyu Chen\u003Cbr>\n238 Fernwood Ave, Edison, NEW JERSEY 08837\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoly Lee\n\nRecipient Title\n\nGeneral Manager\n\nUnimicro Medical Systems-Shenzhen Co., Ltd.\n\n201, Bldg 38 101 Heshui Kou\n\nGongmingzhen Longgang\n\nShenzhen\n\n518106\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJanuary 6, 2022\n\nDear Roly Lee:\n\nDuring an inspection of your firm located in Shenzhen, China, on September 15, 2021, through September 26, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Veress Pneumoperitoneum Needles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements as required by 21 CFR 820.90(a).\n\nFor example: Your firm has not established a disposition process for product that does not conform to specified requirements. Your firm was not able to provide the disposition of (b)(4) package heat sealed nonconforming products. In Nonconforming Product Handling Sheet (No. (b)(4), dated (b)(4)), your firm noted (b)(4) package heat sealing nonconformances. For these (b)(4) nonconforming products, the final determination was stated as “return to warehouse” and no final disposition was provided or conducted, per Nonconforming Product Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). Therefore, it is unknown where these products are or how they were handled. Additionally, your firm’s staff was unaware of the nonconforming product procedure or handling and disposition of nonconforming products.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to stop any products exporting to the United States of America until corrective actions are completed and deactivate all products from your Device Listings until the corrective actions are completed. You also plan to modify the Nonconforming Product Control Procedure, train relevant personnel of the design, purchasing, quality, production, warehouse, logistics, and sales department according to the revised procedure. You state you will also perform retrospective review for all products which have been sold for the US market, to analyze if there is any quality issue or adverse events that have occurred. However, to ensure a sufficient evaluation of the risk posed by the situation, you should also actively evaluate the risks associated with the device presently and take any needed actions to mitigate those risks. This should not rely only on adverse event reporting or other outside reporting. Additionally, your Corrective Action Plan does not include ensuring the disposition of nonconforming products are documented. As part of your corrective actions, you should document the disposition of the identified nonconforming products.\n\n2. Failure to adequately establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met as required by 21 CFR 820.30(a).\n\nFor example: Your firm was unable to provide documentation and\u002For evidence of conducting Design and Development activities as described in the Design and Development Control Procedures (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)), related to the veress pneumoperitoneum needles. In this document, the procedures for design control are described in detail. The procedures include steps to review the design input, output, verification and validation, design changes, design transfer, and design history. However, your firm was unable to provide documentation and data demonstrating design requirements for the veress pneumoperitoneum needles wet met, as required by the Design and Development Control Procedures.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the Design and Development Control Procedure based on the requirements of 21 CFR 820.30 Design Control, train all design personnel according to the revised procedure, and to retrospectively review all products which have been sold for the U.S market, to analyze if there is any quality issue or adverse events occurred. However, you have no plan to evaluate the retrospectively conduct design control activities for affected products. You should conduct a review of your products to determine which products did not have design control activities conducted and retrospectively conduct those activities to ensure products meet design requirements. In addition, you should actively assess if lack of design control activities could have led to the distribution of nonconforming products (aside from review of adverse event or malfunction reports). If any risks are identified, you should take appropriate action to mitigate those risks.\n\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\n\nFor example: Your firm was unable to provide validation documentation with objective evidence and data for activities related to the manufacturing of medical devices, specifically EtO Sterilization, Heat Sealing Packaging, and UV Glue Curing documented in the Validation Management Control Procedure (Doc No. (b)(4), Ver. No. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), Sealing Machine Sealing Effect Re-Verification Report (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)), UV Curing Re-Verification Program (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)). Your firm also did not have personnel familiar with process validation.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021 and have concluded it is not adequate. You plan to modify the validation management control procedure based on the requirement of 21 CFR 820.75 Process validation, train all validation personnel according to the revised procedure, re-validate all other special processes identified for U.S products such as the ultrasonic cleaning process and ultrasonic welding process, and re-validate the EtO sterilization process, heat sealing packaging process, and UV glue curing process. However, these activities have not been completed. In addition, you have not indicated if or how you plan to assess any potential impacts of the lack of process validation on previously distributed product and how you plan to mitigate any associated risks. To ensure safety and conformity of product, it is important that you assess the potential impact the lack of process validation as described above, may have had on previously distributed products as part of your corrective action plan.\n\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action as required by 21 CFR 820.100(a).\n\nFor example: Your firm did not provide a severity determination, or a root cause analysis conducted for CAPA events deemed “necessary”. The CAPA states a root cause analysis is required to be conducted only if necessary. However, your firm has not defined what CAPA events are necessary in the Corrective and Preventive Actions Control Procedure (Doc No. (b)(4) Ver. (b)(4) dated (b)(4)). In the document, your firm utilizes an in-process CAPA, which requires a severity determination, which is not defined in the procedure. There is no documented definition, requirement, or guidance in the procedure for the severity determination. Also, no root cause analysis was performed in your firm’s two most recent CAPAs, (Abnormal Manufacturing Process Feedback Memo (b)(4) for Model MND11500 and Model MND11200).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the Corrective and Preventive Action Control Procedure to define severity (Major, Moderate, or Minor), and define what is “necessary” when requiring a root cause analysis. You intend to train relevant personnel of all departments according to the revised procedure. You also state you will investigate the past CAPAs and customer complaints, to confirm whether there is any improper handling of CAPAs or customer complaints, and to evaluate the risks to the products that have been sold in the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n5. Failure to adequately establish and maintain procedures to ensure that equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nFor example: Your firm was not able to provide calibration documentation and data related to equipment and instruments including leakage tester and push & pull tester, used in the manufacturing of medical devices intended for the US market. Your firm was able to provide the calibration procedure, Production Equipment Management Control Procedure (Doc No. (b)(4), Ver. (b)(4), and dated (b)(4)). However, when calibration documentation for equipment and instruments used during the manufacturing of the Class II Veress Needles, such as their Leakage Tester and Push & Pull Tester, your firm was unable to provide calibration documentation and data.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to modify the production equipment management control procedure based on the requirements of 21 CFR 820.72(a) and train relevant personnel of quality, production, and warehouse departments according to the revised procedure. You also plan to send Leakage Tester and Push&Pull Tester to the Calibration institute for calibration. Additionally, you state that you will review the impact of their Leakage Tester and Push&Pull Tester on the product test results during the failure period based on the calibration results. Lastly, you plan to review the measuring and test equipment for any of the same issues for other inspection, measuring, and test equipment. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed, and documentation verifying the successful completion of these actions are provided.\n\n6. Failure to adequately establish and maintain acceptance procedures, where appropriate, to ensure that specified requirements for in-process product are met as required by 21 CFR 820.80(c).\n\nFor example: Your firm’s Veress Needle Quality Inspection Standard (Doc No. (b)(4), Ver. (b)(4), dated (b)(4)) is not adequately established, as the quality control personnel were conducting in-process acceptance activities that did not include connection bond testing, and puncture testing of the subject device. Your firm has not established and maintained in-process acceptance activity procedures to ensure specified requirements for in-process products are met. The quality personnel were conducting acceptance activities based on the Inspection Standard used to conduct in-process acceptance activities for the Veress Needles. However, according to the investigator, your firm’s quality staff conducting the in-process acceptance activities were not familiar with the testing process and stated there were no established in-process acceptance procedures for the connection bond and puncture testing. However, in the Semi-Finished Inspection Record ((b)(4)), there is a requirement included to conduct a connection bond test and puncture test, that the quality staff conducting the in-process acceptance activities were not familiar with. The requirement listed in the semi-finished inspection record was not included in the final Veress Needle Quality Inspection Standard.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan dated October 8, 2021, and have concluded it is not adequate. You plan to modify the Veress Needle Quality Inspection Standard and all other quality inspection standards, train relevant personnel of the quality and production department according to the revised Quality Inspection Standards, and perform retrospective review for all products which had been sold for the U.S market, to analyze if there is any quality issue or adverse event occurred. These actions have not been completed. In addition, your firm has not identified plans to evaluate their document control system, to make changes to ensure the requirements are consistent across documents. To ensure conformance to the standard across all relevant in-process acceptance activities, you should evaluate your document control system as part of your corrective action plan.\n\n7. Failure to adequately establish and maintain procedures to ensure that DHR's for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR, and the requirements of this part as required by 21 CFR 820.184\n\nFor example: Your firm was not able to provide Device History Records for their manufactured medical devices intended and exported to the US market. Your firm was unfamiliar with FDA regulations and requirements for manufactures to include the DHR requirements and their Device History Record Control Procedures (Doc No. (b)(4), Ver. (b)(4) and dated (b)(4)).\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You state you intend to modify their DHR control procedures based on the requirements of 21 CFR 820.184 and perform sample inspection of (b)(4) batches of the subject device based on the revised procedure, to confirm the integrity and correctness of the DHRs. You also plan to train relevant personnel on design, purchasing, quality, production, warehouse, logistics, PMC, and sales department according to the revised procedures and your firm plans to perform a retrospective review for all products which had been sold for the US market. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\n8. Failure to maintain device master records (DMRs) as required by 21 CFR 820.181.\n\nFor example: Your firm has not maintained their Device Master Records related to the subject device, and the personnel was unfamiliar with documents, processes, and medical devices related to the U.S market. Additionally, the manager of the site was not familiar with the FDA regulatory requirements to include DMRs for medical device manufacturers.\n\nWe have reviewed your firm’s response in the 483 Corrective Action Plan. The adequacy of the response dated October 8, 2021, cannot be determined at this time. You plan to output DMRs according to the reorganized Device History File for all products exported and intended for the U.S market, and to retrospectively review for all products which have been sold for the US market, to analyze if there are any quality issues or adverse events that have occurred. These actions have not been completed; therefore, the adequacy of these actions cannot be determined until the activities described have been completed and documentation verifying the successful completion of these actions are provided.\n\nGiven the serious nature of the violations of the Act, Veress Pneumoperitoneum Needles manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as 'detention without physical examination,' until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. Please provide a translation of documentation not in English to facilitate our review.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case #424228 when replying. If you have any questions about the contents of this letter, please contact: OHT Assistant Director, Jason Roberts at jason.roberts@fda.hhs.gov or (240)402-6400\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely Yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nZeyu Chen\n\n238 Fernwood Ave, Edison, NEW JERSEY 08837","Unimicro Medical Systems-Shenzhen Co., Ltd.","unimicro-medical-systems-shenzhen-co-ltd-624560-01062022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Funimicro-medical-systems-shenzhen-co-ltd-624560-01062022","2026-10-26T08:10:17.543342+00:00","2022-03-22","624560","2023-05-31","Roly Lee","2026-08-20T02:05:33.087+00:00","2022-01-06",{"id":316,"raw":317,"subject":116,"body_html":322,"body_text":323,"firm_name":324,"letter_id":325,"created_at":326,"fei_number":20,"letter_url":327,"updated_at":328,"action_type":23,"case_status":66,"posted_date":329,"marcs_cms_no":330,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":331,"body_fetched_at":332,"delivery_method":128,"recipient_title":20,"reference_number":20,"action_taken_date":333,"medical_device_id":20,"response_letter_date":20},1172,[318,319,320,11,321,13,13,13],"\u003Ctime datetime=\"2024-11-12T14:20:00Z\">11\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-01T04:00:00Z\">11\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowens-minor-inc-dba-american-contract-systems-inc-695683-11012024\">Owens &amp; Minor, Inc. dba American Contract Systems, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward A. Pesicka\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owens &amp; Minor, Inc. dba American Contract Systems, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9130 Lockwood Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mechanicsville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>23116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:edpesicka@owens-minor.com\"> edpesicka@owens-minor.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 695683\u003Cbr>\n\u003Cbr>\nDear Mr. Pesicka:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, American Contract Systems, (ACS) Inc., in Tiffin OH, FEI 3008492337, on August 5 through 14, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile convenience kits, such as the C-Section Pack (pack number WECS27G). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Daniel R. Wright, VP, Global QARA, Owens &amp; Minor, Inc., dated September 5, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance of incoming product to ensure that incoming product is inspected, tested, or otherwise verified as conforming to specified requirements, and that acceptance or rejection is documented, as required by 21 CFR 820.80(b). For example:\u003C\u002Fp>\n\n\u003Cp>On at least four occasions, from January 2024 through July 2024, your firm accepted sterilization bag lots (86149183, 86471442, 86740750, 86149178) that failed your thickness requirements. Your Receiving Procedure, RV-01, includes minimum and maximum acceptance criteria for these bags to ensure they are free from defects that may adversely affect gas injection, sealing, or diffusion characteristics during your ethylene oxide (EO) sterilization processes. Acceptance activities for these 4 lots were being performed by ACS personnel at sister facilities in Florida. Each of these lots were deemed acceptable and the lots were used for EO processing at this Tiffin, OH facility, as well as other ACS facilities.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You indicated that CAPA 2024-0021 was opened but did not provide a copy that describes the preventive actions you are planning to address this serious observation.\u003C\u002Fp>\n\n\u003Cp>Your response states that on August 6, 2024, you placed a hold on all raw material sterilization bags at all ACS locations, including Tiffin, OH. All finished goods in ACS manufacturing locations and O&amp;M distribution centers were then placed on distribution hold on August 7, 2024, while you investigated these failures. Your investigation included performing a retest of all available bags in inventory at your Fort Myers facility and you indicated that all retests passed your specifications. However, your response did not provide a systemic response describing how your firm will prevent this significant failure from recurring.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>You did not implement your Design Control Procedure, DE-01.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not completed design verification and validation activities for 25 different FDA product codes in use at this facility, to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process, as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>For example, two out of 26 components that are included in your C-Section Pack (pack number WECS27G) have not been verified as acceptable for your EO sterilization process. The “CAUTERY| ES ROCKER COATED SMOKE EVAC NS” is classified as a “medium” risk component and there was no documentation that this component was evaluated, as required by your “design verification and validation activities” that are described in your design control procedure.\u003C\u002Fp>\n\n\u003Cp>Your Design Control Procedure, DE-01, requires component evaluation be performed as part of your design verification and validation process, including your C-Section Pack, designated as FDA Code OHM, class 2. The procedure also requires that all these review records be included in the design history file.\u003C\u002Fp>\n\n\u003Cp>Also, your firm did not have complete design history files for 25 different FDA product codes being manufactured at your facility, as required by 21 CFR 820.30(j).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You acknowledged documentation indicating component approval for products was lacking at this facility and were not part of your DHF’s. You now plan to remediate all components and approve all DHFs, by January 31, 2025, in part to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process. Your firm did not provide enough detail to describe how you plan on prioritizing and implementing this review for all 25 product codes in use at this location.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>. As part of your response to this observation, please describe how you will complete this review of components to ensure that only devices with complete DHF’s, including complete component evaluations, are currently being distributed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 695683 when replying. If you have any questions about the contents of this letter, please contact: Gina Brackett, EAT Assistant Director at (513) 288-7055 or gina.brackett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>\nDirector\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>, Operations Manager, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>@owens-minor.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEdward A. Pesicka\n\nRecipient Title\n\nPresident & Chief Executive Officer\n\nOwens & Minor, Inc. dba American Contract Systems, Inc.\n\n9130 Lockwood Boulevard\n\nMechanicsville, VA 23116\n\nUnited States\n\nedpesicka@owens-minor.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 695683\n\nDear Mr. Pesicka:\n\nDuring an inspection of your firm, American Contract Systems, (ACS) Inc., in Tiffin OH, FEI 3008492337, on August 5 through 14, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile convenience kits, such as the C-Section Pack (pack number WECS27G). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Daniel R. Wright, VP, Global QARA, Owens & Minor, Inc., dated September 5, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance of incoming product to ensure that incoming product is inspected, tested, or otherwise verified as conforming to specified requirements, and that acceptance or rejection is documented, as required by 21 CFR 820.80(b). For example:\n\nOn at least four occasions, from January 2024 through July 2024, your firm accepted sterilization bag lots (86149183, 86471442, 86740750, 86149178) that failed your thickness requirements. Your Receiving Procedure, RV-01, includes minimum and maximum acceptance criteria for these bags to ensure they are free from defects that may adversely affect gas injection, sealing, or diffusion characteristics during your ethylene oxide (EO) sterilization processes. Acceptance activities for these 4 lots were being performed by ACS personnel at sister facilities in Florida. Each of these lots were deemed acceptable and the lots were used for EO processing at this Tiffin, OH facility, as well as other ACS facilities.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You indicated that CAPA 2024-0021 was opened but did not provide a copy that describes the preventive actions you are planning to address this serious observation.\n\nYour response states that on August 6, 2024, you placed a hold on all raw material sterilization bags at all ACS locations, including Tiffin, OH. All finished goods in ACS manufacturing locations and O&M distribution centers were then placed on distribution hold on August 7, 2024, while you investigated these failures. Your investigation included performing a retest of all available bags in inventory at your Fort Myers facility and you indicated that all retests passed your specifications. However, your response did not provide a systemic response describing how your firm will prevent this significant failure from recurring.\n\n(b)(4)\n\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nYou did not implement your Design Control Procedure, DE-01.\n\nSpecifically, your firm has not completed design verification and validation activities for 25 different FDA product codes in use at this facility, to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process, as required by 21 CFR 820.30(g).\n\nFor example, two out of 26 components that are included in your C-Section Pack (pack number WECS27G) have not been verified as acceptable for your EO sterilization process. The “CAUTERY| ES ROCKER COATED SMOKE EVAC NS” is classified as a “medium” risk component and there was no documentation that this component was evaluated, as required by your “design verification and validation activities” that are described in your design control procedure.\n\nYour Design Control Procedure, DE-01, requires component evaluation be performed as part of your design verification and validation process, including your C-Section Pack, designated as FDA Code OHM, class 2. The procedure also requires that all these review records be included in the design history file.\n\nAlso, your firm did not have complete design history files for 25 different FDA product codes being manufactured at your facility, as required by 21 CFR 820.30(j).\n\nWe reviewed your firm’s response and concluded that it is not adequate. You acknowledged documentation indicating component approval for products was lacking at this facility and were not part of your DHF’s. You now plan to remediate all components and approve all DHFs, by January 31, 2025, in part to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process. Your firm did not provide enough detail to describe how you plan on prioritizing and implementing this review for all 25 product codes in use at this location.\n\n(b)(4). As part of your response to this observation, please describe how you will complete this review of components to ensure that only devices with complete DHF’s, including complete component evaluations, are currently being distributed.\n\n(b)(4)\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 695683 when replying. If you have any questions about the contents of this letter, please contact: Gina Brackett, EAT Assistant Director at (513) 288-7055 or gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nRDML Sean M. Boyd, MPH, USPHS\n\nDirector\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc: (b)(4) , Operations Manager, (b)(4) @owens-minor.com","Owens & Minor, Inc. dba American Contract Systems, Inc.","owens-minor-inc-dba-american-contract-systems-inc-695683-11012024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowens-minor-inc-dba-american-contract-systems-inc-695683-11012024","2026-10-26T08:09:39.746067+00:00","2024-11-12","695683","Edward A. Pesicka","2026-08-19T18:45:50.726+00:00","2024-11-01",{"id":335,"raw":336,"subject":342,"body_html":343,"body_text":344,"firm_name":345,"letter_id":346,"created_at":42,"fei_number":20,"letter_url":347,"updated_at":348,"action_type":23,"case_status":66,"posted_date":28,"marcs_cms_no":349,"product_type":256,"closeout_date":20,"issuing_office":350,"recipient_name":351,"body_fetched_at":352,"delivery_method":50,"recipient_title":20,"reference_number":20,"action_taken_date":353,"medical_device_id":20,"response_letter_date":20},1979,[337,338,339,340,341,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-05T04:00:00Z\">06\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023\">Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fa>"," Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon D. Tryggestad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>913 S Main St Ste 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-7575\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 23-631303\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Lisa Sooter\u003Cbr>\nGeneral Counsel and Co-Owner\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tryggestad and Ms. Sooter:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your products manufactured since March 2019, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>c. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\u003C\u002Fp>\n\n\u003Cp>d. You have not established and followed written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>b. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> only \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong>-forming microorganisms are routinely detected in your environmental samples.\u003C\u002Fp>\n\n\u003Cp>c. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacture of batches nor is there data or rationale for the cleaning agents used.\u003C\u002Fp>\n\n\u003Cp>d. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192].\u003C\u002Fstrong> For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\u003C\u002Fp>\n\n\u003Cp>a. From January 2021 and November 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include&nbsp;\u003Cem>Cutibacterium acnes, Staphylococcus pasteuri,\u003C\u002Fem> and \u003Cem>Corynebacterium acnes.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>b. From July 2021 and August 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include \u003Cem>Bacillus\u003C\u002Fem> species \u003Cem>non-anthracis, Paenbacillus\u003C\u002Fem> species, and fungi.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year expiration date to your products without stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year shelf life and were manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJon D. Tryggestad\n\nRecipient Title\n\nChief Executive Officer and Co-Owner\n\nStratus Biosystems, LLC dba CellGenuity Regenerative Science\n\n913 S Main St Ste 215\n\nGrapevine, TX 76051-7575\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nJune 5, 2023\n\nWarning Letter #OBPO 23-631303\n\nLisa Sooter\n\nGeneral Counsel and Co-Owner\n\nDear Mr. Tryggestad and Ms. Sooter:\n\nDuring an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).1,2,3 You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.4 Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nBe advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&C Act.\n\nTo lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over (b)(4) vials of your products manufactured since March 2019, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\n\nc. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\n\ni. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\n\nii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\n\nd. You have not established and followed written procedures for the (b)(4) sterilization of the (b)(4) filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\n\n2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example:\n\na. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\n\nb. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a (b)(4) only (b)(4). (b)(4)-forming microorganisms are routinely detected in your environmental samples.\n\nc. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning (b)(4) manufacture of batches nor is there data or rationale for the cleaning agents used.\n\nd. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a (b)(4) agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\n\n4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example:\n\na. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\n\nb. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192]. For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\n\na. From January 2021 and November 2021, your firm has had approximately (b)(4) sterility failures and (b)(4) endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include Cutibacterium acnes, Staphylococcus pasteuri, and Corynebacterium acnes.\n\nb. From July 2021 and August 2021, your firm has had approximately (b)(4) environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include Bacillus species non-anthracis, Paenbacillus species, and fungi.\n\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a (b)(4)- to (b)(4)-year expiration date to your products without stability testing.\n\nWe have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a (b)(4)- to (b)(4)-year shelf life and were manufactured under the above-described conditions.\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n______________________________\n\n1 Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\n\n2 You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n3 Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\n\n4 For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”","Stratus Biosystems, LLC dba CellGenuity Regenerative Science","stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-10-26T08:10:06.541654+00:00","631303","Division of Biological Products Operations II","Jon D. Tryggestad","2026-08-20T00:51:52.85+00:00","2023-06-05",{"id":355,"raw":356,"subject":363,"body_html":364,"body_text":365,"firm_name":366,"letter_id":367,"created_at":368,"fei_number":20,"letter_url":369,"updated_at":370,"action_type":23,"case_status":24,"posted_date":371,"marcs_cms_no":372,"product_type":232,"closeout_date":373,"issuing_office":360,"recipient_name":374,"body_fetched_at":375,"delivery_method":376,"recipient_title":20,"reference_number":20,"action_taken_date":377,"medical_device_id":20,"response_letter_date":20},3552,[357,358,359,360,361,13,362,13],"\u003Ctime datetime=\"2021-02-09T14:20:00Z\">02\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-01T05:00:00Z\">02\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021\">Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","Compounding Pharmacy\u002FAdulterated Drug Products \u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-06272022\">\u003Ctime datetime=\"2022-07-14T04:00:00Z\">07\u002F14\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Emily A. Krug\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director of Pharmacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>79-1019 Haukapila Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kealakekua\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96750\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:emkrug@hhsc.org\"> emkrug@hhsc.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 1, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Krug:\u003C\u002Fp>\n\n\u003Cp>From December 2, 2019, to December 13, 2019, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy, located at 79-1019 Haukapila Street Kealakekua, HI 96750. During the inspection, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on December 13, 2019. FDA acknowledges receipt of your facility’s response, dated January 3, 2020, and subsequent correspondence. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. You failed to remediate the repeated recovery of microbial contamination from the ISO 7 cleanrooms, ISO 5 biological safety cabinet (BSC), and ISO 5 laminar air flow (LAF) hood where drug products intended to be sterile were prepared. Furthermore, you failed to evaluate whether the identified microbial contamination had any impact on aseptically processed drug products that were prepared in your cleanrooms.\u003C\u002Fp>\n\n\u003Cp>2. Your facility design was deficient because:\u003Cbr>\n(i) the cleanrooms did not have \u003Cstrong>(b)(4)\u003C\u002Fstrong>;\u003Cbr>\n(ii) the cleanrooms were provided with HEPA filtered air \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This HEPA filter was not clamped down in the filter housing, had failed leak testing in 2018, and was not tested for leaks during the cleanroom certification performed in June 2019;\u003Cbr>\n(iii) the air returns in the cleanrooms were located in the ceilings in proximity to the air supply vents;\u003Cbr>\n(iv) \u003Cstrong>(b)(4)\u003C\u002Fstrong> between the ISO 7 hazardous buffer room and the unclassified area were \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed opened at the same time;\u003Cbr>\n(v) a differential pressure cascade could not be maintained between rooms of higher air quality and rooms of lower air quality when the doors to the cleanrooms were closed;\u003Cbr>\n(vi) the air supply vents in the ISO 7 non-hazardous drug room and anteroom had accumulated what appeared to be dust.\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 BSC. Therefore, your products intended to be sterile were produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\u003Cbr>\n\u003Cbr>\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483 and subsequent correspondence. We acknowledge that as part of your corrective actions, all drug products intended to be sterile will continue to be assigned a beyond use date (BUD) of 12 hours.\u003C\u002Fp>\n\n\u003Cp>However, regarding your responses related to the insanitary conditions, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. Your response stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;was intended to be completed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not provided details describing the finalized design changes or evidence to demonstrate that the design phase has been completed or that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> activities have been planned or performed.\u003C\u002Fp>\n\n\u003Cp>2. You stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> would be purchased for use while the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not provided evidence to show that this corrective action has been implemented.\u003C\u002Fp>\n\n\u003Cp>3. Your response stated that cleaning the interior of the ISO 5 areas will be performed using sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide supporting evidence to demonstrate that sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> was purchased or whether any modifications or changes have been made to your cleaning practices.\u003C\u002Fp>\n\n\u003Cp>4. You did not provide additional environmental monitoring data to demonstrate that the ISO 5 BSC, ISO 5 LAF, and the cleanrooms are maintained in a state of control.\u003C\u002Fp>\n\n\u003Cp>5. You failed to evaluate whether the recovery of spore-forming organisms indicated a need for more frequent application of a sporicidal agent as part of your routine disinfection program.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Send your written responses to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier 611130. Electronic responses may also be submitted to ORAPHARM4_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Mariza Jafary, Compliance Officer, at \u003Cspan>(949) 608-2977\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>, or Mariza.Jafary@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nEmily A. Krug\n\nRecipient Title\n\nDirector of Pharmacy\n\nHawaii Health Systems Corporation dba Kona Community Hospital Pharmacy\n\n79-1019 Haukapila Street\n\nKealakekua, HI 96750\n\nUnited States\n\nemkrug@hhsc.org\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nFebruary 1, 2021\n\nDear Ms. Krug:\n\nFrom December 2, 2019, to December 13, 2019, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy, located at 79-1019 Haukapila Street Kealakekua, HI 96750. During the inspection, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on December 13, 2019. FDA acknowledges receipt of your facility’s response, dated January 3, 2020, and subsequent correspondence. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nSpecific violations are described below.\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. You failed to remediate the repeated recovery of microbial contamination from the ISO 7 cleanrooms, ISO 5 biological safety cabinet (BSC), and ISO 5 laminar air flow (LAF) hood where drug products intended to be sterile were prepared. Furthermore, you failed to evaluate whether the identified microbial contamination had any impact on aseptically processed drug products that were prepared in your cleanrooms.\n\n2. Your facility design was deficient because:\n\n(i) the cleanrooms did not have (b)(4);\n\n(ii) the cleanrooms were provided with HEPA filtered air (b)(4). This HEPA filter was not clamped down in the filter housing, had failed leak testing in 2018, and was not tested for leaks during the cleanroom certification performed in June 2019;\n\n(iii) the air returns in the cleanrooms were located in the ceilings in proximity to the air supply vents;\n\n(iv) (b)(4) between the ISO 7 hazardous buffer room and the unclassified area were (b)(4) and (b)(4) were observed opened at the same time;\n\n(v) a differential pressure cascade could not be maintained between rooms of higher air quality and rooms of lower air quality when the doors to the cleanrooms were closed;\n\n(vi) the air supply vents in the ISO 7 non-hazardous drug room and anteroom had accumulated what appeared to be dust.\n\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 BSC. Therefore, your products intended to be sterile were produced in an environment that may not provide adequate protection against the risk of contamination.\n\n4. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483 and subsequent correspondence. We acknowledge that as part of your corrective actions, all drug products intended to be sterile will continue to be assigned a beyond use date (BUD) of 12 hours.\n\nHowever, regarding your responses related to the insanitary conditions, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. Your response stated that (b)(4) was intended to be completed by (b)(4). You have not provided details describing the finalized design changes or evidence to demonstrate that the design phase has been completed or that the (b)(4) activities have been planned or performed.\n\n2. You stated that (b)(4) would be purchased for use while the (b)(4). You have not provided evidence to show that this corrective action has been implemented.\n\n3. Your response stated that cleaning the interior of the ISO 5 areas will be performed using sterile (b)(4). However, you did not provide supporting evidence to demonstrate that sterile (b)(4) was purchased or whether any modifications or changes have been made to your cleaning practices.\n\n4. You did not provide additional environmental monitoring data to demonstrate that the ISO 5 BSC, ISO 5 LAF, and the cleanrooms are maintained in a state of control.\n\n5. You failed to evaluate whether the recovery of spore-forming organisms indicated a need for more frequent application of a sporicidal agent as part of your routine disinfection program.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you do not believe that the products discussed above are in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction.\n\nSend your written responses to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nPlease identify your response with unique identifier 611130. Electronic responses may also be submitted to ORAPHARM4_Responses@fda.hhs.gov.\n\nIf you have questions regarding any issues in this letter, please contact Mariza Jafary, Compliance Officer, at (949) 608-2977, or Mariza.Jafary@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.","Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy","hawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhawaii-health-systems-corporation-dba-kona-community-hospital-pharmacy-611130-02012021","2026-10-26T08:08:53.28171+00:00","2021-02-09","611130","2022-07-14","Emily A. Krug","2026-08-20T03:24:27.426+00:00","Via Email","2021-02-01",{"id":379,"raw":380,"subject":385,"body_html":386,"body_text":387,"firm_name":388,"letter_id":389,"created_at":42,"fei_number":20,"letter_url":390,"updated_at":391,"action_type":23,"case_status":66,"posted_date":392,"marcs_cms_no":393,"product_type":394,"closeout_date":20,"issuing_office":243,"recipient_name":395,"body_fetched_at":396,"delivery_method":72,"recipient_title":20,"reference_number":20,"action_taken_date":397,"medical_device_id":20,"response_letter_date":20},1824,[381,382,383,243,384,13,13,13],"\u003Ctime datetime=\"2023-09-29T19:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-28T04:00:00Z\">09\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023\">Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael D. Johnson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2121 2nd Street, Suite C108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Davis\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95618-6567\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lhannan@infinanthealth.com\"> lhannan@infinanthealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: September 28, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance &amp; Regulatory Officer\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 667715\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnson and Ms. Hannan:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\u003C\u002Fp>\n\n\u003Cp>Based on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>Further, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\u003C\u002Fp>\n\n\u003Cp>Therefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&amp;C Act and the PHS Act. You can find the FD&amp;C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and\u003C\u002Fli>\n\t\u003Cli>“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\u003C\u002Fp>\n\n\u003Cp>Because these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Food: Unsafe Food Additive\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348(a)].\u003C\u002Fp>\n\n\u003Cp>The label of your Evivo with MCT Oil product declares the ingredient “\u003Cem>Bifidobacterium longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\u003C\u002Fp>\n\n\u003Cp>Any substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&amp;C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&amp;C Act. There is no food additive regulation that authorizes the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in food for preterm infants, including infant formula, is GRAS.\u003C\u002Fp>\n\n\u003Cp>GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (&lt;37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight &lt;1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\u003C\u002Fp>\n\n\u003Cp>Therefore, based on our review, FDA has determined that the intended use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>During a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector, Office of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nBiologics\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMichael D. Johnson\n\nRecipient Title\n\nCEO\n\nInfinant Health, Inc formerly Evolve Biosystems Inc.\n\n2121 2nd Street, Suite C108\n\nDavis, CA 95618-6567\n\nUnited States\n\nlhannan@infinanthealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nDate: September 28, 2023\n\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance & Regulatory Officer\n\nRE: 667715\n\nDear Mr. Johnson and Ms. Hannan:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains B. longum subsp. infantis EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\n\nBased on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\n\nFurther, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\n\nTherefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act.\n\nAs explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&C Act and the PHS Act. You can find the FD&C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drug and Unlicensed Biological Product\n\nYour website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\n\n“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);1 and\n\n“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).2\n\nAs noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\n\nBecause these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdulterated Food: Unsafe Food Additive\n\nIn addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&C Act [21 U.S.C. §§ 321(s) and 348(a)].\n\nThe label of your Evivo with MCT Oil product declares the ingredient “Bifidobacterium longum subsp. infantis EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\n\nAny substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&C Act. There is no food additive regulation that authorizes the use of B. longum subsp. infantis “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. longum subsp. Infantis “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of B. longum subsp. Infantis “EVC001” in food for preterm infants, including infant formula, is GRAS.\n\nGRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (\u003C37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight \u003C1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\n\nTherefore, based on our review, FDA has determined that the intended use in food for preterm infants of B. longum subsp. infantis is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nDuring a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of B. longum subsp. infantis in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\n\nWe advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector, Office of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nCc: (b)(4)\n\n____________________\n\n1 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\n\n2 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.","Infinant Health, Inc formerly Evolve Biosystems Inc.","infinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","2026-10-26T08:08:58.729306+00:00","2023-09-29","667715","BiologicsFood & Beverages","Michael D. Johnson","2026-08-20T00:37:59.96+00:00","2023-09-28",21,{"510k":400,"classification":401,"enforcement":402,"event":403,"event_backfill":404,"pma":405,"warning_letter":406},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]